Protein Kinase C Inhibitors and Uses Thereof

ABSTRACT

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit under 35 U.S.C. §119(e) ofpending U.S. application 61/366,464, filed Jul. 21, 2010, which ishereby incorporated herein by reference in its entirety.

BACKGROUND

Protein kinase C (“PKC”) is a key enzyme in signal transduction involvedin a variety of cellular functions, including cell growth, regulation ofgene expression, and ion channel activity. The PKC family of isozymesincludes at least 11 different protein kinases that can be divided intoat least three subfamilies based on their homology and sensitivity toactivators. Each isozyme includes a number of homologous (“conserved” or“C”) domains interspersed with isozyme-unique (“variable” or “V”)domains. Members of the “classical” or “cPKC” subfamily, PKC α, β_(i),β_(ii) and γ, contain four homologous domains (C1, C2, C3 and C4) andrequire calcium, phosphatidylserine, and diacylglycerol or phorbolesters for activation. Members of the “novel” or “nPKC” subfamily, PKCδ, ε, η and θ, lack the C2 homologous domain and do not require calciumfor activation. Finally, members of the “atypical” or “αPKC” subfamily,PKC ζ and λ/i, lack both the C2 and one-half of the C1 homologousdomains and are insensitive to diacylglycerol, phorbol esters andcalcium.

SUMMARY

This disclosure concerns compounds which are useful as inhibitors ofprotein kinase C (PKC) and are thus useful for treating a variety ofdiseases and disorders that are mediated or sustained through theactivity of PKC. This disclosure also relates to pharmaceuticalcompositions comprising these compounds, methods of using thesecompounds in the treatment of various diseases and disorders, processesfor preparing these compounds and intermediates useful in theseprocesses.

Exemplary chemical structures are provided throughout the disclosure. Byway of example, such compounds are represented by the following formula:

wherein

R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy, cyano,halogen, acyl, aminoacyl, and nitro;

Y¹ and Y² are independently selected from hydrogen, alkyl, and acyl;

R¹ is selected from hydrogen, alkyl, and substituted alkyl;

R^(a) and R^(b) are independently selected from hydrogen and alkyl;

R^(c) and R^(d) are independently selected from hydrogen and alkyl;

R^(6a) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(6b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R⁸ is selected from hydrogen, C₂₋₁₀ alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7x) is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, andsubstituted cycloalkyl;

wherein at least one of R^(6a), R^(6b), R^(7b), and R⁸ is not hydrogen;

wherein if R⁸ is fluoro, then R^(7b) is not hydrogen; and

-   -   wherein if R^(7b) is cyclopropyl, then at least one of R^(6a),        R^(6b), R⁸, and R^(7x) is not hydrogen;        and wherein if R⁸ is cyclopropyl, then at least one of R^(6a),        R^(6b), R^(7b), and R^(7x) is not hydrogen;

or a salt or stereoisomer thereof.

DETAILED DESCRIPTION

This disclosure concerns compounds which are useful as inhibitors ofprotein kinase C (PKC) and are thus useful for treating a variety ofdiseases and disorders that are mediated or sustained through theactivity of PKC. This disclosure also relates to pharmaceuticalcompositions comprising these compounds, methods of using thesecompounds in the treatment of various diseases and disorders, processesfor preparing these compounds and intermediates useful in theseprocesses.

Before the present invention is further described, it is to beunderstood that this invention is not limited to particular embodimentsdescribed, as such may, of course, vary. It is also to be understoodthat the terminology used herein is for the purpose of describingparticular embodiments only, and is not intended to be limiting, sincethe scope of the present invention will be limited only by the appendedclaims.

It must be noted that as used herein and in the appended claims, thesingular forms “a,” “an,” and “the” include plural referents unless thecontext clearly dictates otherwise. It is further noted that the claimsmay be drafted to exclude any optional element. As such, this statementis intended to serve as antecedent basis for use of such exclusiveterminology as “solely,” “only” and the like in connection with therecitation of claim elements, or use of a “negative” limitation.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is specifically contemplated. The upper and lower limitsof these smaller ranges may independently be included in the smallerranges, and are also encompassed within the invention, subject to anyspecifically excluded limit in the stated range. Where the stated rangeincludes one or both of the limits, ranges excluding either or both ofthose included limits are also included in the invention.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application. Nothingherein is to be construed as an admission that the present invention isnot entitled to antedate such publication by virtue of prior invention.Further, the dates of publication provided may be different from theactual publication dates which may need to be independently confirmed.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described. All publications mentionedherein are incorporated herein by reference to disclose and describe themethods and/or materials in connection with which the publications arecited.

Except as otherwise noted, the methods and techniques of the presentembodiments are generally performed according to conventional methodswell known in the art and as described in various general and morespecific references that are cited and discussed throughout the presentspecification. See, e.g., Loudon, Organic Chemistry, Fourth Edition, NewYork: Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith andMarch, March's Advanced Organic Chemistry: Reactions, Mechanisms, andStructure, Fifth Edition, Wiley-Interscience, 2001; or Vogel, A Textbookof Practical Organic Chemistry, Including Qualitative Organic Analysis,Fourth Edition, New York: Longman, 1978.

The nomenclature used herein to name the subject compounds isillustrated in the Examples herein. This nomenclature has generally beenderived using the commercially-available AutoNom software (MDL, SanLeandro, Calif.).

TERMS

The following terms have the following meanings unless otherwiseindicated. Any undefined terms have their art recognized meanings.

“Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groupshaving from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms.This term includes, by way of example, linear and branched hydrocarbylgroups such as methyl (CH₃—), ethyl (CH₃CH₂—), n-propyl (CH₃CH₂CH₂—),isopropyl ((CH₃)₂CH—), n-butyl (CH₃CH₂CH₂CH₂—), isobutyl ((CH₃)₂CHCH₂—),sec-butyl ((CH₃)(CH₃CH₂)CH—), t-butyl ((CH₃)₃C—), n-pentyl(CH₃CH₂CH₂CH₂CH₂—), and neopentyl ((CH₃)₃CCH₂—).

The term “substituted alkyl” refers to an alkyl group as defined hereinwherein one or more carbon atoms in the alkyl chain have been optionallyreplaced with a heteroatom such as —O—, —N—, —S—, —S(O)_(n)— (where n is0 to 2), —NR— (where R is hydrogen or alkyl) and having from 1 to 5substituents selected from the group consisting of alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-aryl,—SO₂-heteroaryl, and —NR^(a)R^(b), wherein R′ and R″ may be the same ordifferent and are chosen from hydrogen, optionally substituted alkyl,cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl andheterocyclic.

“Alkylene” refers to divalent aliphatic hydrocarbyl groups preferablyhaving from 1 to 6 and more preferably 1 to 3 carbon atoms that areeither straight-chained or branched, and which are optionallyinterrupted with one or more groups selected from —O—, —NR¹⁰—,—NR¹⁰C(O)—, —C(O)NR¹⁰— and the like. This term includes, by way ofexample, methylene (—CH₂—), ethylene (—CH₂CH₂—), n-propylene(—CH₂CH₂CH₂—), iso-propylene (—CH₂CH(CH₃)—), (—C(CH₃)₂CH₂CH₂—),(—C(CH₃)₂CH₂C(O)—), (—C(CH₃)₂CH₂C(O)NH—), (—CH(CH₃)CH₂—), and the like.

“Substituted alkylene” refers to an alkylene group having from 1 to 3hydrogens replaced with substituents as described for carbons in thedefinition of “substituted” below.

The term “alkane” refers to alkyl group and alkylene group, as definedherein.

The term “alkylaminoalkyl”, “alkylaminoalkenyl” and “alkylaminoalkynyl”refers to the groups R′NHR″— where R′ is alkyl group as defined hereinand R″ is alkylene, alkenylene or alkynylene group as defined herein.

The term “alkaryl” or “aralkyl” refers to the groups -alkylene-aryl and-substituted alkylene-aryl where alkylene, substituted alkylene and arylare defined herein.

“Alkoxy” refers to the group —O-alkyl, wherein alkyl is as definedherein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy,isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like. Theterm “alkoxy” also refers to the groups alkenyl-O—, cycloalkyl-O—,cycloalkenyl-O—, and alkynyl-O—, where alkenyl, cycloalkyl,cycloalkenyl, and alkynyl are as defined herein.

The term “substituted alkoxy” refers to the groups substituted alkyl-O—,substituted alkenyl-O—, substituted cycloalkyl-O—, substitutedcycloalkenyl-O—, and substituted alkynyl-O— where substituted alkyl,substituted alkenyl, substituted cycloalkyl, substituted cycloalkenyland substituted alkynyl are as defined herein.

The term “alkoxyamino” refers to the group —NH-alkoxy, wherein alkoxy isdefined herein.

The term “haloalkoxy” refers to the groups alkyl-O— wherein one or morehydrogen atoms on the alkyl group have been substituted with a halogroup and include, by way of examples, groups such as trifluoromethoxy,and the like.

The term “haloalkyl” refers to a substituted alkyl group as describedabove, wherein one or more hydrogen atoms on the alkyl group have beensubstituted with a halo group. Examples of such groups include, withoutlimitation, fluoroalkyl groups, such as trifluoromethyl, difluoromethyl,trifluoroethyl and the like.

The term “alkylalkoxy” refers to the groups -alkylene-O-alkyl,alkylene-O-substituted alkyl, substituted alkylene-O-alkyl, andsubstituted alkylene-O-substituted alkyl wherein alkyl, substitutedalkyl, alkylene and substituted alkylene are as defined herein.

The term “alkylthioalkoxy” refers to the group -alkylene-S-alkyl,alkylene-S-substituted alkyl, substituted alkylene-S-alkyl andsubstituted alkylene-S-substituted alkyl wherein alkyl, substitutedalkyl, alkylene and substituted alkylene are as defined herein.

“Alkenyl” refers to straight chain or branched hydrocarbyl groups havingfrom 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and havingat least 1 and preferably from 1 to 2 sites of double bond unsaturation.This term includes, by way of example, bi-vinyl, allyl, andbut-3-en-1-yl. Included within this term are the cis and trans isomersor mixtures of these isomers.

The term “substituted alkenyl” refers to an alkenyl group as definedherein having from 1 to 5 substituents, or from 1 to 3 substituents,selected from alkoxy, substituted alkoxy, cycloalkyl, substitutedcycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino,acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

“Alkynyl” refers to straight or branched monovalent hydrocarbyl groupshaving from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms andhaving at least 1 and preferably from 1 to 2 sites of triple bondunsaturation. Examples of such alkynyl groups include acetylenyl(—C≡CH), and propargyl (—CH₂C≡CH).

The term “substituted alkynyl” refers to an alkynyl group as definedherein having from 1 to 5 substituents, or from 1 to 3 substituents,selected from alkoxy, substituted alkoxy, cycloalkyl, substitutedcycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino,acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl, and —SO₂-heteroaryl.

“Alkynyloxy” refers to the group —O-alkynyl, wherein alkynyl is asdefined herein. Alkynyloxy includes, by way of example, ethynyloxy,propynyloxy, and the like.

“Acyl” refers to the groups H—C(O)—, alkyl-C(O)—, substitutedalkyl-C(O)—, alkenyl-C(O)—, substituted alkenyl-C(O)—, alkynyl-C(O)—,substituted alkynyl-C(O)—, cycloalkyl-C(O)—, substitutedcycloalkyl-C(O)—, cycloalkenyl-C(O)—, substituted cycloalkenyl-C(O)—,aryl-C(O)—, substituted aryl-C(O)—, heteroaryl-C(O)—, substitutedheteroaryl-C(O)—, heterocyclyl-C(O)—, and substitutedheterocyclyl-C(O)—, wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein. For example, acylincludes the “acetyl” group CH₃C(O)—

“Acylamino” refers to the groups —NR²⁰C(O)alkyl, —NR²⁰C(O)substitutedalkyl, NR²⁰C(O)cycloalkyl, —NR²⁰C(O)substituted cycloalkyl,—NR²⁰C(O)cycloalkenyl, —NR²⁰C(O)substituted cycloalkenyl,—NR²⁰C(O)alkenyl, —NR²⁰C(O)substituted alkenyl, —NR²⁰C(O)alkynyl,—NR²⁰C(O)substituted alkynyl, —NR²⁰C(O)aryl, —NR²⁰C(O)substituted aryl,—NR²⁰C(O)heteroaryl, —NR²⁰C(O)substituted heteroaryl,—NR²⁰C(O)heterocyclic, and —NR²⁰C(O)substituted heterocyclic, whereinR²° is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

“Aminocarbonyl” or the term “aminoacyl” refers to the group—C(O)NR²¹R²², wherein R²¹ and R²² independently are selected from thegroup consisting of hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, substitutedaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic and where R²¹ and R²² are optionally joinedtogether with the nitrogen bound thereto to form a heterocyclic orsubstituted heterocyclic group, and wherein alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

The term “alkoxycarbonylamino” refers to the group —NRC(O)OR where eachR is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl,or heterocyclyl wherein alkyl, substituted alkyl, aryl, heteroaryl, andheterocyclyl are as defined herein.

The term “acyloxy” refers to the groups alkyl-C(O)O—, substitutedalkyl-C(O)O—, cycloalkyl-C(O)O—, substituted cycloalkyl-C(O)O—,aryl-C(O)O—, heteroaryl-C(O)O—, and heterocyclyl-C(O)O— wherein alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl,and heterocyclyl are as defined herein.

“Aminosulfonyl” refers to the group —SO₂NR²¹R²², wherein R²¹ and R²²independently are selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, heteroaryl, substitutedheteroaryl, heterocyclic, substituted heterocyclic and where R²¹ and R²²are optionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group and alkyl, substitutedalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Sulfonylamino” refers to the group —NR²¹SO₂R²², wherein R²¹ and R²²independently are selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic and where R²¹ andR²² are optionally joined together with the atoms bound thereto to forma heterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic are as definedherein.

“Aryl” or “Ar” refers to a monovalent aromatic carbocyclic group of from6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiplecondensed rings (e.g., naphthyl or anthryl) which condensed rings may ormay not be aromatic, provided that the point of attachment is through anatom of the aromatic aryl group. This term includes, by way of example,phenyl and naphthyl. Unless otherwise constrained by the definition forthe aryl substituent, such aryl groups can optionally be substitutedwith from 1 to 5 substituents, or from 1 to 3 substituents, selectedfrom acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl,cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy,substituted alkenyl, substituted alkynyl, substituted cycloalkyl,substituted cycloalkenyl, amino, substituted amino, aminoacyl,acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl,cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl,heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substitutedthioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substitutedalkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl,—SO₂-aryl, —SO₂-heteroaryl and trihalomethyl.

“Aryloxy” refers to the group —O-aryl, wherein aryl is as definedherein, including, by way of example, phenoxy, naphthoxy, and the like,including optionally substituted aryl groups as also defined herein.

“Amino” refers to the group —NH₂.

The term “substituted amino” refers to the group —NRR where each R isindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl,substituted alkynyl, aryl, heteroaryl, and heterocyclyl provided that atleast one R is not hydrogen.

The term “azido” refers to the group —N₃.

“Carboxyl,” “carboxy” or “carboxylate” refers to —CO₂H or salts thereof.

“Carboxyl ester” or “carboxy ester” or the terms “carboxyalkyl” or“carboxylalkyl” refers to the groups —C(O)O-alkyl, —C(O)O-substitutedalkyl, —C(O)O-alkenyl, —C(O)O-substituted alkenyl, —C(O)O-alkynyl,—C(O)O-substituted alkynyl, —C(O)O-aryl, —C(O)O-substituted aryl,—C(O)O-cycloalkyl, —C(O)O-substituted cycloalkyl, —C(O)O-cycloalkenyl,—C(O)O-substituted cycloalkenyl, —C(O)O-heteroaryl, —C(O)O-substitutedheteroaryl, —C(O)O-heterocyclic, and —C(O)O-substituted heterocyclic,wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl,substituted cycloalkenyl, aryl, substituted aryl, heteroaryl,substituted heteroaryl, heterocyclic, and substituted heterocyclic areas defined herein.

“(Carboxyl ester)oxy” or “carbonate” refers to the groups—O—C(O)O-alkyl, —O—C(O)O-substituted alkyl, —O—C(O)O-alkenyl,—O—C(O)O-substituted alkenyl, —O—C(O)O-alkynyl, —O—C(O)O-substitutedalkynyl, —O—C(O)O-aryl, —O—C(O)O-substituted aryl, —O—C(O)O-cycloalkyl,—O—C(O)O-substituted cycloalkyl, —O—C(O)O-cycloalkenyl,—O—C(O)O-substituted cycloalkenyl, —O—C(O)O-heteroaryl,—O—C(O)O-substituted heteroaryl, —O—C(O)O-heterocyclic, and—O—C(O)O-substituted heterocyclic, wherein alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

“Cyano” or “nitrile” refers to the group —CN.

“Cycloalkyl” refers to cyclic alkyl groups of from 3 to 10 carbon atomshaving single or multiple cyclic rings including fused, bridged, andspiro ring systems. Examples of suitable cycloalkyl groups include, forinstance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyland the like. Such cycloalkyl groups include, by way of example, singlering structures such as cyclopropyl, cyclobutyl, cyclopentyl,cyclooctyl, and the like, or multiple ring structures such asadamantanyl, and the like.

The term “substituted cycloalkyl” refers to cycloalkyl groups havingfrom 1 to 5 substituents, or from 1 to 3 substituents, selected fromalkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl,acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

“Cycloalkenyl” refers to non-aromatic cyclic alkyl groups of from 3 to10 carbon atoms having single or multiple rings and having at least onedouble bond and preferably from 1 to 2 double bonds.

The term “substituted cycloalkenyl” refers to cycloalkenyl groups havingfrom 1 to 5 substituents, or from 1 to 3 substituents, selected fromalkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino,substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano,halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy,thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substitutedthioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl,heterocyclooxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,—SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

“Cycloalkynyl” refers to non-aromatic cycloalkyl groups of from 5 to 10carbon atoms having single or multiple rings and having at least onetriple bond.

“Cycloalkoxy” refers to —O-cycloalkyl.

“Cycloalkenyloxy” refers to —O-cycloalkenyl.

“Halo” or “halogen” refers to fluoro, chloro, bromo, and iodo.

“Hydroxy” or “hydroxyl” refers to the group —OH.

“Heteroaryl” refers to an aromatic group of from 1 to 10 carbon atomsand 1 to 4 heteroatoms selected from the group consisting of oxygen,nitrogen, and sulfur within the ring. Such heteroaryl groups can have asingle ring (e.g., pyridinyl, imidazolyl or furyl) or multiple condensedrings (e.g., indolizinyl, quinolinyl, benzimidazolyl or benzothienyl),wherein the condensed rings may or may not be aromatic and/or contain aheteroatom, provided that the point of attachment is through an atom ofthe aromatic heteroaryl group. In certain embodiments, the nitrogenand/or sulfur ring atom(s) of the heteroaryl group are optionallyoxidized to provide for the N-oxide (N→O), sulfinyl, or sulfonylmoieties. This term includes, by way of example, pyridinyl, pyrrolyl,indolyl, thiophenyl, and furanyl. Unless otherwise constrained by thedefinition for the heteroaryl substituent, such heteroaryl groups can beoptionally substituted with 1 to 5 substituents, or from 1 to 3substituents, selected from acyloxy, hydroxy, thiol, acyl, alkyl,alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl,substituted alkoxy, substituted alkenyl, substituted alkynyl,substituted cycloalkyl, substituted cycloalkenyl, amino, substitutedamino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl,carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy,heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy,substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,—SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl, andtrihalomethyl.

The term “heteroaralkyl” refers to the groups -alkylene-heteroaryl wherealkylene and heteroaryl are defined herein. This term includes, by wayof example, pyridylmethyl, pyridylethyl, indolylmethyl, and the like.

“Heteroaryloxy” refers to —O-heteroaryl.

“Heterocycle,” “heterocyclic,” “heterocycloalkyl,” and “heterocyclyl”refer to a saturated or unsaturated group having a single ring ormultiple condensed rings, including fused bridged and Spiro ringsystems, and having from 3 to 15 ring atoms, including 1 to 4 heteroatoms. These ring atoms are selected from the group consisting ofnitrogen, sulfur, or oxygen, wherein, in fused ring systems, one or moreof the rings can be cycloalkyl, aryl, or heteroaryl, provided that thepoint of attachment is through the non-aromatic ring. In certainembodiments, the nitrogen and/or sulfur atom(s) of the heterocyclicgroup are optionally oxidized to provide for the N-oxide, —S(O)—, or—SO₂— moieties.

Examples of heterocycles and heteroaryls include, but are not limitedto, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine,pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole,indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine,naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine,carbazole, carboline, phenanthridine, acridine, phenanthroline,isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine,imidazolidine, imidazoline, piperidine, piperazine, indoline,phthalimide, 1,2,3,4-tetrahydroisoquinoline,4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene,benzo[b]thiophene, morpholinyl, thiomorpholinyl (also referred to asthiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine,tetrahydrofuranyl, and the like.

Unless otherwise constrained by the definition for the heterocyclicsubstituent, such heterocyclic groups can be optionally substituted with1 to 5, or from 1 to 3 substituents, selected from alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino,aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl,oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy,thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl,aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy,hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl,—SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl,—SO₂-heteroaryl, and fused heterocycle.

“Heterocyclyloxy” refers to the group —O-heterocyclyl.

The term “heterocyclylthio” refers to the group heterocyclic-S—.

The term “heterocyclene” refers to the diradical group formed from aheterocycle, as defined herein.

The term “hydroxyamino” refers to the group —NHOH.

“Nitro” refers to the group —NO₂.

“Oxo” refers to the atom (═O).

“Sulfonyl” refers to the group SO₂-alkyl, SO₂-substituted alkyl,SO₂-alkenyl, SO₂-substituted alkenyl, SO₂-cycloalkyl, SO₂-substitutedcycloalkyl, SO₂-cycloalkenyl, SO₂-substituted cycloalkenyl, SO₂-aryl,SO₂-substituted aryl, SO₂-heteroaryl, SO₂-substituted heteroaryl,SO₂-heterocyclic, and SO₂-substituted heterocyclic, wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic are as definedherein. Sulfonyl includes, by way of example, methyl-SO₂—, phenyl-SO₂—,and 4-methylphenyl-SO₂—.

“Sulfonyloxy” refers to the group —OSO₂-alkyl, OSO₂-substituted alkyl,OSO₂-alkenyl, OSO₂-substituted alkenyl, OSO₂-cycloalkyl,OSO₂-substituted cycloalkyl, OSO₂-cycloalkenyl, OSO₂-substitutedcycloalkenyl, OSO₂-aryl, OSO₂-substituted aryl, OSO₂-heteroaryl,OSO₂-substituted heteroaryl, OSO₂-heterocyclic, and OSO₂ substitutedheterocyclic, wherein alkyl, substituted alkyl, alkenyl, substitutedalkenyl, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, heterocyclic, and substitutedheterocyclic are as defined herein.

The term “aminocarbonyloxy” refers to the group —OC(O)NRR where each Ris independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl,or heterocyclic wherein alkyl, substituted alkyl, aryl, heteroaryl andheterocyclic are as defined herein.

“Thiol” refers to the group —SH.

“Thioxo” or the term “thioketo” refers to the atom (═S).

“Alkylthio” or the term “thioalkoxy” refers to the group —S-alkyl,wherein alkyl is as defined herein. In certain embodiments, sulfur maybe oxidized to —S(O)—. The sulfoxide may exist as one or morestereoisomers.

The term “substituted thioalkoxy” refers to the group —S-substitutedalkyl.

The term “thioaryloxy” refers to the group aryl-S— wherein the arylgroup is as defined herein including optionally substituted aryl groupsalso defined herein.

The term “thioheteroaryloxy” refers to the group heteroaryl-S— whereinthe heteroaryl group is as defined herein including optionallysubstituted aryl groups as also defined herein.

The term “thioheterocyclooxy” refers to the group heterocyclyl-S—wherein the heterocyclyl group is as defined herein including optionallysubstituted heterocyclyl groups as also defined herein.

In addition to the disclosure herein, the term “substituted,” when usedto modify a specified group or radical, can also mean that one or morehydrogen atoms of the specified group or radical are each, independentlyof one another, replaced with the same or different substituent groupsas defined below.

In addition to the groups disclosed with respect to the individual termsherein, substituent groups for substituting for one or more hydrogens(any two hydrogens on a single carbon can be replaced with ═O, ═NR⁷⁰,═N—OR⁷⁰, ═N₂ or ═S) on saturated carbon atoms in the specified group orradical are, unless otherwise specified, —R⁶⁰, halo, ═O, —OR⁷⁰, —SR⁷⁰,—NR⁸⁰R⁸⁰, trihalomethyl, —CN, —OCN, —SCN, —NO, —NO₂, ═N₂, —N₃, —SO₂R⁷⁰,—SO₂O⁻M⁺, —SO₂OR⁷⁰, —OSO₂R⁷⁰, —OSO₂O⁻M⁺, —OSO₂OR⁷⁰, —P(O)(O⁻)₂(M⁺)₂,—P(O)(OR⁷⁰)O⁻M⁺, —P(O)(OR⁷⁰)₂, —C(O)R⁷⁰, —C(S)R⁷⁰, —C(NR⁷⁰)R⁷⁰,—C(O)O⁻M⁺, —C(O)OR⁷⁰, —C(S)OR⁷⁰, —C(O)NR⁸⁰R⁸⁰, —C(NR⁷⁰)NR⁸⁰R⁸⁰,—OC(O)R⁷⁰)R⁷⁰, —OC(O)O⁻M⁺, —OC(O)OR⁷⁰, —OC(S)OR⁷⁰, —NR⁷⁰C(O)R⁷⁰,—NR⁷⁰C(S)R⁷⁰, —NR⁷⁰CO₂ ⁻M⁺, —NR⁷⁰CO₂R⁷⁰, —NR⁷⁰C(S)OR⁷⁰,—NR⁷⁰C(O)NR⁸⁰R⁸⁰, —NR⁷⁰C(NR⁷⁰)R⁷⁰ and —NR⁷⁰C(NR⁷⁰)NR⁸⁰R⁸⁰, where R⁶° isselected from the group consisting of optionally substituted alkyl,cycloalkyl, heteroalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl,arylalkyl, heteroaryl and heteroarylalkyl, each R⁷⁰ is independentlyhydrogen or R⁶⁰; each R⁸⁰ is independently R⁷⁰ or alternatively, twoR⁸⁰'s, taken together with the nitrogen atom to which they are bonded,form a 5-, 6- or 7-membered heterocycloalkyl which may optionallyinclude from 1 to 4 of the same or different additional heteroatomsselected from the group consisting of O, N and S, of which N may have —Hor C₁-C₃ alkyl substitution; and each M⁺ is a counter ion with a netsingle positive charge. Each M⁺ may independently be, for example, analkali ion, such as K⁺, Na⁺, Li⁺; an ammonium ion, such as ⁺N(R⁶⁰)₄; oran alkaline earth ion, such as [Ca²⁺]_(0.5), [Mg²⁺]_(0.5), or[Ba²⁺]_(0.5) (“subscript 0.5 means e.g. that one of the counter ions forsuch divalent alkali earth ions can be an ionized form of a compound ofthe invention and the other a typical counter ion such as chloride, ortwo ionized compounds of the invention can serve as counter ions forsuch divalent alkali earth ions, or a doubly ionized compound of theinvention can serve as the counter ion for such divalent alkali earthions). As specific examples, —NR⁸⁰R⁸⁰ is meant to include —NH₂,—NH-alkyl, N-pyrrolidinyl, N-piperazinyl, 4N-methyl-piperazin-1-yl andN-morpholinyl.

In addition to the disclosure herein, substituent groups for hydrogenson unsaturated carbon atoms in “substituted” alkene, alkyne, aryl andheteroaryl groups are, unless otherwise specified, —R⁶⁰, halo, —O⁻M⁺,—OR⁷⁰, —SR⁷⁰, —NR⁸⁰R⁸⁰, trihalomethyl, —CF₃, —CN, —OCN, —SCN, —NO, —NO₂,—N₃, —SO₂R⁷⁰, —SO₃ ⁻M⁺, —SO₃R⁷⁰, —OSO₂R⁷⁰, —OSO₃ ⁻M⁺, —OSO₃R⁷⁰, —PO₃⁻²(M⁺)₂, —P(O)(OR⁷⁰)O⁺M⁺, —P(O)(OR⁷⁰)₂, —C(O)R⁷⁰, —C(S)R⁷⁰, —C(NR⁷⁰)R⁷⁰,—CO₂ ⁻M⁺, —CO₂R⁷⁰, —C(S)OR⁷⁰, —C(O)NR⁸⁰R⁸⁰, —C(NR⁷⁰)NR⁸⁰R⁸⁰, —OC(O)R⁷⁰,—OC(S)R⁷⁰, —OCO₂ ⁻M⁺, —OCO₂R⁷⁰, —OC(S)OR⁷⁰, —NR⁷⁰C(O)R⁷⁰, —NR⁷⁰C(S)R⁷⁰,—NR⁷⁰CO₂ ⁻M⁺, —NR⁷⁰CO₂R⁷⁰, —NR⁷⁰C(S)OR⁷⁰, —NR⁷⁰C(O)NR⁸⁰R⁸⁰, —NR and —NRwhere R⁶⁰, R⁷⁰, R⁸⁰ and M⁺ are as previously defined, provided that incase of substituted alkene or alkyne, the substituents are not —O⁻M⁺,—OR⁷⁰, —SR⁷⁰, or —S⁻M⁺.

In addition to the groups disclosed with respect to the individual termsherein, substituent groups for hydrogens on nitrogen atoms in“substituted” heteroalkyl and cycloheteroalkyl groups are, unlessotherwise specified, —R⁶⁰, —O⁻M⁺, —OR⁷⁰, —SR⁷⁰, —S⁻M⁺, —NR⁸⁰R⁸⁰,trihalomethyl, —CF₃, —CN, —NO, —NO₂, —S(O)₂R⁷⁰, —S(O)₂O⁻M⁺, —S(O)₂OR⁷⁰,—OS(O)₂R⁷⁰—OS(O)₂OR⁷⁰, —P(O)(O)₂(M⁺)₂, —P(O)(OR⁷⁰)O⁻M⁺,—P(O)(OR⁷⁰)(OR⁷⁰), —C(O)R⁷⁰, —C(S)R⁷⁰, —C(NR⁷⁰)R⁷⁰, —C(O)OR⁷⁰,—C(S)OR⁷⁰, —C(O)NR⁸⁰R⁸⁰, —C(NR⁷⁰)NR⁸⁰R⁸⁰, —OC(O)R⁷⁰, —OC(S)R⁷⁰,—OC(O)OR⁷⁰, —OC(S)OR⁷⁰, —NR⁷⁰C(O)R⁷⁰, —NR⁷⁰C(S)R⁷⁰, —NR⁷⁰C(O)OR⁷⁰,—NR⁷⁰C(S)OR⁷⁰, —NR⁷⁰C(O)NR⁸⁰R⁸⁰, —NR⁷⁰C(NR⁷⁰)R⁷⁰ and—NR⁷⁰C(NR⁷⁰)NR⁸⁰R⁸⁰, where R⁶⁰, R⁷⁰, R⁸⁰ and M⁺ are as previouslydefined.

In addition to the disclosure herein, in a certain embodiment, a groupthat is substituted has 1, 2, 3, or 4 substituents, 1, 2, or 3substituents, 1 or 2 substituents, or 1 substituent.

It is understood that in all substituted groups defined above, polymersarrived at by defining substituents with further substituents tothemselves (e.g., substituted aryl having a substituted aryl group as asubstituent which is itself substituted with a substituted aryl group,which is further substituted by a substituted aryl group, etc.) are notintended for inclusion herein. In such cases, the maximum number of suchsubstitutions is three. For example, serial substitutions of substitutedaryl groups are limited to substituted aryl-(substitutedaryl)-substituted aryl.

Unless indicated otherwise, the nomenclature of substituents that arenot explicitly defined herein are arrived at by naming the terminalportion of the functionality followed by the adjacent functionalitytoward the point of attachment. For example, the substituent“arylalkyloxycarbonyl” refers to the group (aryl)-(alkyl)-O—C(O)—.

As to any of the groups disclosed herein which contain one or moresubstituents, it is understood, of course, that such groups do notcontain any substitution or substitution patterns which are stericallyimpractical and/or synthetically non-feasible. In addition, the subjectcompounds include all stereochemical isomers arising from thesubstitution of these compounds.

The term “pharmaceutically acceptable salt” means a salt which isacceptable for administration to a patient, such as a mammal (e.g.,salts having acceptable mammalian safety for a given dosage regime).Such salts can be derived from pharmaceutically acceptable inorganic ororganic bases and from pharmaceutically acceptable inorganic or organicacids. “Pharmaceutically acceptable salt” refers to pharmaceuticallyacceptable salts of a compound, which salts are derived from a varietyof organic and inorganic counter ions well known in the art and include,by way of example only, sodium, potassium, calcium, magnesium, ammonium,tetraalkylammonium, and the like; and when the molecule contains a basicfunctionality, salts of organic or inorganic acids, such ashydrochloride, hydrobromide, formate, tartrate, besylate, mesylate,acetate, maleate, oxalate, and the like.

The term “salt thereof” means a compound formed when the hydrogen of anacid is replaced by a cation, such as a metal cation or an organiccation and the like. Where applicable, the salt is a pharmaceuticallyacceptable salt, although this is not required for salts of intermediatecompounds that are not intended for administration to a patient. By wayof example, salts of the present compounds include those wherein thecompound is protonated by an inorganic or organic acid to form a cation,with the conjugate base of the inorganic or organic acid as the anioniccomponent of the salt.

“Solvate” refers to a complex formed by combination of solvent moleculeswith molecules or ions of the solute. The solvent can be an organiccompound, an inorganic compound, or a mixture of both. Some examples ofsolvents include, but are not limited to, methanol,N,N-dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and water.When the solvent is water, the solvate formed is a hydrate.

“Stereoisomer” and “stereoisomers” refer to compounds that have sameatomic connectivity but different atomic arrangement in space.Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers,and diastereomers.

“Tautomer” refers to alternate forms of a molecule that differ only inelectronic bonding of atoms and/or in the position of a proton, such asenol-keto and imine-enamine tautomers, or the tautomeric forms ofheteroaryl groups containing a —N═C(H)—NH— ring atom arrangement, suchas pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. Aperson of ordinary skill in the art would recognize that othertautomeric ring atom arrangements are possible.

It will be appreciated that the term “or a salt or solvate orstereoisomer thereof” is intended to include all permutations of salts,solvates and stereoisomers, such as a solvate of a pharmaceuticallyacceptable salt of a stereoisomer of subject compound.

“Pharmaceutically effective amount” and “therapeutically effectiveamount” refer to an amount of a compound sufficient to treat a specifieddisorder or disease or one or more of its symptoms and/or to prevent theoccurrence of the disease or disorder. In reference to tumorigenicproliferative disorders, a pharmaceutically or therapeutically effectiveamount comprises an amount sufficient to, among other things, cause thetumor to shrink or decrease the growth rate of the tumor.

“Patient” refers to human and non-human animals, especially mammals.

The term “treating” or “treatment” as used herein means the treating ortreatment of a disease or medical condition in a patient, such as amammal (particularly a human) that includes: (a) preventing the diseaseor medical condition from occurring, i.e., prophylactic treatment of apatient; (b) ameliorating the disease or medical condition, i.e.,eliminating or causing regression of the disease or medical condition ina patient; (c) suppressing the disease or medical condition, i.e.,slowing or arresting the development of the disease or medical conditionin a patient; or (d) alleviating the symptoms of the disease or medicalcondition in a patient.

REPRESENTATIVE EMBODIMENTS

The following substituents and values are intended to providerepresentative examples of various aspects and embodiments. Theserepresentative values are intended to further define and illustrate suchaspects and embodiments and are not intended to exclude otherembodiments or to limit the scope of this invention. In this regard, therepresentation that a particular value or substituent is preferred isnot intended in any way to exclude other values or substituents fromthis invention unless specifically indicated.

These compounds may contain one or more chiral centers and therefore,the embodiments are directed to racemic mixtures; pure stereoisomers(i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures andthe like unless otherwise indicated. When a particular stereoisomer isshown or named herein, it will be understood by those skilled in the artthat minor amounts of other stereoisomers may be present in thecompositions unless otherwise indicated, provided that the desiredutility of the composition as a whole is not eliminated by the presenceof such other isomers.

The compositions of the present disclosure include compounds of FormulaeI-V, shown below. Pharmaceutical compositions and methods of the presentdisclosure also contemplate compounds of Formulae I-V.

Formula I

In one of its composition aspects, the present embodiments provide acompound of formula (I):

wherein

R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy, cyano,halogen, acyl, aminoacyl, and nitro;

Y¹ and Y² are independently selected from hydrogen, alkyl, and acyl;

R¹ is selected from hydrogen, alkyl, and substituted alkyl;

R^(a) and R^(b) are independently selected from hydrogen and alkyl;

R^(c) and R^(d) are independently selected from hydrogen and alkyl;

R^(6a) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(6b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R⁸ is selected from hydrogen, C₂₋₁₀ alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7x) is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, andsubstituted cycloalkyl;

-   -   wherein at least one of R^(6a), R^(6b), R^(7b), and R⁸ is not        hydrogen;

wherein if R⁸ is fluoro, then R^(7b) is not hydrogen; and

wherein if R^(7b) is cyclopropyl, then at least one of R^(6a), R^(6b),R⁸, and R^(7x) is not hydrogen;

and wherein if R⁸ is cyclopropyl, then at least one of R^(6a), R^(6b),R^(7b), and R^(7x) is not hydrogen;

or a salt or stereoisomer thereof.

Formula II

In one of its composition aspects, the present embodiments provide acompound of formula (II):

wherein

R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy, cyano,halogen, acyl, aminoacyl, and nitro;

Y¹ and Y² are independently selected from hydrogen, alkyl, and acyl;

R¹ is selected from hydrogen, alkyl, and substituted alkyl;

R^(a) and R^(b) are independently selected from hydrogen and alkyl;

R^(c) and R^(d) are independently selected from hydrogen and alkyl;

R^(6a) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(6b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R⁸ is selected from hydrogen, C₂₋₁₀ alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7x) is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, andsubstituted cycloalkyl;

wherein at least one of R^(6a) and R^(6b) is not hydrogen;

or a salt or stereoisomer thereof.

Formula III

In one of its composition aspects, the present embodiments provide acompound of formula (III):

wherein

R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy, cyano,halogen, acyl, aminoacyl, and nitro;

Y¹ and Y² are independently selected from hydrogen, alkyl, and acyl;

R¹ is selected from hydrogen, alkyl, and substituted alkyl;

R^(a) and R^(b) are independently selected from hydrogen and alkyl;

R^(c) and R^(d) are independently selected from hydrogen and alkyl;

R^(6a) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(6b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R⁸ is selected from hydrogen, C₂₋₁₀ alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7x) is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, andsubstituted cycloalkyl;

wherein at least one of R^(6a), R^(6b), R^(7b), and R⁸ is halogen; and

wherein at least one of R^(6a), R^(6b), R^(7b), and R⁸ is cycloalkyl,alkyl, or C₂₋₁₀ alkyl; or a salt or stereoisomer thereof.

Formula IV

In one of its composition aspects, the present embodiments provide acompound of formula (IV):

wherein

R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy, cyano,halogen, acyl, aminoacyl, and nitro;

Y¹ and Y² are independently selected from hydrogen, alkyl, and acyl;

R¹ is selected from hydrogen, alkyl, and substituted alkyl;

R^(a) and R^(b) are independently selected from hydrogen and alkyl;

R^(c) and R^(d) are independently selected from hydrogen and alkyl;

R^(6a) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(6b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R⁸ is selected from hydrogen, C₂₋₁₀ alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7x) is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, andsubstituted cycloalkyl;

wherein at least one of R^(6a), R^(6b), R^(7b), and R⁸ is C₂₋₁₀ alkyl;

or a salt or stereoisomer thereof.

Formula V

In one of its composition aspects, the present embodiments provide acompound of formula (V):

wherein

R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy, cyano,halogen, acyl, aminoacyl, and nitro;

Y¹ and Y² are independently selected from hydrogen, alkyl, and acyl;

R¹ is selected from hydrogen, alkyl, and substituted alkyl;

R^(a) and R^(b) are independently selected from hydrogen and alkyl;

R^(c) and R^(d) are independently selected from hydrogen and alkyl;

R^(6a) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(6b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7b) is selected from hydrogen, alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R⁸ is selected from hydrogen, C₂₋₁₀ alkyl, substituted alkyl, cyano,halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;

R^(7x) is haloalkyl;

or a salt or stereoisomer thereof.

In formulae I-V, R⁵ can be selected from haloalkyl, alkoxy, substitutedalkoxy, cyano, halogen, acyl, aminoacyl, and nitro. In certaininstances, R⁵ is haloalkyl. In certain instances, R⁵ is alkoxy orsubstituted alkoxy. In certain instances, R⁵ is cyano. In certaininstances, R⁵ is halogen. In certain instances, R⁵ is fluoro, chloro,bromo, or iodo. In certain instances, R⁵ is fluoro. In certaininstances, R⁵ is acyl or acylamino. In certain instances, R⁵ is —CONH₂.In certain instances, R⁵ is nitro.

In formulae I-V, Y¹ and Y² can independently be selected from hydrogen,alkyl, and acyl. In certain instances, Y¹ is hydrogen. In certaininstances, Y¹ is alkyl. In certain instances, Y¹ is acyl. In certaininstances, Y² is hydrogen. In certain instances, Y² is alkyl. In certaininstances, Y² is acyl.

In formulae I-V, R¹ can be selected from hydrogen, alkyl, andsubstituted alkyl. In certain instances, R¹ is hydrogen or alkyl. Incertain instances, R¹ is hydrogen. In certain instances, R¹ is alkyl. Incertain instances, R¹ is methyl.

In formulae I-V, R^(a) and R^(b) can be independently selected fromhydrogen and alkyl. In certain instances, R^(a) and R^(b) are bothalkyl. In certain instances, R^(a) and R^(b) are both methyl. In certaininstances, at least one of R^(a) and R^(b) is alkyl.

In formulae I-V, R^(c) and R^(d) can be independently selected fromhydrogen and alkyl. In certain instances, R^(c) and R^(d) are bothalkyl. In certain instances, R^(c) and R^(d) are both methyl. In certaininstances, at least one of R^(c) and R^(d) is alkyl.

In formulae I-V, in certain instances, at least one of R^(6a), R^(6b),R^(7b), and R⁸ is selected from C₂₋₁₀ alkyl, halogen, and cycloalkyl.

In formulae I-V, R^(6a) can be selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl. In certain instance, R^(6a) is hydrogen,alkyl, halogen, or cycloalkyl.

In formulae I-V, in certain instances, R^(6a) is hydrogen. In certaininstances, R^(6a) is alkyl. In certain instances, R^(6a) is ethyl,propyl, isopropyl, butyl, sec-butyl, or isobutyl. In certain instances,R^(6a) is isopropyl. In certain instances, R^(6a) is halogen. In certaininstances, R^(6a) is fluoro, chloro, bromo, or iodo. In certaininstances, R^(6a) is fluoro. In certain instances, R^(6a) is cycloalkyl.In certain instances, R^(6a) is cyclopropyl.

In formulae I-V, in certain instances, R^(6a) is substituted alkyl. Incertain instances, R^(6a) is substituted cycloalkyl. In certaininstances, R^(6a) is cyano, acyl, aminoacyl, or nitro.

In formulae I-V, R^(6b) can be selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl. In certain instance, R^(6b) is hydrogen,alkyl, halogen, or cycloalkyl.

In formulae I-V, in certain instances, R^(6b) is hydrogen. In certaininstances, R^(6b) is alkyl. In certain instances, R^(6b) is ethyl,propyl, isopropyl, butyl, sec-butyl, or isobutyl. In certain instances,R^(6b) is isopropyl. In certain instances, R^(6b) is halogen. In certaininstances, R^(6b) is fluoro, chloro, bromo, or iodo. In certaininstances, R^(6b) is fluoro. In certain instances, R^(6b) is cycloalkyl.In certain instances, R^(6b) is cyclopropyl.

In formulae I-V, in certain instances, R^(6b) is substituted alkyl. Incertain instances, R^(6b) is substituted cycloalkyl. In certaininstances, R^(6b) is cyano, acyl, aminoacyl, or nitro.

In formulae I-V, R^(7b) can be selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl. In certain instance, R^(7b) is hydrogen,alkyl, halogen, or cycloalkyl.

In formulae I-V, in certain instances, R^(7b) is hydrogen. In certaininstances, R^(7b) is alkyl. In certain instances, R^(7b) is ethyl,propyl, isopropyl, butyl, sec-butyl, or isobutyl. In certain instances,R^(7b) is isopropyl. In certain instances, R^(7b) is halogen. In certaininstances, R^(7b) is fluoro, chloro, bromo, or iodo. In certaininstances, R^(7b) is fluoro. In certain instances, R^(7b) is cycloalkyl.In certain instances, R^(7b) is cyclopropyl.

In formulae I-V, in certain instances, R^(7b) is substituted alkyl. Incertain instances, R^(7b) is substituted cycloalkyl. In certaininstances, R^(7b) is cyano, acyl, aminoacyl, or nitro.

In formulae I-V, R⁸ can be selected from hydrogen, C₂₋₁₀ alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl. In certain instance, R⁸ is hydrogen, C₂₋₁₀alkyl, halogen, cycloalkyl, or substituted cycloalkyl.

In formulae I-V, in certain instances, R⁸ is hydrogen. In certaininstances, R⁸ is C₂₋₁₀ alkyl. In certain instances, R⁸ is ethyl, propyl,isopropyl, butyl, sec-butyl, or isobutyl. In certain instances, R⁸ isisopropyl. In certain instances, R⁸ is halogen. In certain instances, R⁸is fluoro, chloro, bromo, or iodo. In certain instances, R⁸ is fluoro.In certain instances, R⁸ is cycloalkyl. In certain instances, R⁸ iscyclopropyl. In certain instances, R⁸ is substituted cycloalkyl. Incertain instances, R⁸ is substituted cycloalkyl, wherein the substituentis haloalkyl. In certain instances, R⁸ is substituted cyclopropyl. Incertain instances, R⁸ is substituted cyclopropyl, wherein thesubstituent is haloalkyl. Examples of haloalkyl substituents on acycloalkyl ring include trifluoromethyl, difluoromethyl, andfluoromethyl.

In formulae I-V, in certain instances, R⁸ is substituted alkyl. Incertain instances, R⁸ is cyano, acyl, aminoacyl, or nitro.

In formulae I-IV, R^(7x) can be selected from hydrogen, alkyl,haloalkyl, cycloalkyl, and substituted cycloalkyl. In certain instances,R^(7x) is hydrogen. In certain instances, R^(7x) is alkyl. In certaininstances, R^(7x) is methyl, ethyl, propyl, or isopropyl. In certaininstances, R^(7x) is methyl. In certain instances, R^(7x) is ethyl. Incertain instances, R^(7x) is propyl. In certain instances, R^(7x) isisopropyl. In certain instances, R^(7x) is haloalkyl. In certaininstances, R^(7x) is trifluoromethyl or fluoromethyl. In certaininstances, R^(7x) is trifluoromethyl. In certain instances, R^(7x) isfluoromethyl. In certain instances, R^(7x) is cycloalkyl. In certaininstances, R^(7x) is substituted cycloalkyl. In certain instances,R^(7x) is cyclopropyl.

In formula I:

at least one of R^(6a), R^(6b), R^(7b), and R⁸ is not hydrogen;

if R⁸ is fluoro, then R^(7b) is not hydrogen;

if R^(7b) is cyclopropyl, then at least one of R^(6a), R^(6b), R⁸, andR^(7x) is not hydrogen; and

if R⁸ is cyclopropyl, then at least one of R^(6a), R^(6b), R^(7b), andR^(7x) is not hydrogen.

In formula II, at least one of R^(6a) and R^(6b) is not hydrogen. Incertain instances, in formulae I and II, at least one of R^(6a) andR^(6b) is halogen. In certain instances, at least one of R^(6a) andR^(6b) is fluoro, chloro, bromo, or iodo. In certain instances, at leastone of R^(6a) and R^(6b) is fluoro. In certain instances of formulae Iand II, one of R^(6a) and R^(6b) is fluoro and the other is hydrogen.

In certain instances, in formulae I and II, at least one of R^(6a) andR^(6b) is C₂₋₁₀ alkyl. In certain instances, at least one of R^(6a) andR^(6b) is ethyl, propyl, isopropyl, butyl, sec-butyl, or isobutyl. Incertain instances, at least one of R^(6a) and R^(6b) is isopropyl. Incertain instances, at least one of R^(6a) and R^(6b) is cycloalkyl. Incertain instances, at least one of R^(6a) and R^(6b) is cyclopropyl. Incertain instances, at least one of R^(6a) and R^(6b) is substitutedalkyl. In certain instances, at least one of R^(6a) and R^(6b) issubstituted cycloalkyl. In certain instances, at least one of R^(6a) andR^(6b) is cyano, acyl, aminoacyl, or nitro.

In formula III, at least one of R^(6a), R^(6b), R^(7b), and R⁸ ishalogen and at least one of R^(6a), R^(6b), R^(7b), and R⁸ is cycloalkylor C₂₋₁₀ alkyl. In certain instances, in formulae I and III, at leastone of R^(6a), R^(6b), R^(7b), and R⁸ is halogen and at least one ofR^(6a), R^(6b), R^(7b), and R⁸ is cycloalkyl. In certain instances, atleast one of R^(6a), R^(6b), R^(7b), and R⁸ is halogen and at least oneof R^(6a), R^(6b), R^(7b), and R⁸ is C₂₋₁₀ alkyl. In certain instancesof formula III, at least one of R^(6a) and R^(6b) is fluoro and theother is hydrogen.

In certain instances, in formulae I and III, at least one of R^(6a),R^(6b), R^(7b), and R⁸ is fluoro and at least one of R^(6a), R^(6b),R^(7b), and R⁸ is cycloalkyl. In certain instances, at least one ofR^(6a), R^(6b), R^(7b), and R⁸ is fluoro and at least one of R^(6a),R^(6b), R^(7b), and R⁸ is cyclopropyl. In certain instances, at leastone of R^(6a), R^(6b), R^(7b), and R⁸ is fluoro and at least one ofR^(6a), R^(6b), R^(7b), and R⁸ is C₂₋₁₀ alkyl. In certain instances, atleast one of R^(6a), R^(6b), R^(7b), and R⁸ is fluoro and at least oneof R^(6a), R^(6b), R^(7b), and R⁸ is ethyl, propyl, isopropyl, butyl,sec-butyl, or isobutyl. In certain instances, at least one of R^(6a),R^(6b), R^(7b), and R⁸ is fluoro and at least one of R^(6a), R^(6b),R^(7b), and R⁸ is isopropyl.

In certain instances, in formulae I and III, at least one of R^(6a),R^(6b), R^(7b), and R⁸ is halogen and at least one of R^(6a), R^(6b),R^(7b), and R⁸ is cyclopropyl. In certain instances, at least one ofR^(6a), R^(6b), R^(7b), and R⁸ is halogen and at least one of R^(6a),R^(6b), R^(7b), and R⁸ is ethyl, propyl, isopropyl, butyl, sec-butyl, orisobutyl. In certain instances, at least one of R^(6a), R^(6b), R^(7b),and R⁸ is halogen and at least one of R^(6a), R^(6b), R^(7b), and R⁸ isisopropyl.

In formula IV, at least one of R^(6a), R^(6b), R^(7b), and R⁸ is C₂₋₁₀alkyl. In certain instances, in formulae I and IV, at least one ofR^(6a), R^(6b), R^(7b), and R⁸ is ethyl, propyl, isopropyl, butyl,sec-butyl, or isobutyl. In certain instances, at least one of R^(6a),R^(6b), R^(7b), and R⁸ is isopropyl.

Particular compounds of interest are illustrated in the following table.

TABLE 1

cmpd R¹ R^(a)/R^(b) R^(c)/R^(c) Y R⁵ R^(6a) R^(6b) R^(7b) R⁸ R^(7x) I-1—H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

—H I-2 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —CN —H —F —H

—H I-3 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —CONH₂ —H —F —H

—H I-4 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —CN —H —H —F

—H I-5 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —H —F

—H I-6 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —CN —H —H

—F —H I-7 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —H

—F —H I-8 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —CN —H —F —H

—H I-9 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —H —H

—H I-10 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —CONH₂ —H —H —H

—H I-11 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —CN —H —H —H

—H I-12 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

—H I-13 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H —H —H I-14 —CH₃ —CH₃/—CH₃—CH₃/—CH₃ —H —F —H —F —H —H —H I-15 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —H—H

—CF₃ I-16 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

I-17 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

I-18 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

—CH₃ I-19 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

—CF₃ I-20 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

—CH₂F I-21 —H —CH₃/—CH₃ —CH₃/—CH₃ —H —F —H —F —H

—H

Particular compounds of interest, and salts or solvates or stereoisomersthereof, include:

-   I-1:    N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-2:    2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-3:    2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylic    acid amide;-   I-4:    2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-5:    N2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-6:    2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-7:    N2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-8:    2-(2-Fluoro-4-isopropyl-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-9:    5-Fluoro-N2-(4-isopropyl-3-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-10:    2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylic    acid amide;-   I-11:    2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-12:    N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-13:    5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-14:    5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;    and-   I-15:    N2-[4-Cyclopropyl-3-(5-trifluoromethyl-tetrazol-1-yl)-phenyl]-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;

or a solvate, prodrug, or a pharmaceutically acceptable salt thereof.

Particular compounds of interest, and salts or solvates or stereoisomersthereof, include:

-   I-16:    N2-(4-cyclopropyl-2-fluoro-5-(5-isopropyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;-   I-17:    N2-(4-cyclopropyl-5-(5-cyclopropyl-1H-tetrazol-1-yl)-2-fluorophenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;-   I-18:    N2-(4-cyclopropyl-2-fluoro-5-(5-methyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;-   I-19:    N2-(4-cyclopropyl-2-fluoro-5-(5-(trifluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;-   I-20:    N2-(4-cyclopropyl-2-fluoro-5-(5-(fluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;    and-   I-21:    Trans-5-fluoro-N2-(2-fluoro-5-(1H-tetrazol-1-yl)-4-(2-(trifluoromethyl)cyclopropyl)phenyl)-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;    or a solvate, prodrug, or a pharmaceutically acceptable salt    thereof.

Particular compounds of interest, and salts or solvates or stereoisomersthereof, include:

-   I-1:    N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-2:    2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-3:    2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylic    acid amide;-   I-4:    2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-5:    N2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-6:    2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-7:    N2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-8:    2-(2-Fluoro-4-isopropyl-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-9:    5-Fluoro-N2-(4-isopropyl-3-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-10:    2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylic    acid amide;-   I-11:    2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;-   I-12:    N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-13:    5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-14:    5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-15:    N2-[4-Cyclopropyl-3-(5-trifluoromethyl-tetrazol-1-yl)-phenyl]-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;-   I-16:    N2-(4-cyclopropyl-2-fluoro-5-(5-isopropyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;-   I-17:    N2-(4-cyclopropyl-5-(5-cyclopropyl-1H-tetrazol-1-yl)-2-fluorophenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;    and-   I-18:    N2-(4-cyclopropyl-2-fluoro-5-(5-methyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;-   I-19:    N2-(4-cyclopropyl-2-fluoro-5-(5-(trifluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;-   I-20:    N2-(4-cyclopropyl-2-fluoro-5-(5-(fluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;    and-   I-21:    Trans-5-fluoro-N2-(2-fluoro-5-(1H-tetrazol-1-yl)-4-(2-(trifluoromethyl)cyclopropyl)phenyl)-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;

or a solvate, prodrug, or a pharmaceutically acceptable salt thereof.

The compounds described also include isotopically labeled compoundswhere one or more atoms have an atomic mass different from the atomicmass conventionally found in nature. Examples of isotopes that may beincorporated into the compounds disclosed herein include, but are notlimited to, ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, etc. Thus, thedisclosed compounds may be enriched in one or more of these isotopesrelative to the natural abundance of such isotope. By way of example,deuterium (²H) has a natural abundance of about 0.015%. Accordingly, forapproximately every 6,500 hydrogen atoms occurring in nature, there isone deuterium atom. Specifically contemplated herein are compoundsenriched in deuterium at one or more positions. Thus, deuteriumcontaining compounds of the disclosure have deuterium at one or morepositions (as the case may be) in an abundance of greater than 0.015%.

Compounds may exist in unsolvated forms as well as solvated forms,including hydrated forms. In general, compounds may be hydrated orsolvated. Certain compounds may exist in multiple crystalline oramorphous forms. In general, all physical forms are equivalent for theuses contemplated herein and are intended to be within the scope of thepresent disclosure.

The present disclosure also provides pharmaceutical compositionscomprising a pharmaceutically acceptable carrier and a therapeuticallyeffective amount of a compound of Formulae I-V or a pharmaceuticallyacceptable salt or solvate or stereoisomer thereof.

A disclosed compound can be administered alone, as the sole activepharmaceutical agent, or in combination with one or more additionalcompounds of Formulae I-V or in conjunction with other agents. Whenadministered as a combination, the therapeutic agents can be formulatedas separate compositions that are administered simultaneously or atdifferent times, or the therapeutic agents can be administered togetheras a single composition combining two or more therapeutic agents. Thus,the pharmaceutical compositions disclosed herein containing a compoundof Formulae I-V optionally contain other therapeutic agents.Accordingly, certain embodiments are directed to such pharmaceuticalcomposition, wherein the composition further comprises a therapeuticallyeffective amount of an agent selected as is known to those of skill inthe art.

The subject compounds can inhibit a protein kinase C activity.Accordingly, the compounds are useful for treating a disease or disorderthat is mediated through the activity of a PKC activity in a subject.Also, the compounds are useful for treating a disease or disorder thatis associated with the activation of T-cells in a subject.

The present disclosure provides a method of treating an inflammatorydisease in a subject, the method comprising administering to the subjectwith a compound of Formulae I-V or a salt or solvate or stereoisomerthereof.

The present disclosure also provides a method of treating an autoimmunedisease in a subject, the method comprising administering to the subjectwith a compound of Formulae I-V or a salt or solvate or stereoisomerthereof.

The present disclosure also provides a method of treating an oculardisease or disorder involving inflammatory and/or neovascular events.

The present disclosure also provides a method of treating diseases orconditions of interest including, but are not limited to,atherosclerosis, vascular occlusion due to vascular injury, angioplasty,restenosis, obesity, syndrome X, impaired glucose tolerance, polycysticovary syndrome, hypertension, heart failure, chronic obstructivepulmonary disease, CNS diseases, Alzheimer disease, amyotrophic lateralsclerosis, bipolar disease, cancer, infectious disease, AIDS, septicshock, adult respiratory distress syndrome, ischemia/reperfusion injury,myocardial infarction, stroke, gut ischemia, renal failure, hemorrhageshock, and traumatic shock, and traumatic brain injury.

The present disclosure also provides a method of treating diseases orconditions of interest including, but are not limited to, T-cellmediated acute or chronic inflammatory diseases or disorders orautoimmune diseases, rheumatoid arthritis, osteoarthritis, systemiclupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis,myasthenia gravis, diabetes type I or II and the disorders associatedtherewith, transplant rejection, graft versus host disease, respiratorydiseases, asthma, inflammatory lung injury, inflammatory liver injury,inflammatory glomerular injury, cutaneous manifestations ofimmunologically-mediated disorders or illnesses, inflammatory andhyperproliferative skin diseases, psoriasis, atopic dermatitis, allergiccontact dermatitis, irritant contact dermatitis and further eczematousdermatitises, seborrhoeic dermatitis, inflammatory eye diseases,Sjoegren's syndrome, keratoconjunctivitis, uveitis, inflammatory boweldisease, Crohn's disease or ulcerative colitis, Guillain-Barre syndrome,and allergies.

The subject compounds can be used for treating a cell proliferativedisorder. The present disclosure also provides a method of treatingdiseases or conditions of interest including, but are not limited to,hematopoietic neoplasm, lymphoid neoplasm, T cell neoplasm, Tlymphoblastic leukemia, B cell neoplasm, B-lymphoblastic leukemia,Burkitt's lymphoma, myeloid neoplasm, myeloproferative disease, chronicmyelogenous leukemia (CML), myelodysplastic disease, chronicmyelomonocytic leukemia, myelodysplastic syndrome, and acute myeloidleukemia.

Since subject compounds possess PKC inhibitory properties, suchcompounds are also useful as research tools. Accordingly, the disclosurealso provides for a method for using a compound of Formulae I-V or asalt or solvate or stereoisomer thereof as a research tool for studyinga biological system or sample, or for discovering new chemical compoundshaving PKC inhibitory properties.

The embodiments are also directed to processes and novel intermediatesuseful for preparing compounds of Formulae I-V or a salt or solvate orstereoisomer thereof.

In one embodiment, the above process further comprises the step offorming a salt of a compound of Formulae I-V. Embodiments are directedto the other processes described herein; and to the product prepared byany of the processes described herein.

The embodiments are also directed to a compound of Formulae I-V or asalt or solvate or stereoisomer thereof, for use in therapy or as amedicament.

Additionally, the embodiments are directed to the use of a compound ofFormulae I-V or a salt or solvate or stereoisomer thereof, for themanufacture of a medicament; especially for the manufacture of amedicament for the inhibition of protein kinase C (PKC) activity. Theembodiments are also directed to the use of a compound of Formulae I-Vor a salt or solvate or stereoisomer thereof for the manufacture of amedicament for the treatment of a disease or disorder mediated orsustained through the activity of PKC activity. The embodiments are alsodirected to the use of a compound of Formulae I-V or a salt or solvateor stereoisomer thereof for the manufacture of a medicament for thetreatment of a disease or disorder associated with the activation ofT-cells. Diseases or conditions of interest include, but are not limitedto, an inflammatory disease, an immunological disorder, an autoimmunedisease, an ocular disease or disorder involving inflammatory and/orneovascular events, organ and bone marrow transplant rejection, acute orchronic inflammation, allergies, contact dermatitis, psoriasis,rheumatoid arthritis, multiple sclerosis, type I diabetes, type IIdiabetes, inflammatory bowel disease, Guillain-Barre syndrome, Crohn'sdisease, ulcerative colitis, graft versus host disease, and lupuserythematosus.

The embodiments are also directed to the use of a compound of FormulaeI-V or a salt or solvate or stereoisomer thereof for the manufacture ofa medicament for the treatment of a cell proliferative disorder.Diseases or conditions of interest include, but are not limited to,hematopoietic neoplasm, lymphoid neoplasm, T cell neoplasm, Tlymphoblastic leukemia, B cell neoplasm, B-lymphoblastic leukemia,Burkitt's lymphoma, myeloid neoplasm, myeloproferative disease, chronicmyelogenous leukemia (CML), myelodysplastic disease, chronicmyelomonocytic leukemia, myelodysplastic syndrome, acute myeloidleukemia.

General Synthetic Procedures

Many general references providing commonly known chemical syntheticschemes and conditions useful for synthesizing the disclosed compoundsare available (see, e.g., Smith and March, March's Advanced OrganicChemistry: Reactions, Mechanisms, and Structure, Fifth Edition,Wiley-Interscience, 2001; or Vogel, A Textbook of Practical OrganicChemistry, Including Qualitative Organic Analysis, Fourth Edition, NewYork: Longman, 1978).

Compounds as described herein can be purified by any of the means knownin the art, including chromatographic means, such as HPLC, preparativethin layer chromatography, flash column chromatography and ion exchangechromatography. Any suitable stationary phase can be used, includingnormal and reversed phases as well as ionic resins. Most typically thedisclosed compounds are purified via silica gel and/or aluminachromatography. See, e.g., Introduction to Modern Liquid Chromatography,2nd Edition, ed. L. R. Snyder and J. J. Kirkland, John Wiley and Sons,1979; and Thin Layer Chromatography, ed E. Stahl, Springer-Verlag, NewYork, 1969.

During any of the processes for preparation of the subject compounds, itmay be necessary and/or desirable to protect sensitive or reactivegroups on any of the molecules concerned. This may be achieved by meansof conventional protecting groups as described in standard works, suchas J. F. W. McOmie, “Protective Groups in Organic Chemistry”, PlenumPress, London and New York 1973, in T. W. Greene and P. G. M. Wuts,“Protective Groups in Organic Synthesis”, Third edition, Wiley, New York1999, in “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer),Academic Press, London and New York 1981, in “Methoden der organischenChemie”, Houben-Weyl, 4^(th) edition, Vol. 15/1, Georg Thieme Verlag,Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, “Aminosauren, Peptide,Proteine”, Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982,and/or in Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide andDerivate”, Georg Thieme Verlag, Stuttgart 1974. The protecting groupsmay be removed at a convenient subsequent stage using methods known fromthe art.

The subject compounds can be synthesized via a variety of differentsynthetic routes using commercially available starting materials and/orstarting materials prepared by conventional synthetic methods. Suitableexemplary methods that can be routinely adapted to synthesize the2,4-pyrimidinediamine compounds and prodrugs of the invention are foundin U.S. Pat. No. 5,958,935, the disclosure of which is incorporatedherein by reference. Specific examples describing the synthesis ofnumerous 2,4-pyrimidinediamine compounds and prodrugs, as well asintermediates therefore, are described in the U.S. publication No.US2004/0029902A1, the contents of which are incorporated herein byreference. Suitable exemplary methods that can be routinely used and/oradapted to synthesize active 2,4-pyrimidinediamine compounds can also befound in WO 03/063794, U.S. application Ser. No. 10/631,029 filed Jul.29, 2003, WO2004/014382, U.S. publication No. 2005-0234049 A1, andWO005/016893, the disclosures of which are incorporated herein byreference. All of the compounds described herein (including prodrugs)can be prepared by routine adaptation of these methods.

Exemplary synthetic methods for the 2,4-substituted pyrimidinediaminesdescribed herein are described below. Those of skill in the art willalso be able to readily adapt these methods for the synthesis ofspecific 2,4-substituted pyrimidinediamines as described herein.

A variety of exemplary synthetic routes that can be used to synthesizethe 2,4-pyrimidinediamine compounds of the invention are described inschemes below. These methods can be routinely adapted to synthesize the2,4-pyrimidinediamine compounds and prodrugs described herein.

Synthesis of Compounds

In a certain embodiment, the compounds can be synthesized fromsubstituted or unsubstituted uracils as illustrated in Scheme 1, below:

In Scheme 1, R¹, R^(a), R^(b), R^(c), R^(d), R⁵, R^(6a), R^(6b), R^(7b),R^(7x), R⁸ are as set forth hereinbefore.

According to Scheme 1, uracil A-1 is dihalogenated at the 2- and4-positions using a standard dehydrating-halogenating agent such asPOCl₃ (phosphorus oxychloride) (or other standard halogenating agent)under standard conditions to yield 2,4 dichloropyrimidine A-2. Dependingupon the substituents in pyrimidinediamine A-2, the chloride at the C4position is more reactive towards nucleophiles than the chloride at theC2 position. This differential reactivity can be exploited by firstreacting 2,4 dichloropyrimidine A-2 with one equivalent of amine A-3,yielding 4N-substituted-2-chloro-4-pyrimidineamine A-4, followed byamine A-5 to yield a 2,4-pyrimidinediamine derivative A-6.

Typically, the C4 halide is more reactive towards nucleophiles, asillustrated in the scheme. However, as will be recognized by skilledartisans, the identity of the substituent may alter this reactivity. Forexample, when the substituent is trifluoromethyl, a 50:50 mixture of4N-substituted-4-pyrimidineamine A-4 and the corresponding2N-substituted-2-pyrimidineamine is obtained. The regioselectivity ofthe reaction can also be controlled by adjusting the solvent and othersynthetic conditions (such as temperature), as is well-known in the art.

In a certain embodiment, to couple compounds with an electrophilicleaving group, such as halides or pseudohalides, and compounds with anamino group, nucleophilic aromatic substitution can be used. Forexample, a halogen substituent on Compound A-2 and the amino group onCompound A-3 can react. Also for example, a halogen substituent onCompound A-4 and the amino group on Compound A-5 can react. Conditionsfor nucleophilic aromatic substitution include the compounds reacting ina polar aprotic solvent or polar protic solvent. Suitable solventsinclude alcohols (such as isopropanol, methanol, ethanol), formic acid,dimethylsulfoxide, dimethylformamide, dioxane, and tetrahydrofuran. Thereaction can be run at room temperature or can be heated.

In a certain embodiment, to couple compounds with an electrophilicleaving group, such as halides or pseudohalides, and aryl compounds withan amino group, a coupling reaction, such as a Buchwald couplingreaction, can be used. The Buchwald coupling reaction involvespalladium-catalyzed synthesis of aryl amines. Starting materials arearyl halides or pseudohalides (for example, triflates) and primary orsecondary amines. Such reaction can be performed using a variety ofmethods well known in the art and specific examples can be had byreference to the Examples hereunder described.

The reactions depicted in Scheme 1 may proceed more quickly when thereaction mixtures are heated via microwave. When heating in thisfashion, the following conditions can be used: heat to 175° C. inethanol for 5-20 min. in a Smith Reactor (Personal Chemistry, Uppsala,Sweden) in a sealed tube (at 20 bar pressure).

A specific embodiment of Scheme 1 utilizing 5-fluorouracil (Aldrich#32,937-1) as a starting material is illustrated in Scheme 2, below.

In Scheme 2, R¹, R^(a), R^(b), R^(c), R^(d), R^(6a), R^(6b), R^(7b),R^(7x), R⁸ are as set forth hereinbefore.

Asymmetric 2N,4N-disubstituted-5-fluoro-2,4-pyrimidinediamine A-10 canbe obtained by reacting 2,4-dichloro-5-fluoropyrimidine A-8 with oneequivalent of amine A-3 (to yield2-chloro-N4-substituted-5-fluoro-4-pyrimidineamine A-9) followed by oneor more equivalents of amine A-5.

Specific embodiment of Scheme 1 to form cyano derivatives is illustratedin Scheme 3, below.

In Scheme 3, R¹, R^(a), R^(b), R^(c), R^(d), R^(6a), R^(6b), R^(7b),R^(7x), R⁸ are as set forth hereinbefore.

Asymmetric 2N,4N-disubstituted-5-cyano-2,4-pyrimidinediamine A-15 can beobtained by reacting 2,4-dichloro-5-carbamoylpyrimidine A-12 with oneequivalent of amine A-3 (to yield2-chloro-N4-substituted-5-carbamoyl-4-pyrimidineamine A-13). The amidegroup of Compound A-13 is converted to a cyano group to yield CompoundA-14, followed by reaction with one or more equivalents of amine A-5.Conversion of the amide group to the cyano group can be accomplishedwith dehydration, such as with use of Burgess reagent or trifluoroaceticanhydride.

Uracil Starting Materials and Intermediates

The uracil A-1, A-7, and A-11 starting materials can be purchased fromcommercial sources or prepared using standard techniques of organicchemistry. Commercially available uracils that can be used as startingmaterials in the schemes disclosed herein include, by way of example andnot limitation, uracil (Aldrich #13,078-8; CAS Registry 66-22-8); 5bromouracil (Aldrich #85,247-3; CAS Registry 51-20-7; 5 fluorouracil(Aldrich #85,847-1; CAS Registry 51-21-8); 5 iodouracil (Aldrich#85,785-8; CAS Registry 696-07-1); 5 nitrouracil (Aldrich #85,276-7; CASRegistry 611-08-5); 5 (trifluoromethyl)-uracil (Aldrich #22,327-1; CASRegistry 54-20-6). Additional 5-substituted uracils are available fromGeneral Intermediates of Canada, Inc., Edmonton, Calif. and/orInterchim, Cedex, France, or can be prepared using standard techniques.Myriad textbook references teaching suitable synthetic methods areprovided infra.

Amino Starting Materials and Intermediates

Amines, such as A-3 and A-5 can be purchased from commercial sources or,alternatively, can be synthesized utilizing standard techniques. Forexample, suitable amines can be synthesized from nitro precursors usingstandard chemistry. See also Vogel, 1989, Practical Organic Chemistry,Addison Wesley Longman, Ltd. and John Wiley & Sons, Inc.

Tetrazole Intermediates

Compound A-5 with an N-linked tetrazole in Schemes 1-3 was prepared asillustrated in Scheme 4 and may be incorporated into the presentcompounds according to the procedure illustrated in Scheme 4.

In Scheme 4, R^(6a), R^(6b), R^(7b), R⁸, and R^(7x) are as previouslydefined.

To prepare Compound A-5, Compound A-16 was reacted to form tetrazoleCompound A-17 by treatment with sodium azide and trimethyl orthoformateor triethyl orthoformate. The reaction is general to any appropriateaminophenyl compound. Compound A-17 was reacted to reduce the nitrogroup to form Compound A-5. Compound A-5 can also be prepared accordingto the procedures provided by Satoh et al., Tetrahedron Lett, 1995, 36,1749; Gupta et al. Tetrahedron Lett, 2004, 45, 4113; Su et al. Eur. J.Org. Chem., 2006, 2723; and Potewar et al., Tetrahedron Lett, 2007, 48,172.

Substitution of the ring with substituents can be performed withstandard chemistry. In certain embodiment, substitution of the ring withsubstituents can be performed with nucleophilic aromatic substitution.For example, a halogen substituent can be replaced with anothersubstituent with nucleophilic aromatic substitution. In certainembodiment, substitution of the ring with substituents can be performedwith a metal catalyzed coupling reaction. For example, a halogensubstituent can be replaced with another substituent with utilization ofa metal catalyst. Suitable metal catalyzed reactions to placeappropriate substituents include Suzuki coupling, Stille coupling, andBuchwald coupling.

The nitro group of Compound A-17 was converted to an amino group toproduce Compound A-5. The conversion of the nitro group to an aminogroup can be accomplished by various methods. A suitable method forreduction of nitro group is catalytic hydrogenation which uses hydrogenand a catalyst, such as, but not limited to, palladium on carbon,platinum oxide, Raney nickel, and samarium diiodide.

Compound A-16 can be purchased from commercial sources or prepared usingstandard techniques of organic chemistry. For example, Compound A-16 canbe prepared from the corresponding amine with standard techniques oforganic chemistry. In certain embodiment, Compound A-16 can be preparedfrom the corresponding dinitro compound in which one of the nitro groupsis reduced to an amino group. Myriad textbook references teachingsuitable synthetic methods are provided infra.

Although many of the synthetic schemes discussed above do not illustratethe use of protecting groups, skilled artisans will recognize that insome instances certain substituents may include functional groupsrequiring protection. The exact identity of the protecting group usedwill depend upon, among other things, the identity of the functionalgroup being protected and the reaction conditions used in the particularsynthetic scheme, and will be apparent to those of skill in the art.Guidance for selecting protecting groups, their attachment and removalsuitable for a particular application can be found, for example, inGreene & Wuts, supra.

Prodrugs as described herein can be prepared by routine modification ofthe above-described methods. Alternatively, such prodrugs can beprepared by reacting a suitably protected 2,4-pyrimidinediamine with asuitable progroup. Conditions for carrying out such reactions and fordeprotecting the product to yield prodrugs as described herein arewell-known.

Myriad references teaching methods useful for synthesizing pyrimidinesgenerally, as well as starting materials described in Schemes (I)-(VII),are known in the art. For specific guidance, the reader is referred toBrown, D. J., “The Pyrimidines”, in The Chemistry of HeterocyclicCompounds, Volume 16 (Weissberger, A., Ed.), 1962, IntersciencePublishers, (A Division of John Wiley & Sons), New York (“Brown I”);Brown, D. J., “The Pyrimidines”, in The Chemistry of HeterocyclicCompounds, Volume 16, Supplement I (Weissberger, A. and Taylor, E. C.,Ed.), 1970, Wiley-Interscience, (A Division of John Wiley & Sons), NewYork (Brown II”); Brown, D. J., “The Pyrimidines”, in The Chemistry ofHeterocyclic Compounds, Volume 16, Supplement II (Weissberger, A. andTaylor, E. C., Ed.), 1985, An Interscience Publication (John Wiley &Sons), New York (“Brown III”); Brown, D. J., “The Pyrimidines” in TheChemistry of Heterocyclic Compounds, Volume 52 (Weissberger, A. andTaylor, E. C., Ed.), 1994, John Wiley & Sons, Inc., New York, pp. 1-1509(Brown IV″); Kenner, G. W. and Todd, A., in Heterocyclic Compounds,Volume 6, (Elderfield, R. C., Ed.), 1957, John Wiley, New York, Chapter7 (pyrimidines); Paquette, L. A., Principles of Modern HeterocyclicChemistry, 1968, W. A. Benjamin, Inc., New York, pp. 1-401 (uracilsynthesis pp. 313, 315; pyrimidinediamine synthesis pp. 313-316; aminopyrimidinediamine synthesis pp. 315); Joule, J. A., Mills, K. and Smith,G. F., Heterocyclic Chemistry, 3rd Edition, 1995, Chapman and Hall,London, UK, pp. 1-516; Vorbrüggen, H. and Ruh-Pohlenz, C., Handbook ofNucleoside Synthesis, John Wiley & Sons, New York, 2001, pp. 1-631(protection of pyrimidines by acylation pp. 90-91; silylation ofpyrimidines pp. 91-93); Joule, J. A., Mills, K. and Smith, G. F.,Heterocyclic Chemistry, 4th Edition, 2000, Blackwell Science, Ltd,Oxford, UK, pp. 1-589; and Comprehensive Organic Synthesis, Volumes 1-9(Trost, B. M. and Fleming, I., Ed.), 1991, Pergamon Press, Oxford, UK.

Pharmaceutical Compositions

The disclosed compounds are useful, at least, for the inhibition of PKCactivity and the treatment of a disease or disorder that is mediatedthrough the activity of a PKC activity. Accordingly, pharmaceuticalcompositions comprising at least one disclosed compound are alsodescribed herein.

A pharmaceutical composition comprising a subject compound may beadministered to a patient alone, or in combination with othersupplementary active agents. The pharmaceutical compositions may bemanufactured using any of a variety of processes, including, withoutlimitation, conventional mixing, dissolving, granulating, dragee-making,levigating, emulsifying, encapsulating, entrapping, and lyophilizing.The pharmaceutical composition can take any of a variety of formsincluding, without limitation, a sterile solution, suspension, emulsion,lyophilisate, tablet, pill, pellet, capsule, powder, syrup, elixir orany other dosage form suitable for administration.

A subject compound may be administered to the host using any convenientmeans capable of resulting in the desired reduction in disease conditionor symptom. Thus, a subject compound can be incorporated into a varietyof formulations for therapeutic administration. More particularly, asubject compound can be formulated into pharmaceutical compositions bycombination with appropriate pharmaceutically acceptable carriers ordiluents, and may be formulated into preparations in solid, semi-solid,liquid or gaseous forms, such as tablets, capsules, powders, granules,ointments, solutions, suppositories, injections, inhalants and aerosols.

Formulations for pharmaceutical compositions are well known in the art.For example, Remington's Pharmaceutical Sciences, by E. W. Martin, MackPublishing Co., Easton, Pa., 19th Edition, 1995, describes exemplaryformulations (and components thereof) suitable for pharmaceuticaldelivery of disclosed compounds. Pharmaceutical compositions comprisingat least one of the subject compounds can be formulated for use in humanor veterinary medicine. Particular formulations of a disclosedpharmaceutical composition may depend, for example, on the mode ofadministration and/or on the location of the infection to be treated. Insome embodiments, formulations include a pharmaceutically acceptablecarrier in addition to at least one active ingredient, such as a subjectcompound. In other embodiments, other medicinal or pharmaceuticalagents, for example, with similar, related or complementary effects onthe affliction being treated can also be included as active ingredientsin a pharmaceutical composition.

Pharmaceutically acceptable carriers useful for the disclosed methodsand compositions are conventional in the art. The nature of apharmaceutical carrier will depend on the particular mode ofadministration being employed. For example, parenteral formulationsusually comprise injectable fluids that include pharmaceutically andphysiologically acceptable fluids such as water, physiological saline,balanced salt solutions, aqueous dextrose, glycerol or the like as avehicle. For solid compositions (e.g., powder, pill, tablet, or capsuleforms), conventional non-toxic solid carriers can include, for example,pharmaceutical grades of mannitol, lactose, starch, or magnesiumstearate. In addition to biologically neutral carriers, pharmaceuticalcompositions to be administered can optionally contain minor amounts ofnon-toxic auxiliary substances (e.g., excipients), such as wetting oremulsifying agents, preservatives, and pH buffering agents and the like;for example, sodium acetate or sorbitan monolaurate. Other non-limitingexcipients include, nonionic solubilizers, such as cremophor, orproteins, such as human serum albumin or plasma preparations.

Some examples of materials which can serve aspharmaceutically-acceptable carriers include: (1) sugars, such aslactose, glucose and sucrose; (2) starches, such as corn starch andpotato starch; (3) cellulose, and its derivatives, such as sodiumcarboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4)powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients,such as cocoa butter and suppository waxes; (9) oils, such as peanutoil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil andsoybean oil; (10) glycols, such as propylene glycol; (11) polyols, suchas glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters,such as ethyl oleate and ethyl laurate; (13) agar; (14) bufferingagents, such as magnesium hydroxide and aluminum hydroxide; (15) alginicacid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer'ssolution; (19) ethyl alcohol; (20) pH buffered solutions; (21)polyesters, polycarbonates and/or polyanhydrides; and (22) othernon-toxic compatible substances employed in pharmaceutical formulations.

The disclosed pharmaceutical compositions may be formulated as apharmaceutically acceptable salt of a disclosed compound.Pharmaceutically acceptable salts are non-toxic salts of a free baseform of a compound that possesses the desired pharmacological activityof the free base. These salts may be derived from inorganic or organicacids. Non-limiting examples of suitable inorganic acids arehydrochloric acid, nitric acid, hydrobromic acid, sulfuric acid,hydroiodic acid, and phosphoric acid. Non-limiting examples of suitableorganic acids are acetic acid, propionic acid, glycolic acid, lacticacid, pyruvic acid, malonic acid, succinic acid, malic acid, maleicacid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamicacid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,p-toluenesulfonic acid, methyl sulfonic acid, salicylic acid, formicacid, trichloroacetic acid, trifluoroacetic acid, gluconic acid,asparagic acid, aspartic acid, benzenesulfonic acid, p-toluenesulfonicacid, naphthalenesulfonic acid, and the like. Lists of other suitablepharmaceutically acceptable salts are found in Remington'sPharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton,Pa., 1985. A pharmaceutically acceptable salt may also serve to adjustthe osmotic pressure of the composition.

A subject compound can be used alone or in combination with appropriateadditives to make tablets, powders, granules or capsules, for example,with conventional additives, such as lactose, mannitol, corn starch orpotato starch; with binders, such as crystalline cellulose, cellulosederivatives, acacia, corn starch or gelatins; with disintegrators, suchas corn starch, potato starch or sodium carboxymethylcellulose; withlubricants, such as talc or magnesium stearate; and if desired, withdiluents, buffering agents, moistening agents, preservatives andflavoring agents. Such preparations can be used for oral administration.

A subject compound can be formulated into preparations for injection bydissolving, suspending or emulsifying them in an aqueous or nonaqueoussolvent, such as vegetable or other similar oils, synthetic aliphaticacid glycerides, esters of higher aliphatic acids or propylene glycol;and if desired, with conventional additives such as solubilizers,isotonic agents, suspending agents, emulsifying agents, stabilizers andpreservatives. The preparation may also be emulsified or the activeingredient encapsulated in liposome vehicles. Formulations suitable forinjection can be administered by an intravitreal, intraocular,intramuscular, subcutaneous, sublingual, or other route ofadministration, e.g., injection into the gum tissue or other oraltissue. Such formulations are also suitable for topical administration.

In some embodiments, a subject compound can be delivered by a continuousdelivery system. The term “continuous delivery system” is usedinterchangeably herein with “controlled delivery system” and encompassescontinuous (e.g., controlled) delivery devices (e.g., pumps) incombination with catheters, injection devices, and the like, a widevariety of which are known in the art.

A subject compound can be utilized in aerosol formulation to beadministered via inhalation. A subject compound can be formulated intopressurized acceptable propellants such as dichlorodifluoromethane,propane, nitrogen and the like.

Furthermore, a subject compound can be made into suppositories by mixingwith a variety of bases such as emulsifying bases or water-solublebases. A subject compound can be administered rectally via asuppository. The suppository can include vehicles such as cocoa butter,carbowaxes and polyethylene glycols, which melt at body temperature, yetare solidified at room temperature.

The term “unit dosage form,” as used herein, refers to physicallydiscrete units suitable as unitary dosages for human and animalsubjects, each unit containing a predetermined quantity of a subjectcompound calculated in an amount sufficient to produce the desiredeffect in association with a pharmaceutically acceptable diluent,carrier or vehicle. The specifications for a subject compound depend onthe particular compound employed and the effect to be achieved, and thepharmacodynamics associated with each compound in the host.

The dosage form of a disclosed pharmaceutical composition will bedetermined by the mode of administration chosen. For example, inaddition to injectable fluids, topical or oral dosage forms may beemployed. Topical preparations may include eye drops, ointments, spraysand the like. Oral formulations may be liquid (e.g., syrups, solutionsor suspensions), or solid (e.g., powders, pills, tablets, or capsules).Methods of preparing such dosage forms are known, or will be apparent,to those skilled in the art.

Certain embodiments of the pharmaceutical compositions comprising asubject compound may be formulated in unit dosage form suitable forindividual administration of precise dosages. The amount of activeingredient administered will depend on the subject being treated, theseverity of the affliction, and the manner of administration, and isknown to those skilled in the art. Within these bounds, the formulationto be administered will contain a quantity of the extracts or compoundsdisclosed herein in an amount effective to achieve the desired effect inthe subject being treated.

Each therapeutic compound can independently be in any dosage form, suchas those described herein, and can also be administered in various ways,as described herein. For example, the compounds may be formulatedtogether, in a single dosage unit (that is, combined together in oneform such as capsule, tablet, powder, or liquid, etc.) as a combinationproduct. Alternatively, when not formulated together in a single dosageunit, an individual subject compound may be administered at the sametime as another therapeutic compound or sequentially, in any orderthereof.

Methods of Administration

The subject compounds can inhibit a protein kinase C activity.Accordingly, the subject compounds are useful for treating a disease ordisorder that is mediated through the activity of a PKC activity in asubject. Accordingly, the subject compounds are useful for treating adisease or disorder that is associated with the activation of T-cells ina subject.

The route of administration will be selected according to a variety offactors including, but not necessarily limited to, the condition to betreated, the formulation and/or device used, the patient to be treated,and the like. Routes of administration useful in the disclosed methodsinclude but are not limited to oral and parenteral routes, such asintravenous (iv), intraperitoneal (ip), rectal, topical, ophthalmic,nasal, and transdermal. Formulations for these dosage forms aredescribed herein.

An effective amount of a subject compound will depend, at least, on theparticular method of use, the subject being treated, the severity of theaffliction, and the manner of administration of the therapeuticcomposition. A “therapeutically effective amount” of a composition is aquantity of a specified compound sufficient to achieve a desired effectin a subject (host) being treated. For example, this may be the amountof a subject compound necessary to prevent, inhibit, reduce or relieve adisease or disorder that is mediated through the activity of a PKCactivity in a subject. Ideally, a therapeutically effective amount of acompound is an amount sufficient to prevent, inhibit, reduce or relievea disease or disorder that is mediated through the activity of a PKCactivity in a subject without causing a substantial cytotoxic effect onhost cells.

Therapeutically effective doses (or growth inhibitory amounts) of asubject compound or pharmaceutical composition can be determined by oneof skill in the art, with a goal of achieving local (e.g., tissue)concentrations that are at least as high as the IC₅₀ of an applicablecompound disclosed herein.

An example of a dosage range is from about 0.1 to about 200 mg/kg bodyweight orally in single or divided doses. In particular examples, adosage range is from about 1.0 to about 100 mg/kg body weight orally insingle or divided doses, including from about 1.0 to about 50 mg/kg bodyweight, from about 1.0 to about 25 mg/kg body weight, from about 1.0 toabout 10 mg/kg body weight (assuming an average body weight ofapproximately 70 kg; values adjusted accordingly for persons weighingmore or less than average). For oral administration, the compositionsare, for example, provided in the form of a tablet containing from about50 to about 1000 mg of the active ingredient, particularly about 75 mg,about 100 mg, about 200 mg, about 400 mg, about 500 mg, about 600 mg,about 750 mg, or about 1000 mg of the active ingredient for thesymptomatic adjustment of the dosage to the subject being treated. Inone exemplary oral dosage regimen, a tablet containing from about 500 mgto about 1000 mg active ingredient is administered once (e.g., a loadingdose) followed by administration of ½ dosage tablets (e.g., from about250 to about 500 mg) each 6 to 24 hours for at least 3 days.

The specific dose level and frequency of dosage for any particularsubject may be varied and will depend upon a variety of factors,including the activity of the subject compound, the metabolic stabilityand length of action of that compound, the age, body weight, generalhealth, sex and diet of the subject, mode and time of administration,rate of excretion, drug combination, and severity of the condition ofthe host undergoing therapy.

The present disclosure also contemplates combinations of one or moredisclosed compounds with one or more other agents or therapies useful inthe treatment of a disease or disorder. In certain instances, thedisease or disorder is mediated through the activity of a PKC activityin a subject. In certain instances, the disease or disorder is cellproliferative disorder. For example, one or more disclosed compounds maybe administered in combination with effective doses of other medicinaland pharmaceutical agents, or in combination other non-medicinaltherapies, such as hormone or radiation therapy. The term“administration in combination with” refers to both concurrent andsequential administration of the active agents.

Protein Kinase C

Protein Kinase C

PKC is a family of enzymes that function as serine/threonine kinases.The isoenzymes of PKC differ in their tissue distribution, enzymaticselectivity, requirement for Ca²⁺, and regulation. PKCs play animportant role in cell-cell signaling, gene expression and in thecontrol of cell differentiation and growth.

The subject compound can be a selective inhibitor of PKC, e.g. aninhibitor selective for PKC over one or more other protein kinases, e.g.over one or more tyrosine kinases, for instance, over one or morenon-receptor or receptor tyrosine kinases, e.g. over one or more of PKA,PKB, Abl Met, Src, Ins-R, Flt-3, JAK-2, KDR and/or Ret proteins. Theselective PKC inhibitors may optionally be selective over one or moreserine/threonine kinases, e.g. one or more serine/threonine kinaseswhich do not belong to the CDK family. The subject compounds can exhibita selectivity of at least 10 fold, or 20 fold, or 100 fold for the PKCover one or more other protein kinases, e.g. over one or more tyrosinekinases, e.g. over Flt-3, JAK-2, KDR and/or Ret proteins, or over one ormore serine/threonine kinases which do not belong to the CDK family.

The selectivity of a selective inhibitor of PKC over other proteinkinases may be calculated as the ratio of the IC₅₀ measured for PKC inan assay described herein over the IC₅₀ determined for another kinase.In a certain instance, there is provided a PKC inhibitor for which theratio of the IC₅₀ value as determined in an Allogeneic Mixed LymphocyteReaction (MLR) assay to the IC₅₀ value as determined in a BM assay ishigher than 5, 10, 20, or 30. MLR and BM assays can be done according toknown methods, e.g. mouse or human MLR and BM assays, such as disclosedherein.

The disclosure provides an inhibitor of PKC, which can be anisozyme-selective PKC inhibitor, wherein the subject compound possessesselectivity for the isoforms θ and α of PKC over one or more of theother PKC isoforms. In a certain instance, the subject compoundpossesses selectivity for the isoform θ of PKC over one or more of theother PKC isoforms. In a certain instance, the subject compoundpossesses selectivity for the isoform α of PKC over one or more of theother PKC isoforms. In one embodiment, the disclosed compounds exhibitselectivity for PKC θ and PKC β over at least one PKC isoform.

A subject compound can show a selectivity of at least 10 fold, or 20fold, or 100 fold for the isoforms θ or α of PKC over one or more of theother PKC isoforms. Selectivity for the isoforms θ or α of PKC over oneor more of the other PKC isoforms can be measured by comparing the IC₅₀of the subject compound for the isoforms θ or α of PKC to the IC₅₀ ofthe subject compound for the other PKC isoforms. In a certain instance,the selectivity can be determined by calculating the ratio of IC₅₀ ofthe subject compound for the other isoforms of PKC to the IC₅₀ of thesubject compound for θ or α isoforms of PKC. In certain examples subjectcompounds exhibit a selectivity for PKC θ, α or both over another PKCisoform of at least about 2-fold, such as from about 3-fold to about300-fold, from about 10-fold to about 100-fold or from about 5-fold to50-fold. IC₅₀ values are obtained, for example, according to PKC assaysdescribed herein. The subject compounds can show an IC₅₀ value for theisoforms θ or α of PKC of 1 μM or less, such as less than about 300 nM,such as from about 1 nM to about 250 nM, less than 100 nM or even lessthan 10 nM in the assays disclosed herein.

The subject compounds can show a selectivity of the isoforms θ or μ ofPKC over other isoforms of PKC, as well as a selectivity over one ormore of the other protein kinases, e.g. over one or more tyrosinekinases, or over one or more serine/threonine kinases which do notbelong to the CDK-family, e.g. over one or more of PKA, PKB, Abl, Met,Src, Ins-it, Flt-3, JAK-2, KDR and Ret proteins, e.g. over one or moreof Flt-3, JAK-2, KDR and Ret proteins.

Certain isozymes of PKC have been implicated in the mechanisms ofvarious disease states, including, but not necessarily limited to, thefollowing: cancer (PKC α, βI, βII, and δ); cardiac hypertrophy and heartfailure (PKC βI and PKC βII) nociception (PKC γ and ε); ischemiaincluding myocardial infarction (PKC ε and δ); immune response,particularly T-cell mediated (PKC θ and α); and fibroblast growth andmemory (PKC δ and ζ). The role of PKC ε is also implicated in painperception. PKC inhibitors can also be used for treating an oculardisease or disorder involving inflammatory and/or neovascular events.

The subject compounds can be used in the treatment of mammalian(especially human) disease states characterized by aberrant, elevatedactivity of a PKC isozyme in a tissue as compared to non-disease tissueof the same origin. PKC isozymes and disease states and/or biologicalfunctions amenable to therapy by inhibition of activity of the PKCisozyme include, but are not necessarily limited to: PKC α(hyperproliferative cellular diseases, such as cancer); PKC βI and PKCβII (cardiac hypertrophy and heart failure); PKC γ (pain management);PKC δ (ischemia, hypoxia (e.g., such as in myocardial infarction and instroke); apoptosis induced by UV irradiation; and aberrant fibroblastgrowth (e.g., as may occur in wound healing)); PKC ε (pain management,myocardial dysfunction); PKC θ (immune system diseases, particularlythose involving T-cell mediated responses); and PKC ζ (memory andfibroblast growth).

PKC Theta

PKC θ is expressed predominantly in lymphoid tissue and skeletal muscle.PKC θ is selectively expressed in T-cells and plays a role in matureT-cell activation. It has been shown that PKC θ is involved in T-cellreceptor (TCR)-mediated T-cell activation but inessential duringTCR-dependent thymocyte development. PKC θ, but not other PKC isoforms,translocates to the site of cell contact between antigen-specificT-cells and antigen presenting cells (APC), where it localizes with theTCR in the central core of the T-cell activation. PKC θ, but not the α,ε, or ζ isoenzymes, can selectively activate a FasL promoter-reportergene and upregulate the mRNA or cell surface expression of endogenousFasL. On the other hand, PKC θ and ε can promote T-cell survival byprotecting the cells from Fas-induced apoptosis, and this protectiveeffect was mediated by promoting p90Rsk-dependent phosphorylation ofBCL-2 family member BAD. Thus, PKC θ appears to play a dual regulatoryrole in T-cell apoptosis.

PKC θ inhibitors can find use in the treatment or prevention ofdisorders or diseases mediated by T lymphocytes, for example, autoimmunedisease such as rheumatoid arthritis, psoriasis and lupus erythematosus,and inflammatory disease such as asthma and inflammatory bowel diseases.

PKC θ is a drug target for immunosuppression in transplantation andautoimmune diseases (Isakov et al. (2002) Annual Review of Immunology,20, 761-794). PCT Publication WO2004/043386 identifies PKC θ as a targetfor treatment of transplant rejection and multiple sclerosis. PKC θ alsoplays a role in inflammatory bowel disease (The Journal of Pharmacologyand Experimental Therapeutics (2005), 313 (3), 962-982), asthma (WO2005062918), and lupus (Current Drug Targets: Inflammation & Allergy(2005), 4 (3), 295-298).

In addition, PKC θ is highly expressed in gastrointestinal stromaltumors (Blay, P. et al. (2004) Clinical Cancer Research, 10, 12, Pt. 1),it has been suggested that PKC θ is a molecular target for treatment ofgastrointestinal cancer (Wiedmann, M. et al. (2005) Current Cancer DrugTargets 5(3), 171).

Experiments induced in PKC θ knock-out mice led to the conclusion thatPKC θ inactivation prevented fat-induced defects in insulin signallingand glucose transport in skeletal muscle (Kim J. et al, 2004, The J. ofClinical Investigation 114 (6), 823). This data indicates PKC θ is atherapeutic target for the treatment of type 2 diabetes, and hence PKC θinhibitors can be useful for treating such disease.

Therapeutic Applications

The subject compounds are useful for treating a disease or disorder thatis mediated through, or exacerbated by, the activity of a PKC in asubject in need of treatment. Also, the compounds are useful fortreating a disease or disorder that is associated with aberrant orotherwise undesirable T cell activation in a subject.

Accordingly, the present disclosure provides methods of treating aninflammatory disease in a subject by administering an effective amountof a subject compound, including a salt or solvate or stereoisomerthereof, so as to treat inflammation. Inflammatory diseases contemplatedfor therapy include acute and chronic inflammation mediated orexacerbated by PKC activity

The present disclosure also provides methods of treating an autoimmunedisease in a subject by administering to the subject an effective amountof a subject compound, including a salt or solvate or stereoisomerthereof, so as to treat the autoimmune disease.

The present disclosure also provides methods of treating an oculardisease or disorder involving inflammatory and/or neovascular events byadministration of a subject compound, including a salt or solvate orstereoisomer thereof, in an effective amount.

Diseases or conditions of interest for treatment according to thepresent disclosure include, but are not limited to, atherosclerosis,vascular occlusion due to vascular injury such as angioplasty,restenosis, obesity, syndrome X, impaired glucose tolerance, polycysticovary syndrome, hypertension, heart failure, chronic obstructivepulmonary disease, CNS diseases such as Alzheimer disease or amyotrophiclateral sclerosis, cancer, infectious diseases such as: AIDS, septicshock or adult respiratory distress syndrome, ischemia/reperfusioninjury, e.g.: myocardial infarction, stroke, gut ischemia, renal failureor hemorrhage shock, and traumatic shock, e.g. traumatic brain injury.

Further diseases or conditions of interest for treatment according tothe present disclosure include, but are not limited to, T-cell mediatedacute or chronic inflammatory diseases or disorders or autoimmunediseases, rheumatoid arthritis, osteoarthritis, systemic lupuserythematosus, Hashimoto's thyroiditis, multiple sclerosis, myastheniagravis, diabetes type I or II and the disorders associated therewith,transplant rejection, graft versus host disease, respiratory diseases,asthma, inflammatory lung injury, inflammatory liver injury,inflammatory glomerular injury, cutaneous manifestations ofimmunologically-mediated disorders or illnesses, inflammatory andhyperproliferative skin diseases (such as psoriasis, atopic dermatitis,allergic contact dermatitis, irritant contact dermatitis and furthereczematous dermatitises, seborrhoeic dermatitis), inflammatory eyediseases (such as Sjoegren's syndrome, keratoconjunctivitis, uveitis)inflammatory bowel disease, Crohn's disease or ulcerative colitis,Guillain-Barre syndrome, and allergies.

The subject compounds can also be used for preventing or treating ordelaying ocular diseases and disorders involving inflammation and/orneovascularization. Ocular diseases or disorders involving inflammatoryand/or neovascular events include, but are not limited to, maculardegeneration (AMD), diabetic ocular diseases or disorders, uveitis,optic neuritis, ocular edema, ocular angiogenesis, ischemic retinopathy,anterior ischemic optic neuropathy, optic neuropathy and neuritis,macular edema, cystoid macular edema (CME), retinal disease or disorder,such as retinal detachment, retinitis pigmentosa (RP), Stargart'sdisease, Best's vitelliform retinal degeneration, Leber's congenitalamaurosis and other hereditary retinal degenerations, Sorsby's fundusdystrophy, pathologic myopia, retinopathy of prematurity (ROP), Leber'shereditary optic neuropathy, corneal transplantation or refractivecorneal surgery, keratoconjunctivitis, or dry eye.

Generally, cell proliferative disorders treatable with the subjectcompound disclosed herein relate to any disorder characterized byaberrant cell proliferation. These include various tumors and cancers,benign or malignant, metastatic or non-metastatic. Specific propertiesof cancers, such as tissue invasiveness or metastasis, can be targetedusing the methods described herein. Cell proliferative disorders includea variety of cancers, including, among others, breast cancer, ovariancancer, renal cancer, gastrointestinal cancer, kidney cancer, bladdercancer, pancreatic cancer, lung squamous carcinoma, and adenocarcinoma.

In some embodiments, the cell proliferative disorder treated is ahematopoietic neoplasm, which is aberrant growth of cells of thehematopoietic system. Hematopoietic malignancies can have its origins inpluripotent stem cells, multipotent progenitor cells, oligopotentcommitted progenitor cells, precursor cells, and terminallydifferentiated cells involved in hematopoiesis. Some hematologicalmalignancies are believed to arise from hematopoietic stem cells, whichhave the ability for self renewal. For instance, cells capable ofdeveloping specific subtypes of acute myeloid leukemia (AML) upontransplantation display the cell surface markers of hematopoietic stemcells, implicating hematopoietic stem cells as the source of leukemiccells. Blast cells that do not have a cell marker characteristic ofhematopoietic stem cells appear to be incapable of establishing tumorsupon transplantation (Blaire et al., 1997, Blood 89:3104-3112). The stemcell origin of certain hematological malignancies also finds support inthe observation that specific chromosomal abnormalities associated withparticular types of leukemia can be found in normal cells ofhematopoietic lineage as well as leukemic blast cells. For instance, thereciprocal translocation t(9q34;22q11) associated with approximately 95%of chronic myelogenous leukemia appears to be present in cells of themyeloid, erythroid, and lymphoid lineage, suggesting that thechromosomal aberration originates in hematopoietic stem cells. Asubgroup of cells in certain types of CML displays the cell markerphenotype of hematopoietic stem cells.

Although hematopoietic neoplasms often originate from stem cells,committed progenitor cells or more terminally differentiated cells of adevelopmental lineage can also be the source of some leukemias. Forexample, forced expression of the fusion protein Bcr/Abl (associatedwith chronic myelogenous leukemia) in common myeloid progenitor orgranulocyte/macrophage progenitor cells produces a leukemic-likecondition. Moreover, some chromosomal aberrations associated withsubtypes of leukemia are not found in the cell population with a markerphenotype of hematopoietic stem cells, but are found in a cellpopulation displaying markers of a more differentiated state of thehematopoietic pathway (Turhan et al., 1995, Blood 85:2154-2161). Thus,while committed progenitor cells and other differentiated cells may haveonly a limited potential for cell division, leukemic cells may haveacquired the ability to grow unregulated, in some instances mimickingthe self-renewal characteristics of hematopoietic stem cells (Passegueet al., Proc. Natl. Acad. Sci. USA, 2003, 100:11842-9).

In some embodiments, the hematopoietic neoplasm treated is a lymphoidneoplasm, where the abnormal cells are derived from and/or display thecharacteristic phenotype of cells of the lymphoid lineage. Lymphoidneoplasms can be subdivided into B-cell neoplasms, T and NK-cellneoplasms, and Hodgkin's lymphoma. B-cell neoplasms can be furthersubdivided into precursor B-cell neoplasm and mature/peripheral B-cellneoplasm. Exemplary B-cell neoplasms are precursor B-lymphoblasticleukemia/lymphoma (precursor B-cell acute lymphoblastic leukemia) whileexemplary mature/peripheral B-cell neoplasms are B-cell chroniclymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocyticleukemia, lymphoplasmacytic lymphoma, splenic marginal zone B-celllymphoma, hairy cell leukemia, plasma cell myeloma/plasmacytoma,extranodal marginal zone B-cell lymphoma of MALT type, nodal marginalzone B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, diffuselarge B-cell lymphoma, mediastinal large B-cell lymphoma, primaryeffusion lymphoma, and Burkitt's lymphoma/Burkitt cell leukemia. T-celland Nk-cell neoplasms are further subdivided into precursor T-cellneoplasm and mature (peripheral) T-cell neoplasms. Exemplary precursorT-cell neoplasm is precursor T-lymphoblastic lymphoma/leukemia(precursor T-cell acute lymphoblastic leukemia) while exemplary mature(peripheral) T-cell neoplasms are T-cell prolymphocytic leukemia T-cellgranular lymphocytic leukemia, aggressive NK-cell leukemia, adult T-celllymphoma/leukemia (HTLV-1), extranodal NK/T-cell lymphoma, nasal type,enteropathy-type T-cell lymphoma, hepatosplenic gamma-delta T-celllymphoma, subcutaneous panniculitis-like T-cell lymphoma, Mycosisfungoides/Sezary syndrome, Anaplastic large-cell lymphoma, T/null cell,primary cutaneous type, Peripheral T-cell lymphoma, not otherwisecharacterized, Angioimmunoblastic T-cell lymphoma, Anaplastic large-celllymphoma, T/null cell, primary systemic type. The third member oflymphoid neoplasms is Hodgkin's lymphoma, also referred to as Hodgkin'sdisease. Exemplary diagnosis of this class that can be treated with thecompounds include, among others, nodular lymphocyte-predominantHodgkin's lymphoma, and various classical forms of Hodgkin's disease,exemplary members of which are Nodular sclerosis Hodgkin's lymphoma(grades 1 and 2), Lymphocyte-rich classical Hodgkin's lymphoma, Mixedcellularity Hodgkin's lymphoma, and Lymphocyte depletion Hodgkin'slymphoma.

In some embodiments, the hematopoietic neoplasm treated is a myeloidneoplasm. This group comprises a large class of cell proliferativedisorders involving or displaying the characteristic phenotype of thecells of the myeloid lineage. Myeloid neoplasms can be subdivided intomyeloproliferative diseases, myelodysplastic/myeloproliferativediseases, myelodysplastic syndromes, and acute myeloid leukemias.Exemplary myeloproliferative diseases are chronic myelogenous leukemia(e.g., Philadelphia chromosome positive (t(9;22)(qq34;q11)), chronicneutrophilic leukemia, chronic eosinophilic leukemialhypereosinophilicsyndrome, chronic idiopathic myelofibrosis, polycythemia vera, andessential thrombocythemia. Exemplary myelodysplastic/myeloproliferativediseases are chronic myelomonocytic leukemia, atypical chronicmyelogenous leukemia, and juvenile myelomonocytic leukemia. Exemplarymyelodysplastic syndromes are refractory anemia, with ringedsideroblasts and without ringed sideroblasts, refractory cytopenia(myelodysplastic syndrome) with multilineage dysplasia, refractoryanemia (myelodysplastic syndrome) with excess blasts, 5q-syndrome, andmyelodysplastic syndrome with t(9;12)(q22;p12) (TEL-Syk fusion; see,e.g., Kuno et al., 2001, Blood 97:1050).

In some embodiments, the composition can be used to treat acute myeloidleukemias (AML), which represent a large class of myeloid neoplasmshaving its own subdivision of disorders. These subdivisions include,among others, AMLs with recurrent cytogenetic translocations, AML withmultilineage dysplasia, and other AML not otherwise categorized.Exemplary AMLs with recurrent cytogenetic translocations include, amongothers, AML with t(8;21)(q22;q22), AML1(CBF-alpha)/ETO, Acutepromyelocytic leukemia (AML with t(15;17)(q22;q11-12) and variants,PML/RAR-alpha), AML with abnormal bone marrow eosinophils(inv(16)(p13q22) or t(16;16)(p13;q11), CBFb/MYH11X), and AML with 11q23(MLL) abnormalities. Exemplary AML with multilineage dysplasia are thosethat are associated with or without prior myelodysplastic syndrome.Other acute myeloid leukemias not classified within any definable groupinclude, AML minimally differentiated, AML without maturation, AML withmaturation, Acute myelomonocytic leukemia, Acute monocytic leukemia,Acute erythroid leukemia, Acute megakaryocytic leukemia, Acutebasophilic leukemia, and Acute panmyelosis with myelofibrosis.

In other aspects, cell proliferative disorders comprise virally mediatedtumors. These can arise from infection of cells by an oncogenic virusthat has the capability of transforming a normal cell into a tumor cell.Because rates of viral infection far exceed the number of actualincidence of cell transformation, viral mediated transformationgenerally act together with other cellular factors to generate atransformed tumor cell. Thus, a virally mediated tumor does not requirethe virus to be the sole causative agent of the cell proliferativedisorder, but rather that the viral infection or persistent presence ofvirus is associated with the generation of the tumor. Generally, tumorswhere the causative agent is a virus typically has continual expressionof a limited number of viral genes and that viral these oncogenes,expressed as part of the viral infection or through persistence of thevirus, disrupts the normal cellular gene expression and signaltransduction pathways. Without being bound by theory, viral oncogenesinvolved in cell transformation appear to disrupt four main cellularprocesses: cell surface receptors that interact with growth factors andextracellular matrix, transmembrane signaling networks, cytosolicelements such as soluble proteins and second messengers, and nuclearproteins including DNA binding proteins and factors which functiondirectly and indirectly in gene regulation and replication.

Characterization of Functional Properties

The following are exemplary assays useful in characterizing activitiesof a compound of interest.

A. In Vitro

1. Protein Kinase C assay

The inhibition of PKC activity was measured by monitoring the productionof phosphorylated peptide by fluorescence polarization at differentconcentrations of the inhibitor. Reactions were carried out in 96-wellplate format with a total volume of 20 μL containing 20 mM HEPES, pH7.4, 5 mM MgCl₂, 0.2 mM CaCl₂, 1 mM DTT, 0.02% Brij-35, 0.1 mg/mLphosphatidylserine, 0.02 mg/mL dioleoyl-sn-glycerol and 5 μM each of ATPand the peptide substrate. Compounds were first diluted serially in DMSOand then transferred to a solution containing the above concentrationsof HEPES, MgCl₂, CaCl₂, DTT, and Brij-35 to yield 5× compound solutionsin 2% DMSO, which was then added to the reaction solution. Reactionswere initiated by the addition of PKC at a typical concentration asdescribed in the table below, and then allowed to incubate at roomtemperature for 20 minutes. At the end of this time, a combination ofquench (EDTA) and detection (peptide tracer and antibody) reagents wasadded using the protocol of Invitrogen P2748 (Carlsbad, Calif.), aProtein Kinase C Fluorescence polarization Assay Kit. After a 30 minuteperiod of incubation, the amount of phosphorylated peptide generated wasmeasured by fluorescence polarization (Ex=485 nm, Em=535 nm) using aTecan Polarian instrument (Switzerland).

TABLE 2 enzyme Peptide Enzyme concen- substrate SEQ ID source trationPKC RFARKGSLRQKNV Seq ID Upstate Bio- 40 theta No. 1 technologies, ng/mLTemecula, CA, cat. #14-444 PKC RFARKGSLRQKNV Seq ID Upstate Bio- 50epsilon No. 1 technologies, ng/mL Temecula, CA, cat. #14-518

2. IL-2 ELISA, Human Primary T Cell, Anti-CD3+CD28+ Assays

Human Primary T Cell Isolation and Culture:

Human primary T cells were prepared as follows. Fresh PBMC's from AllCells (Cat # PB002) were re-suspended in RPMI (RPMI-1640 withL-Glutamine; Mediatech, Inc., Herndon Va., cat. #10-040-CM) with 10% FBSand seeded into flasks and incubated at 37° C. for 2 hours to allow themonocytes to adhere. The non-adherent cells were then centrifuged andre-suspended in RPMI medium containing 40 U/ml IL2 and seeded into aflask pre-coated with 1 μg/ml aCD3 and 5 ug/ml aCD28 (Anti-Human CD3, BDPharmingen Catalog #555336, Anti-Human CD28, Beckman Coulter Catalog#1M1376). The cells were stimulated for 3-4 days, then transferred to afresh flask and maintained in RPMI (RPMI-1640 with L-Glutamine;Mediatech, Inc., Herndon Va., cat. #10-040-CM) with 10% FBS and 40 U/mLIL-2.

Primary T Cell Stimulation and IL2 ELISA:

Human primary T cells (100,000 cells per well) were pre-incubated withor without test compound in RPMI-1640 with L-Glutamine and 10% FBS for 1hr at 37° C. Cells were then stimulated by transferring them toround-bottom 96-well plates pre-coated with 1 μg/ml αCD3 and 5 μg/mlαCD28. For counter assay, cells were instead stimulated by adding 8×stock solutions of PMA and ionomycin in RPMI-1640 with L-Glutamine and10% FBS (for final concentrations of 0.5 ng/ml PMA and 0.1 μM ionomycin,both from Calbiochem). Cells were incubated at 37° C. for 24 hoursbefore 100 μL supernatants were harvested for quantification of IL-2 byELISA using Human IL-2 Duoset ELISA Kit from R and D Systems, Cat. #DY202E.

3. Protein Kinase C assay

The subject compounds can be tested for activity on different PKCisoforms according to the following method. Assay is performed in awhite with clear bottom 384-well microtiterplate with non-bindingsurface. The reaction mixture (25 μl) contains 1.5 μM of atridecapeptide acceptor substrate that mimics the pseudo substratesequence of PKC α with the Ala→Ser replacement, 10 μM ³³P-ATP, 10 mMMg(NO₃)₂, 0.2 mM CaCl₂, PKG at a protein concentration varying from 25to 400 ng/ml (depending on the isotype used), lipid vesicles (containing30 mol % phosphatidylserine, 5 mol % DAG and 65 mol %phosphatidylcholine) at a final lipid concentration of 0.5 mM, in 20 mMTris-HCl buffer pH 7.4+0.1% BSA. Incubation is performed for 60 minutesat room temperature. Reaction is stopped by adding 50 μl of stop mix(100 mM EDTA, 200 μM ATP, 0.1% Triton X-100, 0.375 mg/wellstreptavidin-coated SPA beads in phosphate buffered saline w/o Ca, Mg.After 10 minutes incubation at room temperature, the suspension is spundown for 10 minutes at 300 g. Incorporated radioactivity is measured ina Trilux counter for 1 minute. IC₅₀ measurement is performed on aroutine basis by incubating a serial dilution of inhibitor atconcentrations ranging between 1-1000 μM. IC₅₀ values are calculatedfrom the graph by curve fitting with XL Fit® software.

4. Protein Kinase C α Assay

Human recombinant PKC α is obtained from Oxford Biomedical Research andis used under the assay conditions as described under Section A.1 above.

5. Protein Kinase C β1 Assay

Human recombinant PKC β1 is obtained from Oxford Biomedical Research andis used under the assay conditions as described under Section A.1 above.

6. Protein Kinase C δ Assay

Human recombinant PKC δ is obtained from Oxford Biomedical Research andis used under the assay conditions as described under Section A.1 above.

7. Protein Kinase C ε Assay

Human recombinant PKC ε is obtained from Oxford Biomedical Research andis used under the assay conditions as described under Section A.1 above.

8. Protein Kinase C η Assay

Human recombinant PKC η is obtained from PanVera and is used under theassay conditions as described under Section A.1 above.

9. Protein Kinase C θ Assay

Human recombinant PKC θ is used under the assay conditions as describedabove.

10. CD28 Costimulation Assay

The assay is performed with Jurkat cells transfected with a humaninterleukin-2 promoter/reporter gene construct as described by Baumann Get al. in Transplant. Proc. 1992; 24:43-8, the β-galactosidase reportergene being replaced by the luciferase gene (de Wet J., et al., Mol.Cell. Biol. 1987, 7(2), 725-737). Cells are stimulated by solidphase-coupled antibodies or phorbol myristate acetate (PMA) and the Ca⁺⁺ionophore ionomycin as follows. For antibody-mediated stimulationMicrolite TM1 microtiter plates (Dynatech) are coated with 3 μg/ml goatanti-mouse IgG Fc antibodies (Jackson) in 55 μl phosphate-bufferedsaline (PBS) per well for three hours at room temperature. Plates areblocked after removing the antibodies by incubation with 2% bovine serumalbumin (BSA) in PBS (300 μl per well) for 2 hours at room temperature.After washing three times with 300 μl PBS per well, 10 ng/ml anti-T cellreceptor antibodies (WT31, Becton & Dickinson) and 300 ng/ml anti-CD28antibodies (15E8) in 50 μl 2% BSA/PBS are added as stimulatingantibodies and incubated overnight at 4° C. Finally the plates arewashed three times with 300 μl PBS per well. Seven three-fold serialdilutions of test compounds in duplicates in assay medium (RPMI 1640/10%fetal calf serum (FCS) containing 50 μM 2-mercaptoethanol, 100 units/mlpenicillin and 100 μg/ml streptomycin) are prepared in separate plates,mixed with transfected Jurkat cells (clone K22 290_H23) and incubatedfor 30 minutes at 37° C. in 5% CO₂ 100 μl of this mixture containing1×10⁵ cells are then transferred to the antibody-coated assay plates. Inparallel 100 μl are incubated with 40 ng/ml PMA and 2 μM ionomycin.After incubation for 5.5 hours at 37° C. in 5% CO₂, the level ofluciferase is determined by bioluminescence measurement. The plates arecentrifuged for 10 minutes at 500 g and the supernatant is removed byflicking. Lysis buffer containing 25 mM Tris-phosphate, pH 7.8, 2 mMDTT, 2 mM 1,2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid, 10% (v/v)glycerol and 1% (v/v) Triton X-100 is added (20 μl per well). The platesare incubated at room temperature for 10 minutes under constant shaking.Luciferase activity is assessed with a bioluminescence reader(Labsystem, Helsinki, Finland) after automatic addition of 50 μl perwell luciferase reaction buffer containing 20 mM Tricine, 1.07 mM(MgCO₃)₄Mg(OH)₂×5H₂O, 2.67 mM MgSO₄, 0.1 mM EDTA, 33.3 mM DTT, 270 μMcoenzyme A, 470 μM luciferin (Chemie Brunschwig AG), 530 μM ATP, pH 7.8.Lag time is 0.5 seconds, total measuring time is 1 or 2 seconds. Lowcontrol values are light units from anti-T cell receptor- orPMA-stimulated cells, high controls are from anti-T cellreceptor/anti-CD28- or PMA/ionomycin-stimulated cells without any testsample. Low controls are subtracted from all values. The inhibitionobtained in the presence of a test compound is calculated as percentinhibition of the high control. The concentration of test compoundsresulting in 50% inhibition (IC₅₀) is determined from the dose-responsecurves.

11. Bone Marrow Proliferation (BM) Assay

Bone marrow cells from CBA mice (2.5×104 cells per well in flat bottomtissue culture microtiter plates) are incubated in 100 μl RPMI mediumcontaining 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin (GibcoBRL, Basel, Switzerland), 50 UM 2-mercaptoethanol (Fluke, Buchs,Switzerland), WEHI-3 conditioned medium (7.5% v/v) and L929 conditionedmedium (3% v/v) as a source of growth factors and serially dilutedcompounds. Seven three-fold dilution steps in duplicates per testcompound are performed. After four days of incubation 1 μCi ³H-thymidineis added. Cells are harvested after an additional five-hour incubationperiod, and incorporated ³H-thymidine is determined according tostandard procedures. Conditioned media are prepared as follows. WEHI-3cells 1 (ATCC TIB68) and L929 cells (ATCC CCL 1) are grown in RPMImedium until confluence for 4 days and one week, respectively. Cells areharvested, resuspended in the same culture flasks in medium C containing1% FCS (Schreier and Tees 1981) for WEHI-3 cells and RPMI medium forL929 cells and incubated for 2 days (WEHI-3) or one week (L929). Thesupernatant is collected, filtered through 0.2 μm and stored in aliquotsat −80° C. Cultures without test compounds and without WEHI-3 and L929supernatants are used as low control values. Low control values aresubtracted from all values. High controls without any sample are takenas 100% proliferation. Percent inhibition by the samples is calculatedand the concentrations required for 50% inhibition (IC₅₀ values) aredetermined.

12. Allogeneic Mixed Lymphocyte Reaction (MLR)

The two-way MLR is performed according to standard procedures (J.Immunol. Methods, 1973, 2, 279 and Meo T. et al., Immunological Methods,New York, Academic Press, 1979, 227-39). Briefly, spleen cells from CBAand BALB/c mice (1.6×10⁵ cells from each strain per well in flat bottomtissue culture microtiter plates, 3.2×10⁵ in total) are incubated inRPMI medium containing 10% FCS, 100 U/ml penicillin, 100 μg/mlstreptomycin (Gibco BRL, Basel, Switzerland), 50 μM 2-mercaptoethanol(Fluka, Buchs, Switzerland) and serially diluted compounds. Seventhree-fold dilution steps in duplicates per test compound are performed.After four days of incubation 1 μCi ³H-thymidine is added. Cells areharvested after an additional five-hour incubation period, andincorporated ³H-thymidine is determined according to standardprocedures. Background values (low control) of the MLR are theproliferation of BALB/c cells alone. Low controls are subtracted fromall values. High controls without any sample are taken as 100%proliferation. Percent inhibition by the samples is calculated, and theconcentrations required for 50% inhibition (IC₅₀ values) are determined.

B. In Vivo Heart Transplantation Model

The strain combination used: Male Lewis (RT¹ haplotype) and BN (RT¹haplotype). The animals are anaesthetised using inhalationalisofluorane. Following heparinisation of the donor rat through theabdominal inferior vena cava with simultaneous exsanguination via theaorta, the chest is opened and the heart rapidly cooled. The aorta isligated and divided distal to the first branch and the brachiocephalictrunk is divided at the first bifurcation. The left pulmonary artery isligated and divided and the right side divided but left open. All othervessels are dissected free, ligated and divided and the donor heart isremoved into iced saline.

The recipient is prepared by dissection and cross-clamping of theinfra-renal abdominal aorta and vena cava. The graft is implanted withend-to-side anastomoses, using 1010 monofilament suture, between thedonor brachiocephalic trunk and the recipient aorta and the donor rightpulmonary artery to the recipient vena cava. The clamps are removed, thegraft tethered retroabdominally, the abdominal contents washed with warmsaline and the animal is closed and allowed to recover under a heatinglamp. Graft survival is monitored by daily palpation of the beatingdonor heart through the abdominal wall. Rejection is considered to becomplete when-heart beat stops. Graft survival is monitored in animalstreated with compounds.

Graft v. Host Model

Spleen cells (2×10⁷) from Wistar/F rats are injected subcutaneously intothe right hind footpad of (Wistar/F×Fischer 344)F₁ hybrid rats. The leftfootpad is left untreated. The animals are treated with the testcompounds on 4 consecutive days (0-3). The popliteal lymph nodes areremoved on day 7, and the weight differences between two correspondinglymph nodes are determined. The results are expressed as the inhibitionof lymph node enlargement (given in percent) comparing the lymph nodeweight differences in the experimental groups to the weight differencebetween the corresponding lymph nodes from a group of animals leftuntreated with a test compound. In certain instances the test compoundis a selective PKC inhibitor. For example, disclosed compounds that areparticularly useful for treating graft versus host disease and relateddisorders are selective PKC α and θ inhibitors.

Rat Collagen-Induced Arthritis Model (CIA)

Rheumatoid arthritis (RA) is characterized by chronic joint inflammationeventually leading to irreversible cartilage destruction. IgG-containingIC are abundant in the synovial tissue of patients with RA. While it isstill debated what role these complexes play in the etiology andpathology of the disease, IC communicate with the hematopoetic cells viathe FcγR.

CIA is a widely accepted animal model of RA that results in chronicinflammatory synovitis characterized by pannus formation and jointdegradation. In this model, intradermal immunization with native type IIcollagen, emulsified with incomplete Freund's adjuvant, results in aninflammatory polyarthritis within 10 or 11 days and subsequent jointdestruction in 3 to 4 weeks.

Study Protocol

Syngeneic LOU rats are immunized with native type II collagen on Day 0,and efficacy of a test compound is evaluated in a prevention regimen anda treatment regimen. In the prevention protocol, either vehicle orvarious doses of a test compound are administered via oral gavagestarting on day of immunization (Day 0). In the treatment protocol,after clinical signs of arthritis develop on Day 10, treatment with atest compound is initiated (e.g., 300 mg/kg by oral gavage, qd) andcontinued until sacrifice on Day 28. In both protocols, clinical scoresare obtained daily, and body weights are measured twice weekly. At Day28, radiographic scores are obtained, and serum levels of collagen IIantibody are measured by ELISA.

Determination of Results

By 10 days after immunization, rats can develop clinical CIA, asdetermined by an increase in their arthritis scores. The mean arthriticscore gradually increases in the rats treated with vehicle alone afterDay 10, and by Day 28 the mean clinical score can reach about 6.75. Meanclinical scores in animals treated from the day of immunization (Day 0)with a test compound can be significantly reduced on Days 10-28 comparedwith vehicle controls. In the rats treated with a test compound atdisease onset, there can be a significantly lower arthritis scorebeginning around Day 16, and this difference can be observed until theend of the study on Day 28.

Blinded radiographic scores (scale 0-6) can be obtained on Day 28 of CIAand compared between the animals in the vehicle group, animals in theprevention group, and animals in the treatment group.

The groups administered with a test compound, either prophylactically(at immunization) or after disease onset can preclude the development oferosions and reduced soft tissue swelling. Similarly, the groupsadministered with a test compound can result in reduction of serumanti-collagen II antibody.

Mouse Experimental Autoimmune Encephalomyelitis

The in vivo efficacy of a test compound towards autoimmune diseases canbe demonstrated in a mouse model of experimental autoimmuneencephalomyelitis (EAE).

Model Description

EAE is a useful model for multiple sclerosis (MS), an autoimmune diseaseof the CNS that is caused by immune-cell infiltration of the CNS whitematter. Inflammation and subsequent destruction of myelin causeprogressive paralysis. Like the human disease, EAE is associated withperipheral activation of T cells autoreactive with myelin proteins, suchas myelin basic protein (MBP), proteolipid protein (PLP), or myelinoligodendrocyte protein (MOG). Activated neuroantigen-specific T cellspass the blood-brain barrier, leading to focal mononuclear cellinfiltration and demyelination. EAE can be induced in susceptible mousestrains by immunization with myelin-specific proteins in combinationwith adjuvant. In the SJL mouse model used in these studies, hind limband tail paralysis is apparent by Day 10 after immunization, the peak ofdisease severity can be observed between Days 10 and 14, and a cycle ofpartial spontaneous remission followed by relapse can be observed up toDay 35. The results can demonstrate the potential of the test compoundto suppress disease severity and prevent relapse of disease symptomsthat may be the result of FcγR-mediated cytokine release from immunecells.

Study Protocol

In the SJL murine model of EAE, each mouse is sensitized with PLP/CFA.(150 μg PLP139-151 with 200 μg CFA in 0.05 ml of homogenate on foursites of hind flank for a total of 0.2 ml emulsion is used to induceEAE). In a suppression protocol, either vehicle or various doses of atest compound are administered via oral gavage starting on the day ofimmunization (Day 0). In a treatment protocol, at onset of disease,animals are separated to achieve groups with a similar mean clinicalscore at onset and administered vehicle or various dose frequencies oftest compounds via oral gavage. In both protocols, clinical scores aremonitored daily, and body weights are measured twice weekly.

Determination of Results

By 10 days after PLP immunization, SJL mice can develop clinical EAE, asevidenced by an increase in their mean clinical scores. The paralyticscore can gradually increase in the animals treated with vehicle onlyfrom the day of immunization (Day 0), and by Day 14 the mean score canreach a peak of about 5.1. At disease peak (e.g., Day 14), the meanclinical score in animals treated with either daily or twice daily canbe significantly reduced. By Day 16, animals can exhibit a partialremission of mean clinical severity, which is a characteristic of theSJL model. The lower clinical scores in animals treated twice daily witha test compound can remain significant throughout the experiment untilthe animals are sacrificed on Day 30. These lower scores throughout thetreatment period are reflected in the significantly lower cumulativedisease index (CDI) and increase in cumulative weight index (CWI).

SJL mice treated with a test compound at disease onset (e.g., Day 11)can show a significant decrease in CDI. Further, there can be a decreasein the number of relapses in animals treated with a test compoundcompared with the number of relapses in animals treated with vehicle.

Research Applications

Since subject compounds can inhibit a PKC activity, such compounds arealso useful as research tools. The present disclosure also provides amethod for using subject compounds as a research tool for studying abiological system or sample, or for discovering new chemical compoundsthat can inhibit a PKC activity.

The disclosure provides for a method of studying a biological system orsample known to comprise PKC, the method comprising: (a) contacting thebiological sample with a compound of Formulae I-V or a salt or solvateor stereoisomer thereof; and (b) determining the inhibiting effectscaused by the compound on the biological sample.

Any suitable biological sample having PKC can be employed in suchstudies which can be conducted either in vitro or in vivo.Representative biological samples suitable for such studies include, butare not limited to, cells, cellular extracts, plasma membranes, tissuesamples, isolated organs, mammals (such as mice, rats, guinea pigs,rabbits, dogs, pigs, humans, and so forth), and the like, with mammalsbeing of particular interest.

When used as a research tool, a biological sample comprising PKC istypically contacted with a PKC activity-inhibiting amount of a subjectcompound. After the biological sample is exposed to the compound, theeffects of inhibition of a PKC activity are determined usingconventional procedures and equipment, such as the assays disclosedherein. Exposure encompasses contacting the biological sample with thecompound or administering the compound to a subject. The determiningstep can involve measuring a response (a quantitative analysis) or caninvolve making an observation (a qualitative analysis). Measuring aresponse involves, for example, determining the effects of the compoundon the biological sample using conventional procedures and equipment,such as radioligand binding assays and measuring ligand-mediated changesin functional assays. The assay results can be used to determine theactivity level as well as the amount of compound necessary to achievethe desired result, that is, a PKC activity-inhibiting amount.

Additionally, subject compounds can be used as research tools forevaluating other chemical compounds, and thus are also useful inscreening assays to discover, for example, new compounds having a PKCinhibiting activity. In this manner, a subject compound can be used as astandard in an assay to allow comparison of the results obtained with atest compound and with the subject compounds to identify those testcompounds that have about equal or superior activity, if any. Forexample, IC₅₀ data for a test compound or a group of test compounds iscompared to the IC₅₀ data for a subject compound to identify those testcompounds that have the desired properties, for example, test compoundshaving an IC₅₀ about equal or superior to a subject compound, if any.

This aspect includes, as separate embodiments, both the generation ofcomparison data (using the appropriate assays) and the analysis of testdata to identify test compounds of interest. Thus, a test compound canbe evaluated in a biological assay, by a method comprising the steps of:(a) conducting a biological assay with a test compound to provide afirst assay value; (b) conducting the biological assay with a subjectcompound to provide a second assay value; wherein step (a) is conductedeither before, after or concurrently with step (b); and (c) comparingthe first assay value from step (a) with the second assay value fromstep (b). The assays that can be used for generation of comparison dataare disclosed herein, such as the PKC assays.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the embodiments, and are not intended to limit the scope ofwhat the inventors regard as their invention nor are they intended torepresent that the experiments below are all or the only experimentsperformed. Efforts have been made to ensure accuracy with respect tonumbers used (e.g. amounts, temperature, etc.) but some experimentalerrors and deviations should be accounted for. Unless indicatedotherwise, parts are parts by weight, molecular weight is weight averagemolecular weight, temperature is in degrees Celsius, and pressure is ator near atmospheric. Standard abbreviations may be used.

Example 1 Synthesis of2-Chloro-5-Fluoro-N4-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-Pyrimidineamine,HCL Salt

4-Amino-1,2,2,6,6-pentamethylpiperidine (1 g) and2,6-dichloro-5-fluoropyrimidine (1.5 g) were dissolved in methanol (10mL). The reaction solution was stirred at room temperature overnight.The reaction solution was evaporated and crystallized from ethyl acetateand hexanes to give2-chloro-5-fluoro-N4-(1,2,2,6,6-pentamethylpiperidin-4-yl)-4-pyrimidineamineHCl salt (1.65 g, 93%).

¹H NMR (DMSO-d₆): δ 9.66 (br. s, 1H), 8.32 (d, J=6.9 Hz, 1H), 8.10 (d,J=3.3 Hz, 1H), 4.33 (br. s, 1H), 2.68 (d, J=4.8 Hz, 3H), 2.02 (m, 4H),1.48 (s, 6H), 1.38 (s, 6H).

Example 2

Synthesis of2-Chloro-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)-4-Pyrimidineamine,HCL Salt

2,4-Dichloro-5-fluoropyrimidine (21.7 g) was dissolved in methanol (400mL) and cooled to 0° C. 4-Amino-2,2,6,6-tetramethylpiperidine (19.2 mL)was added dropwise. The resulting mixture was slowly warmed to roomtemperature and stirred overnight. The reaction solution was evaporatedand triturated with ethyl to2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)-4-pyrimidineamine,HCl salt (36.2 g, 93%).

¹H NMR (DMSO-d₆): δ 8.24 (d, 1H), 8.16 (d, 1H), 4.38 (m, 1H), 1.92 (d,2H), 1.63 (t, 2H), 1.39 (d, 12H); m/z=287 (M+H)⁺.

Example 3 Synthesis of 5-Carboxyamide-2,4-Dichloropyrimidine

To a 2 L round bottom flask equipped with water condenser and a CaCl₂drying tube, 2,4-dihydroxypyrimidine (25 g, 0.16 mole) was added to PCl₅(117 g, 0.56 mole), and POCl₃ (250 ml, 2.6 mole). The mixture was heatedat 115° C. overnight to give a clear, slightly light yellow solution.The mixture was cooled to room temperature, and was concentrated underreduced pressure to give pale yellowish oil.

To this oil, anhydrous 1,4-dioxane (300 ml) was added and the mixturewas cooled to 0° C. in an ice/water bath. 35 ml of NH₃ in water (28%)was added dropwise to the mixture with stirring, temperature was keptbelow 5° C. The mixture changed from clear to white with precipitateforming, and was stirred for 1 hour at 0° C., reaction was followed byTLC (1:1 Hexanes: Ethyl Acetate). Ethyl acetate (700 ml) and water (500ml) were added to the mixture, the 2 layers were separated. The organiclayer was dried with Na₂SO₄, and filtered. The solution was concentratedunder reduced pressure to give a light yellow solid. This light yellowsolid was sonicated with methylene chloride (200 ml), and filtered togive a pale yellow solid (16 g). This pale yellow solid was dissolvedinto ethyl acetate (1.5 L) and washed with sat. NaHCO₃ (500 ml). Theorganic layer was dried with Na₂SO₄, filtered, and concentrated underreduced pressure to give 13.1 g of product as a white solid (44% yield).

¹H NMR (DMSO-d₆, 300 MHz): δ 8.86 (s, 1H), 8.14 (bs, 1H), 8.02 (bs, 1H).

Example 4 Synthesis of 5-Carboxyamide-2,4-Dichloropyrimidine

Concentrated ammonium hydroxide solution in H₂O (assumed to be 8.5M;14.1 mL; 120 mmol) was added over 15-20 minutes to a stirred solution of2,4-dichloropyrimidine-5-carbonyl chloride (12.5 g; 60 mmol; ManchesterOrganics, Sutton Weaver, England) in CH₂Cl₂ (300 mL) at −15 to −20° C.(internal temperature) [n.b.: a precipitate is formed during theaddition]. After complete addition, the mixture was filtered (the filtercake comprises desired product and an impurity—for purification seelater). H₂O (50 mL) was added to the filtrate, which was partitioned.The organic layer was dried (NaSO₄), filtered and the solvent removedunder vacuum to give the desired product (1.1 g) as a solid. The filtercake from above was triturated with hot (ca. 50° C.) EtOAc (300 mL) andthe mixture filtered—this was repeated another 2 times. The combinedfiltrates from the trituration were concentrated under vacuum to giveanother 9.1 g of desired product. The total yield from the reaction is10.2 g (88%). Data identical to previously reported.

Example 5 Synthesis of5-Carboxyamide-2-Chloro-N4-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-Pyrimidineamine,HCL Salt

5-Carboxyamide-2,4-dichloropyrimidine (7.5 g, 0.04 mole) was dissolvedinto MeOH (300 ml)/H₂O (30 ml). The solution was cooled to 0° C. in aice/water bath, 4-amino-1,2,2,6,6-pentamethylpiperidine (6.65 g, 0.04mole) was added drop wise. The mixture was stirred at 0° C. and letwarmed up to room temperature over a weekend. Solution was concentratedunder reduced pressure to give a light yellow slush. Ethyl acetate (250ml×2) was added and then concentrated under reduced pressure to removethe remaining traces of methanol and water to give a light yellowishsolid. This solid was then sonicated with methylene chloride (100 ml),and filtered using a Buchner funnel, to give 9.5 g of pale yellow solid(75% yield) of the desired product as a HCl salt.

¹H NMR (DMSO d₆, 300 MHz): δ 9.74 (s, 1H), 9.23 (s, 1H), 8.6 (bs, 1H),8.39 (bs, 1H), 7.76 (s, 1H), 4.36 (bs, 1H), 2.68 (s, 3H), 2.14 (d, 2H),1.88 (t, 2H), 1.48 (s, 6H), 1.39 (s, 6H).

Example 6 Synthesis of5-Carboxyamide-2-Chloro-N4-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-PyrimidineamineFree Base

5-Carboxyamide-2,4-dichloropyrimidine (7.5 g, 0.04 mole) was dissolvedinto MeOH (300 ml)/H₂O (30 ml). The solution was cooled to 0° C. in aice/water bath, 4-amino-2,2,6,6-tetramethylpiperidine (6.8 ml, 0.04mole) was added drop wise. The mixture was stirred at 0° C. and letwarmed up to room temperature over 2 days. Solution was concentratedunder reduced pressure to give a light yellow slush. Ethyl acetate (250ml×2) was added and then concentrated under reduced pressure to removethe remaining traces of methanol and water to give a light yellowishsolid. This solid was then sonicated with methylene chloride (100 ml),and filtered using a Buchner funnel, to give a pale yellow solid.

This solid was treated with ethyl acetate (2 L), and sat. NaHCO₃, the 2layers were separated, and the organic layer was dried with Na₂SO₄. Thedrying agent was filtered off and the solution was concentrated underreduced pressure to give a white solid (5 g, 41% yield). More of theproduct can be retrieved from the aqueous layer by back extracting itwith more ethyl acetate.

¹H NMR (DMSO-d₆, 300 MHz): δ 9.14 (d, 1H), 8.54 (s, 1H), 8.18 (bs, 1H),7.68 (s, 1H), 4.30 (bs, 1H), 1.79 (d, 2H), 1.15 (s, 6H), 1.02 (s, 6H);m/z=312.2 (M+H)⁺.

Example 7 Synthesis of5-Cyano-2-Chloro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)-4-Pyrimidineamine

Burgess reagent—methyl (N-triethylammoniumsulfonyl)carbamate—(238 mg;1.0 mmol) was added in one portion to a stirred solution of5-carboxamide-2-chloro-N4-(2,2,6,6,-tetramethylpiperidin-4-yl)-4-pyrimidineamine(156 mg; 0.5 mmol) in 1,2-dichloroethane (3 mL) at room temperature. Themixture was heated to 70° C. and stirred for 2 hours. After allowing tocool to room temperature the mixture was diluted with further1,2-dichloroethane (20 mL) and H₂O (30 mL). The aqueous and organiclayers were partitioned and the organic layer washed with sat. NaHCO₃then dried (Na₂SO₄), filtered and the solvent removed under vacuum toleave a crude viscous oil (NMR shows this to be product and unreactedBurgess reagent). The crude oil was purified by column chromatography onsilica gel using EtOAc:MeOH (9:1) then EtOAc:MeOH:Et₃N (90:8:2) aseluent to give the desired product (75 mg, 51%) as a foam solid. Thissolid was usually used directly in the next step.

Example 8 Synthesis of5-Cyano-2-Chloro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)-4-Pyrimidineamine

Trifluoroacetic anhydride (9.4 mL; 67.3 mmol) was added dropwise over30-45 minutes to a stirred solution of5-carboxyamide-2-chloro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)-4-pyrimidineamine(2.1 g, 6.7 mmol) and Et₃N (11.3 mL; 80.8 mmol) in THF (40 mL) at −78°C. under nitrogen. After complete addition, the mixture was stirred at−78° C. for a further 60 minutes, then a saturated solution of NaHCO₃(30 mL) was added dropwise keeping the internal temperature below −30°C. After complete addition of the NaHCO₃, EtOAc (150 mL) and H₂O (100mL) was added and the mixture was stirred for 10 minutes. Further H₂O(200 mL) was added and the organic and aqueous layers were partitioned.The aqueous layer was extracted with EtOAc (4×150 mL)—untilsubstantially all precipitated material had gone in to solution. Thecombined organic extracts were washed with brine (1×50 mL), dried(Na₂SO₄), filtered and the solvent removed under vacuum to leave a crudesolid with TFAA and Et₃N residues. The solid was triturated with Et₂O(50 mL) and filtered to give the product (2.1 g) as a TFA salt.

Example 9 Formation of Free Base of5-Cyano-2-Chloro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)-4-Pyrimidineamine

The TFA product of5-cyano-2-chloro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)-4-pyrimidineamine(2.1 g) was partitioned between EtOAc (100 mL) and 0.2 M NaOH (50 mL).The organic layer was washed with brine (1×50 mL), dried (Na₂SO₄),filtered and the solvent removed under vacuum to leave the product (1.35g, 68%) as a solid.

¹H NMR (DMSO-d₆, 300 MHz): δ 8.51 (s, 1H), 8.34 (br. s, 1H), 4.42 (t,1H), 1.61 (br. d, 2H), 1.23 (t, 2H), 1.14 (s, 6H), 1.02 (s, 6H);m/z=294.1 (M+H)⁺ for ³⁵C1.

Example 10 Synthesis of5-Cyano-2-Chloro-N4-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-Pyrimidineamine

Trifluoroacetic anhydride (9.35 mL; 67.3 mmol, 10 eq) was added dropwiseover 30-45 min to a stirred solution of5-carboxyamide-2-chloro-N4-(1,2,2,6,6-pentamethylpiperidin-4-yl)-4-pyrimidineaminehydrochloride (2.19 g, 6.73 mmol, 1 eq) and Et₃N (11.26 mL; 80.76 mmol,12 eq) in THF (45 mL) at −78° C. under nitrogen. After completeaddition, the mixture was stirred at −78° C. for a further 60 minutes,then a saturated solution of NaHCO₃ (30 mL) was added dropwise keepingthe internal temperature below −30° C. After complete addition of theNaHCO₃, EtOAc (100 mL) and H₂O (100 mL) was added and the mixture wasstirred for 10 minutes. Further H₂O (100 mL) was added and the organicand aqueous layers were partitioned. The aqueous layer was extractedwith EtOAc (4×100 mL)—until all precipitated material had gone in tosolution. The combined organic extracts were washed with brine (1×50mL), dried (Na₂SO₄), filtered and the solvent removed under vacuum toleave a crude solid with TFAA and Et₃N residues. The crude solid wasdissolved in 100 mL of EtOAc and partitioned with 1 N aq. NaOH (50 mL).The ethyl acetate layer was extracted with 2×50 mL aqueous 1N NaOH. Thecombined organic extracts were washed with brine (1×50 mL), dried(Na₂SO₄), filtered and the solvent removed under vacuum to give lightyellow solid (1.80 g, in 87% yield).

¹H NMR (DMSO-d₆, 300 MHz): δ 8.51 (s, 1H), 8.37 (d, 1H), 4.31 (br. m,1H), 2.15 (s, 3H), 1.47-1.66 (m, 4H), 1.06 (s, 6H), 1.00 (s, 6H);m/z=309 (M+H)⁺.

Example 11 Synthesis of 2-Bromo-4-Fluoro-5-Nitroaniline

2-Bromo-4-fluoroaniline (47.5 g, 250 mmol) was added to a solution ofconcentrated H₂SO₄ (300 mL) keeping the internal temperature below 30°C. The mixture was aged for ca. 30-60 minutes then cooled to −20° C. 90%HNO₃ (35 g) was added dropwise over ca. 60 minutes keeping the internaltemperature between −15 to −20° C. TLC indicated a slight amount ofstarting material, so a further aliquot of 90% HNO₃ (3 g) was added over5 minutes at −15 to −20° C. The cold mixture was then poured on to iceH₂O (ca. 1 L ice+500 mL H₂O) and EtOAc (1 L). The aqueous and organiclayers were partitioned and the organic layer was washed with sat.NaHCO₃ (2×500 mL), dried (Na₂SO₄), filtered and the solvent removedunder vacuum to leave a dark solid (35 g, 60%).

¹H NMR (DMSO-d₆, 300 MHz): δ 8.27 (br. s, 2H), 7.70 (d 1H), 7.47 (d,1H); m/z=275.9 (M+MeCN+H)⁺ for ⁷⁹Br.

Example 12 Synthesis of 2-Cyclopropyl-4-Fluoro-5-Nitroaniline

A mixture of 2-bromo-4-fluoro-5-nitroaniline (12 g, 51 mmol),cyclopropylboronic acid MIDA ester (Aldrich; 20.1 g, 102 mmol), Pd(OAc)₂(1.72 g, 7.7 mmol), Cy₃P (4.3 g, 15.3 mmol) and Cs₂CO₃ (98.8 g, 306mmol) in toluene (120 mL) and H₂O (40 mL) was de-gassed with N₂ for 15minutes. The mixture was then heated at 100° C. (oil bath temperature)overnight (the reaction mixture can also be heated to reflux). Afterallowing to cool to room temperature, the mixture was diluted with EtOAc(200 mL) and H₂O (100 mL) and the mixture filtered through Celite. Thefilter cake was washed with EtOAc (2×100 mL) and the filtratepartitioned. The organic layer was dried (Na₂SO₄), filtered and thesolvent removed under vacuum to leave a crude residue. The residue waspurified by column chromatography on silica gel (residue dry-loaded onto silica gel) using EtOAc/hexanes (1:4 to 3:7) as eluent to give theproduct (8.1 g, 81%) as a dark solid.

¹H NMR (DMSO-d₆, 300 MHz): δ 7.27 (d 1H), 6.84 (d, 1H), 5.52 (br. S,2H), 1.74-1.83 (m, 1H), 0.92-0.98 (m, 2H), 0.62-0.73 (m, 2H); m/z=238.0(M+MeCN+H)⁺.

Example 13 Synthesis of 2-Cyclopropyl-4-Fluoro-5-Nitroaniline UsingPotassium Cyclopropyltrifluoroborate

A mixture of 2-bromo-4-fluoro-5-nitroaniline (13.1 g, 56 mmol),potassium cyclopropyltrifluoroborate (16.5 g, 112 mmol), Pd(OAc)₂ (1.89g, 8.4 mmol), Cy₃P (4.7 g, 16.8 mmol) and Cs₂CO₃ (109.5 g, 336 mmol) intoluene (150 mL) and H₂O (60 mL) was de-gassed with N₂ for 15 minutes.The mixture was then heated at reflux overnight (120° C. oil bathtemperature). After allowing to cool to room temperature, the mixturewas diluted with EtOAc (200 mL) and H₂O (200 mL) and the mixturefiltered through Celite. The filter cake was washed with EtOAc (3×100mL) and the filtrate transferred to a separating funnel. Brine (200 mL)was added and the aqueous and organic layers partitioned. The organiclayer was dried (Na₂SO₄), filtered and the solvent removed under vacuumto leave a crude residue. The residue was purified by columnchromatography on silica gel (residue dry-loaded on to silica gel) usingEtOAc/hexanes (1:9 to 1:4) as eluent to give the product (8.3 g, 76%) asa dark solid. Data same as above.

The reaction in Example 13 was performed with other reaction conditions.For example, the following modifications to the reaction conditions ofExample 13 have been used:

-   -   1) Ratio of potassium cyclopropyltrifluoroborate to        2-bromo-4-fluoro-5-nitroaniline ranging from 1.1 to 1.5;    -   2) Molar percentage of Pd(OAc)₂ ranging from 0.1 to 15;    -   3) Molar percentage of Cy₃P ranging from 0.2 to 30;    -   4) Molar equivalents of Cs₂CO₃ ranging from 2 to 6;    -   5) Use of K₃PO₄ or K₃CO₃ instead of Cs₂CO₃ as a base in molar        equivalents ranging from 2 to 6;    -   6) The volume of solvent ranging being 7 ml for reaction of 500        mg of 2-bromo-4-fluoro-5-nitroaniline;    -   7) The solvent mixture being dioxane/water;    -   8) The reaction temperature ranging from 60° C. to reflux;    -   9) The reaction time ranging from 16 hours to 22 hours.

Example 14 Synthesis of1-(2-Cyclopropyl-4-Fluoro-5-Nitrophenyl)-1H-Tetrazole

N.b.: TMS-N₃ and tetrazole product are potentially explosive. Use ablast shield for this reaction and glassware with no scratches, cracks,etc. Avoid contact with metals, including metal spatulas. Keep theproduct slightly wet with residual solvent from the column.

A mixture of 2-cyclopropyl-4-fluoro-5-nitroaniline (10.9 g, 55.6 mmol),trimethylsilyl azide (14.6 mL, 111.1 mmol), trimethylorthoformate (60.9mL, 556 mmol) in AcOH (110 mL) was heated to 70° C. and stirredovernight and performed behind a blast shield. After allowing thereaction mixture to cool to room temperature, the mixture wasconcentrated under vacuum behind a blast shield. The crude residue waspartitioned between EtOAc (500 mL) and H₂O which had been adjusted toca. pH 12-14 with 3N NaOH (300 mL). The aqueous and organic layers werepartitioned and the aqueous extracted with EtOAc (2×150 mL). Thecombined organic extracts were washed with brine (1×100 mL), dried(Na₂SO₄), filtered and the solvent removed under vacuum—silica gel wasadded at this stage so that the crude product was absorbed directly onto silica gel. The crude product was purified by column chromatographyon silica gel using EtOAc/hexanes (30-60% EtOAc in increments of 10%EtOAc) to give the product (12.28 g, 89%) as a pale solid.

¹H NMR (CDCl₃, 300 MHz): δ 8.97 (s, 1H), 8.18 (d 1H), 7.01 (d, 1H),1.58-1.66 (m, 1H), 1.14-1.21 (m, 2H), 0.86-0.90 (m, 2H); m/z=291.1(M+MeCN+H)⁺.

A differential scanning calorimetry was run and indicated that theproduct has a large energy release (′exo-peak′) above 170° C.

Example 15 Synthesis of4-Cyclopropyl-2-Fluoro-5-(1H-Tetrazol-1-yl)Benzenamine

A Parr vessel was charged with1-(2-cyclopropyl-4-fluoro-5-nitrophenyl)-1H-tetrazole (27.20 g, 109.14mmol), EtOH (1000 mL), AcOH (14 mL), and 10% Pd/C (50% in water, Degussatype E101; 5.44 g, 20% by weight of the starting nitro compound) givinga suspension. The vessel was sealed, degassed, and back-filled with H₂(×3). The vessel was then charged with 30 psi H₂ and allowed to shakeuntil LCMS analysis indicated complete conversion. The reaction mixturewas filtered through a pad of celite, and the pad of celite was rinsedwith DCM/MeOH (1:9, 200 mL). The filtrate was evaporated to dryness, andthe resulting solid was dried in vacuo overnight in a 30° C. water bathto remove any traces of AcOH. The crude product was triturated with MeOHto give the product,4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (18.60 g, 78%) asa yellow solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.81 (s, 1H), 9.78 (br. s, 1H), 6.90 (d,1H, J=12.3 Hz), 6.80 (d, 1H, J=8.7 Hz), 5.47 (bs, 2H), 1.36-1.45 (m,1H), 0.580-0.643 (m, 2H), 0.413-0.465 (m, 2H); m/z=220 (M+H)⁺.

Example 16 Synthesis of4-(2,2,6,6-Tetramethylpiperidin-4-ylamino)-2-(4-Cyclopropyl-2-Fluoro-5-(1H-Tetrazol-1-yl)Phenylamino)Pyrimidine-5-Carbonitrile

A mixture of4-(2,2,6,6-tetramethylpiperidin-4-ylamino)-2-chloropyrimidine-5-carbonitrile(112 mg, 0.380 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (100 mg, 0.456mmol, 1.2 equiv), and para-toluenesulfonic acid monohydrate (58 mg,0.304 mmol, 0.8 equiv) in IPA (4 mL) were heated to 80° C. overnight.LCMS indicated desired product plus approximately 18% of5-fluoro-2-isopropoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminebyproduct. After cooling to ambient temperature, the crude mixture wasquenched with 2M NH₃/MeOH followed by concentrating to dryness andrepeating once. The crude product was purified by flash chromatographyand eluted with DCM:2M NH₃/MeOH (100:0 to 95:5 using 1% 2M NH₃/MeOHincrements) to provide the desired product which was recrystallized withDCM/IPA to give the title compound (88 mg, 49%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.81 (s, 1H), 9.51 (br. s, 1H), 8.28 (s,1H), 7.64 (d, J=7.8 Hz, 1H), 7.38 (d, J=7.8 Hz, 1H), 7.08 (d, J=11.7 Hz,1H), 4.28 (br. s, 1H), 1.44-1.47 (m, 2H), 1.08-1.17 (m, 2H), 0.76-0.94(m, 16H), 0.57-0.59 (m, 2H); m/z=477 (M+H)⁺.

Example 17 Synthesis of5-Fluoro-N2-(2-Fluoro-5-(1H-Tetrazol-1-yl)Phenyl)-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (100 mg, 0.309 mmol, 1 equiv),2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (90 mg, 0.495 mmol, 1.6 equiv.,Chembridge, San Diego, Calif.), and TFA (100 μL, 1.24 mmol, 4 equiv) inIPA (3 mL) were heated to 100° C. in shaker overnight affording a melt.LCMS indicated pyrimidine:product ratio=29:71. IPA (1 mL) and TFA (100μL, 1.24 mmol, 4 equiv) were added and the mixture was heated to 100° C.in shaker overnight affording a melt. LCMS indicatedpyrimidine:product=4:96. IPA (1 mL) and TFA (1000 μL, 12.4 mmol, 40equiv) were added and the mixture was heated to 100° C. in shaker for anadditional 5 hours affording a melt. LCMS indicated complete conversionto product. The crude solid was quenched with 2M NH₃/MeOH (1-2 mL), anddiluted with DCM (3-5 mL), then loaded into a column packed with silicaand filled with DCM. The crude product was purified by flashchromatography and eluted with DCM:2M NH₃/MeOH=100:0 to 96:4 using 1% 2MNH₃/MeOH increments to provide the desired product (90 mg, 68%) as asolid.

¹H NMR (DMSO d₆, 300 MHz): δ 10.06 (d, 1H, J=2.10 Hz), 8.75 (br. s, 1H),8.35-8.37 (m, 1H), 7.86-7.88 (m, 1H), 7.42-7.52 (m, 2H), 7.22 (d, 1H,J=8.40 Hz), 4.17-4.26 (m, 1H), 1.50-1.59 (m, 2H), 0.80-1.18 (m, 15H);LCMS (m/z): 430 (MH⁺)

Example 18

Synthesis of5-Fluoro-N2-(2-Fluoro-5-(1H-Tetrazol-1-yl)Phenyl)-N4-(1,2,2,6,6-Pentamethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (100 mg, 0.296 mmol, 1 equiv),2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (85 mg, 0.474 mmol, 1.6 equiv),and TFA (100 μL, 1.19 mmol, 4 equiv) in IPA (3 mL) were heated to 100°C. in shaker overnight affording a melt. LCMS indicatedpyrimidine:product=5:95. IPA (1 mL) and TFA (100 μL, 1.19 mmol, 4 equiv)were added and the mixture was heated to 100° C. in shaker ON affordinga melt. LCMS indicated pyrimidine:product=2:98. IPA (1 mL) and TFA (1000uL, 11.9 mmol, 40 equiv) were added and the mixture was heated to 100°C. in shaker for an additional 5 hours affording a melt. LCMS indicatedcomplete conversion to product. The crude solid was quenched with 2MNH₃/MeOH (1-2 mL), and diluted with DCM (3-5 mL), then loaded into acolumn packed with silica and filled with DCM. The crude product waspurified by flash chromatography and eluted with DCM:2M NH₃/MeOH=100:0to 97:3 using 1% 2M NH₃/MeOH increments to provide the desired product(91 mg, 69%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): 810.06 (d, 1H, J=2.10 Hz), 8.77 (br. s, 1H),8.34-8.37 (m, 1H), 7.88 (br. s, 1H), 7.42-7.52 (m, 2H), 7.23 (bs, 1H),4.17-4.25 (m, 1H), 2.05 (br. s, 3H), 1.50-1.59 (m, 2H), 1.29-1.37 (m,2H), 0.97 (br. s, 6H), 0.66 (br. s, 6H); LCMS (m/z): 444 (MH⁺).

Example 19 Synthesis of4-(2,2,6,6-Tetramethylpiperidin-4-ylamino)-2-(4-Cyclopropyl-2-Fluoro-5-(1H-Tetrazol-1-yl)Phenylamino)Pyrimidine-5-Carboxamide

A mixture of4-(2,2,6,6-tetramethylpiperidin-4-ylamino)-2-chloropyrimidine-5-carboxamide(178 mg, 0.570 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (150 mg, 0.684mmol, 1.2 equiv), and PTSA monohydrate (230 mg, 1.20 mmol, 2.1 equiv) inIPA (6 mL) were heated to 100° C. overnight giving a precipitate. Theprecipitate was collected by vacuum filtration and rinsed with IPA. Thesolid was taken in EtOAc then adjusted to ca. pH 12-14 with 1N NaOH. Theaqueous and organic layers were partitioned. The aqueous layer wasextracted with EtOAc (2×150 mL). The combined organics were washed with1N NaOH (1×150 mL), dried (Na₂SO₄), filtered, and concentrated to givethe desired product (128 mg, 50%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.83 (s, 1H), 9.08 (br. s, 1H), 8.96 (d,1H, J=8.70 Hz), 8.47 (s, 1H), 7.77 (d, 2H, J=6.90 Hz), 7.09 (d, 2H,J=11.70 Hz), 4.20-4.22 (m, 1H), 1.63-1.67 (m, 2H), 1.43-1.49 (m, 1H),0.99-1.19 (m, 1H), 0.73-0.95 (m, 15H), 0.57-0.61 (m, 2H); LCMS (m/z):495 (MH⁺).

Example 20 Synthesis ofN2-(4-Cyclopropyl-2-Fluoro-5-(1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine1.5 Formic Acid

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (184 mg, 5.70 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (150 mg, 0.684mmol, 1.2 equiv), and PTSA monohydrate (87 mg, 0.456 mmol, 0.8 equiv) inIPA (6 mL) were heated to 70° C. for 4 days. LCMS indicated 2-4% of thecleaved tetrazole product (the corresponding anilineN2-(5-amino-4-cyclopropyl-2-fluorophenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine)and 5-7% unreacted2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-amine.After cooling to ambient temperature, the crude mixture was concentratedto dryness. The residue was taken in ice-cold water and EtOAc thenadjusted to ca. pH 12-14 with 1N NaOH. The aqueous and organic layerswere partitioned, and the aqueous layer was extracted with EtOAc (1×150mL). The combined organic extracts were dried (Na₂SO₄), filtered, andthe solvent removed under vacuum. The crude product was purified byreverse-phase HPLC using formic acid as a modifier in water andacetonitrile to give formate salt (141 mg, 46%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.84 (s, 1H), 8.66 (br. s, 1H), 8.31 (s,1.5H, formic acid), 7.89 (d, 1H, J=7.5 Hz), 7.85 (d, 1H, J=2.1 Hz), 7.42(d, 1H, J=8.01 Hz), 7.08 (d, 1H, J=12.0 Hz), 4.31-4.20 (m, 1H),1.60-1.75 (m, 2H), 1.10-1.51 (m, 16H), 0.70-0.77 (m, 2H), 0.54-0.59 (m,2H); LCMS (m/z): 470 (MH⁺) free base.

Alternative synthesis using a scavenging technique to remove unreacted2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-amineis as follows.

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (6.68 g, 20.68 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (6.80 g, 31.02mmol, 1.5 equiv), and PTSA monohydrate (3.15 g, 16.54 mmol, 0.8 equiv)in IPA (200 mL) were heated to 70° C. for 4 days. LCMS indicated 2-4% ofthe cleaved tetrazole product and 7-9% unreacted2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-amine.After cooling the reaction mixture to ambient temperature, 3-aminobenzoic acid (8.51 g, 62.04 mmol, 3 equiv) was added and heated to 70°C. for overnight to scavenge the unreacted pyrimidine. After cooling toambient temperature, the crude mixture was concentrated to dryness. Theresidue was taken in ice-cold water and EtOAc then adjusted to ca. pH12-14 with 1N NaOH (300 mL). The aqueous and organic layers werepartitioned, and the organic layer washed with 1N NaOH (2×300 mL). Theaqueous layer was extracted with EtOAc (1×150 mL). The combined organicextracts were dried (Na₂SO₄), filtered, and the solvent removed undervacuum. The crude product was purified by flash chromatography andeluted with DCM:2M NH₃/MeOH=100:0 to 96:4 using 1% 2M NH₃/MeOHincrements to provide the desired product which was triturated withEtOAc/hexane to give the title compound (5.16 g, 53%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.82 (d, 1H, J=1.50 Hz), 8.58 (br. s, 1H),7.87 (d, 1H, J=7.5 Hz), 7.81 (d, 1H, J=2.1 Hz), 7.18 (d, 1H, J=8.0 Hz),7.06 (d, 1H, J=12.0 Hz), 4.20-4.22 (m, 1H), 1.54-1.58 (m, 2H), 1.42-1.43(m, 1H), 0.91-1.11 (m, 15H), 0.71-0.74 (m, 2H), 0.55-0.56 (m, 2H); LCMS(m/z): 470 (MH⁺).

A certain large-scale synthesis procedure is as follows:

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (16.2 g, 50.2 mmol),4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (15.0 g, 60.2mmol) and para-toluenesulfonic acid monohydrate (7.64 g, 40.1) in IPA(400 mL) were heated to 70° C. and stirred for 4-5 days. After cooling,the mixture was filtered and the filter cake was washed with isopropylalcohol (2×50 mL). The filter cake was suspended in EtOAc (500 mL) andH₂O (300 mL). 1N NaOH was added to basify the mixture. The organic andaqueous layers were partitioned and the organic layer was washed with 1NNaOH (300 mL), brine (300 mL), then dried (MgSO₄), filtered and thesolvent removed under vacuum to leave a solid (LC/MS indicated thissolid to be >96% purity). The solid was triturated with EtOAc/hexanes(1:9; ca. 300 mL)—the mixture heated to ca. 50° C. and allowed to coolto room temperature, then filtered and the filter cake washed withEtOAc/hexanes (1:9; 2×100 mL) to give the title compound (15 g, 64%) asa solid. Characterization data is the same to that shown above.

Example 21 Synthesis of 4,6-Dinitro-2-Fluorophenol

To 2-fluorophenol (10 mL, 12.1 g, 108 mmol, 1 equiv) in anhydrous DCM at0° C. was added 90% HNO₃ (12.6 mL, 17.0 g, 270 mmol, 2.5 equiv)dropwise. The mixture was warmed to room temperature and stirred for 2hours, then cooled to 0° C. again and quenched with 2N NaOH solution topH 5 (ca. 80 mL). The mixture was concentrated, diluted with water andextracted with EtOAc (3×150 mL). The combined organic layers was driedover MgSO₄, filtered and concentrated. The residue was triturated inhexanes to give the product (18 g, 82%) as a yellow solid.

¹H NMR (CDCl₃, 300 MHz): δ 10.97 (br. s, 1H), 8.92-8.90 (m, 1H), 8.32(dm, J=9.3 Hz, 1H); m/z=201 (M−H)⁺.

Example 22 Synthesis of 2-Bromo-1,5-Dinitro-3-Fluorobenzene

To a solution of 4,6-dinitro-2-fluorophenol (8 g, 39.60 mmol, 1 equiv)in DMF (24 mL) and toluene (160 mL), PBr₃ (5.6 mL, 59.40 mmol, 1.5equiv) was added at room temperature. Then the reaction mixture washeated at 110° C. for 1 hour. After allowing to cool to roomtemperature, the upper colorless layer was poured into a separate funneland diluted with hexanes. The organic layer was washed with water, driedover MgSO₄ and evaporated to dryness to give the product (10.3 g, 98%)as a yellow solid.

¹H NMR (CDCl₃, 300 MHz): δ 8.54 (d, J=1.2 Hz, 1H), 8.22 (dd, J=7.5, 0.9Hz, 1H); m/z=264 (M)⁺.

Example 23 Synthesis of 2-Bromo-3-Fluoro-5-Nitroaniline and4-Bromo-3-Fluoro-5-Nitroaniline

A mixture of 2-bromo-1,5-dinitro-3-fluorobenzene (100 mg, 0.38 mmol, 1equiv) and iron powder (64 mg, 1.14 mmol, 3 equiv) in 3 mL of HOAc wasstirred at room temperature for 90 minutes. The reaction mixture wasdiluted with EtOAc (20 mL) and saturated NaHCO₃ (to ca. pH 7-8). Theorganic layer was separated and evaporated under vacuum. The cruderesidue was purified by column chromatography on silica gel usingEtOAc/hexanes (1:4) as eluent to give 47 mg of2-bromo-3-fluoro-5-nitroaniline (52%).

¹H NMR (CDCl₃, 300 MHz): δ 7.43-7.32 (m, 2H), 4.63 (br. s, 2H),1.40-1.35 (m, 1H), 1.25-1.20 (m, 2H), 0.85-0.80 (m, 2H); m/z=235 (M)⁺.

A later fraction gave 28 mg of 4-Bromo-3-fluoro-5-nitroaniline (31%).

¹H NMR (CDCl₃, 300 MHz): δ 6.94 (d, J=2.7 Hz, 1H), 6.62 (dd, J=9.6, 2.7Hz, 1H), 4.15 (br. s, 2H), 1.40-1.35 (m, 1H), 1.28-1.23 (m, 2H),0.88-0.85 (m, 2H); m/z=237 (M+2H)⁺.

Example 24 Synthesis of 2-Cyclopropyl-3-Fluoro-5-Nitroaniline

A mixture of 2-bromo-3-fluoro-5-nitroaniline (1.6 g, 6.81 mmol, 1equiv), cyclopropylboronic acid MIDA ester (Aldrich; 4.0 g, 20.43 mmol,3 equiv), Pd(OAc)₂ (238 mg, 1.06 mmol, 0.15 equiv), Cy₃P (578 mg, 2.06mmol, 0.3 equiv) and Cs₂CO₃ (13.26 g, 40.8 mmol, 6 equiv) in toluene (70mL) and H₂O (14 mL) was de-gassed with N₂ for 5 minutes. The mixture wasthen heated at 100° C. (oil bath temperature) overnight. After allowingto cool to room temperature, the mixture was diluted with EtOAc (100 mL)and H₂O (50 mL) and the mixture filtered through Celite. The filter cakewas washed with EtOAc (2×50 mL) and the filtrate partitioned. Theorganic layer was evaporated under vacuum to leave a crude residue whichwas purified by column chromatography on silica gel using EtOAc/hexanes(1:4) as eluent to give the product (1.2 g, 90%) as a dark yellow solid.

¹H NMR (CDCl₃, 300 MHz): δ 7.29-7.21 (m, 2H), 4.44 (br. s, 2H),1.52-1.42 (m, 1H), 1.11-1.05 (m, 2H), 0.73-0.67 (m, 2H); m/z=197 (M+H)⁺

Example 25 Synthesis of1-(2-Cyclopropyl-3-Fluoro-5-Nitrophenyl)-1H-Tetrazole

N.b.: TMS-N₃ and tetrazole product are potentially explosive. Use ablast shield for this reaction and glassware with no scratches, cracks,etc. Avoid contact with metals, including metal spatulas. Keep theproduct slightly wet with residual solvent from the column.

A mixture of 2-cyclopropyl-3-fluoro-5-nitroaniline (300 mg, 1.53 mmol, 1equiv), trimethylsilyl azide (1.0 mL, 7.65 mmol, 5 equiv),trimethylorthoformate (1.67 mL, 15.29 mmol, 10 equiv) in AcOH (3 mL) washeated to 70° C. and stirred for 7 hours behind a blast shield. Afterallowing to cool to room temperature, the mixture was further cooled inice-water and basified to ca. pH 12-14 with 1N NaOH and diluted withEtOAc. The aqueous and organic layers were partitioned and the aqueousextracted with EtOAc (2×150 mL). The combined organic extracts werewashed with 1N NaOH (1×100 mL), dried (Na₂SO₄), filtered, and thesolvent removed under vacuum—silica gel was added at this stage so thatthe crude product was absorbed directly on to silica gel. The crudeproduct was purified by column chromatography on silica gel usingEtOAc/hexanes (30-50% EtOAc in increments of 10% EtOAc) to give theproduct 1-(2-cyclopropyl-3-fluoro-5-nitrophenyl)-1H-tetrazole (343 mg,90%) as a white solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.96 (br.s, 1H), 8.38-8.44 (m, 2H),1.79-1.88 (m, 1H), 0.757-0.821 (m, 2H), 0.375-0.428 (m, 2H); LCMS (m/z):250 (MH⁺).

Example 26 Synthesis of4-Cyclopropyl-3-Fluoro-5-(1H-Tetrazol-1-yl)Benzenamine

A round-bottom flask was charged with1-(2-cyclopropyl-3-fluoro-5-nitrophenyl)-1H-tetrazole (288 mg, 1.16mmol), EtOH (12 mL), and 10% Pd/C (50% in water, Degussa type E101; 246mg, 85% by weight of the starting nitro compound) giving a suspension.The flask was sealed with a rubber septum, degassed, and back-filledwith H₂ (×3) from a balloon filled with H₂. The reaction was stirred for1 hour using a H₂ filled balloon. LCMS analysis indicated 4% cleavage ofthe cyclopropyl moiety to the isopropyl. The reaction mixture wasfiltered through a pad of Celite, and the pad of Celite was rinsed withDCM/MeOH (1:9, 100 mL). The filtrate was evaporated to dryness—silicagel was added at this stage so that the crude product was absorbeddirectly on to silica gel. The crude product was purified by columnchromatography on silica gel using EtOAc/hexanes (50-60% EtOAc inincrements of 10% EtOAc) to give the product,4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)benzenamine (234 mg, 92%) asa light-brown solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.81 (br. s, 1H), 6.49-6.54 (m, 2H), 5.78(br. s, 2H), 1.51-1.60 (m, 1H), 0.50-0.55 (m, 2H), 0.00-0.04 (m, 2H);LCMS (m/z): 220 (MH⁺).

Example 27 Synthesis of4-(2,2,6,6-Tetramethylpiperidin-4-ylamino)-2-(4-Cyclopropyl-3-Fluoro-5-(1H-Tetrazol-1-yl)Phenylamino)Pyrimidine-5-Carbonitrile

A mixture of4-(2,2,6,6-tetramethylpiperidin-4-ylamino)-2-chloropyrimidine-5-carbonitrile(72 mg, 0.243 mmol, 1 equiv),4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)benzenamine (64 mg, 0.292mmol, 1.2 equiv), and PTSA monohydrate (37 mg, 0.195 mmol, 0.8 equiv) inIPA (2.5 mL) were heated to 50° C. for 4 hours. After cooling to ambienttemperature, the crude mixture was quenched with 2M NH₃/MeOH followed byconcentrating to dryness and repeating once. The crude product waspurified by flash chromatography and eluted with DCM:2M NH₃/MeOH=100:0to 96:4 using 1% 2M NH₃/MeOH increments to provide the desired productwhich was recrystallized with IPA/hexane to give desired compound (61mg, 53%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 10.12 (br. s, 1H), 9.80-9.90 (m, 1H),8.22-8.33 (m, 1H), 7.90-7.94 (m, 1H), 7.43-7.50 (m, 2H), 4.40 (br. s,1H), 1.51-1.61 (m, 3H), 0.93-1.22 (m, 15H), 0.53-0.55 (m, 2H), 0.37-0.39(m, 2H); LCMS (m/z): 477 (MH⁺).

Example 28 Synthesis ofN2-(4-Cyclopropyl-3-Fluoro-5-(1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (72 mg, 0.190 mmol, 1 equiv),4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)benzenamine (50 mg, 0.228mmol, 1.2 equiv), and PTSA monohydrate (30 mg, 0.152 mmol, 0.8 equiv) inIPA (2 mL) were heated to 70° C. for 3 days. LCMS indicated 2-4% of thecleaved tetrazole product. After cooling to ambient temperature, thecrude mixture was quenched with 2M NH₃/MeOH followed by concentrating todryness and repeating once. The crude product was purified by flashchromatography and eluted with DCM:2M NH₃/MeOH=100:0 to 96:4 using 1% 2MNH₃/MeOH increments to provide the desired product which wasrecrystallized with IPA/hexane to give desired compound (58 mg, 65%) asa solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.86 (br. s, 1H), 9.48 (br. s, 1H),7.91-7.95 (m, 1H), 7.82-7.86 (m, 1H), 7.48 (br. s, 1H), 7.26-7.30 (m,1H), 4.26-4.32 (m, 1H), 1.54-1.62 (m, 4H), 0.94-1.13 (m, 14H), 0.51-0.41(m, 2H), 0.11-0.12 (m, 2H); LCMS (m/z): 470 (MH⁺).

Example 29 Synthesis of 1-Bromo-2-Fluoro-3,5-Dinitrobenzene

To 1-fluoro-2,4-dinitrobenzene (13.0 g, 69.85 mmol, 1 equiv) dissolvedin sulfuric acid (190 mL) at room temperature was added bromine (4.30mL, 83.82 mmol, 1.2 equiv) dropwise followed by the slow dropwiseaddition of nitric acid (70%, d=1.500; 3.25 mL, 76.84 mmol, 1.1 equiv).The reaction vessel was fitted with a refluxing condenser, and thereaction mixture was heated at 80° C. for 10 hours. LCMS indicated areactant:product ratio of 1:1. After allowing to cool to roomtemperature, the mixture was poured into ice and diluted with DCM. Theaqueous and organic layers were partitioned, and the aqueous extractedwith DCM (2×300 mL). The combined organic extracts were washed withsaturated Na₂S₂O₃ (2×200 mL), dried (Na₂SO₄), filtered, and concentratedto dryness. The crude product was purified using a pad of silica gel andeluted with EtOAc/hexanes (25-35% EtOAc in increments of 5% EtOAc) togive the product 1-bromo-2-fluoro-3,5-dinitrobenzene (5.55 g, 30%) as alight-yellow solid.

¹H NMR (DMSO d₆, 300 MHz): δ 8.96-9.02 (m, 1H), 8.82-8.89 (m, 1H); LCMS(m/z): 266 (WO.

Example 30 Synthesis of 3-Bromo-2-Fluoro-5-Nitrobenzenamine

To a solution of 1-bromo-2-fluoro-3,5-dinitrobenzene (5.4 g, 20.38 mmol,1 equiv) in acetic acid (200 mL) at room temperature (using a waterbath) was added powdered iron portion-wise (5.70 g, 102 mmol, 5 equiv).The resulting solution was stirred for 3 hours keeping the temperatureof the mixture below 30° C. LCMS indicated the formation of threeproducts: 3-bromo-2-fluoro-5-nitrobenzenamine-F3 (86%),3-bromo-4-fluoro-5-nitrobenzenamine-F2 (5%), and5-bromo-4-fluorobenzene-1,3-diamine-F1 (9%). [Note: After completion ofthis experiment, to identify regioisomers,3-bromo-2-fluoro-5-nitrobenzenamine was diazotized and deaminated (see,E. S. Adams and K. L. Rinehart. The Journal of Antibiotics 1994, 47(12), 1456-1465) to give 3-bromo-4-fluoro-nitrobenzene. This wascompared to an authentic sample obtained from a commercial source]. DCMwas added to the mixture, and the resulting mixture was filtered througha pad of Celite, and the pad of Celite was rinsed with MeOH. Thefiltrate was evaporated to dryness. The residue was quenched with 2MNH₃/MeOH followed by concentrating to dryness and repeating once—silicagel was added at this stage so that the crude product was absorbeddirectly on to silica gel. The crude product was purified by columnchromatography on silica gel using DCM to give the desired product3-bromo-2-fluoro-5-nitrobenzenamine (F1 on TLC; 1.87 g, 39%) as a yellowsolid.

¹H NMR (DMSO d₆, 300 MHz): δ 7.55-7.60 (m, 2H), 6.19 (bs, 2H); ¹⁹F NMR(DMSO d₆, 282 MHz): δ −120 (s, 1F); LCMS (m/z): 236 (MH⁺).

Further elution with DCM provided 3-bromo-4-fluoro-5-nitrobenzenamine(F2 on TLC). ¹H NMR (DMSO d₆, 300 MHz): δ 7.13-7.22 (m, 2H), 5.84 (br.s, 2H); ¹⁹F NMR (DMSO d₆, 282 MHz): δ −132 (s, 1F); LCMS (m/z): 236(MH⁺).

Further elution with DCM gave 5-bromo-4-fluorobenzene-1,3-diamine (F3 onTLC). ¹H NMR (DMSO d₆, 300 MHz): δ 5.89-5.95 (m, 2H), 5.07 (br. s, 2H),4.84 (br. s, 2H); ¹⁹F NMR (DMSO d₆, 282 MHz): δ −146 (s, 1F); LCMS(m/z): 206 (MH⁺).

Example 31 Synthesis of 3-Cyclopropyl-2-Fluoro-5-Nitroaniline

A mixture of 3-bromo-2-fluoro-5-nitroaniline (2.20 g, 9.36 mmol, 1equiv), cyclopropylboronic acid MIDA ester (Aldrich; 11.07 g, 56.17mmol, 6 equiv), Cy₃P (1.05 g, 3.74 mmol, 0.4 equiv), Cs₂CO₃ (54.90 g,168.50 mmol, 18 equiv) in toluene/H₂O (5:1; 450 mL:90 mL) followed byPd(OAc)₂ (0.420 g, 1.87 mmol. 0.20 equiv) was de-gassed by sonicatingunder vacuum for 10 minutes and back-filled with N₂. The mixture wasthen heated at 100° C. overnight. After allowing to cool to roomtemperature, the mixture was concentrated to dryness. The residue wastaken in DCM, and silica gel was added at this stage so that the residuewas absorbed directly on to silica gel. After removing the solvent undervacuum, the crude product was purified by column chromatography onsilica gel using DCM to give the product3-cyclopropyl-2-fluoro-5-nitroaniline (1.27 g, 69%) as a yellow solid.

¹H NMR (DMSO d₆, 300 MHz): δ 7.38-7.42 (m, 1H), 6.90 (dd, J=2.7, 5.7 Hz,1H), 5.80 (br. s, 2H), 2.00-2.09 (m, 1H), 0.95-1.01 (m, 2H), 0.71-0.76(m, 2H); LCMS (m/z): 197 (MH⁺).

Example 32 Synthesis of1-(3-Cyclopropyl-2-Fluoro-5-Nitrophenyl)-1H-Tetrazole

N.b.: TMS-N₃ and tetrazole product are potentially explosive. Use ablast shield for this reaction and glassware with no scratches, cracks,etc. Avoid contact with metals, including metal spatulas. Keep theproduct slightly wet with residual solvent from the column.

A mixture of 3-cyclopropyl-2-fluoro-5-nitroaniline (1.27 g, 6.47 mmol, 1equiv), trimethylsilyl azide (4.26 mL, 32.37 mmol, 5 equiv),trimethylorthoformate (7.09 mL, 67.74 mmol, 10 equiv) in AcOH (15 mL)was heated to 70° C. and stirred for 7 hours behind a blast shield.After allowing to cool to room temperature, the mixture was furthercooled in ice-water and basified to ca. pH 12-14 with 1N NaOH anddiluted with EtOAc. The aqueous and organic layers were partitioned andthe aqueous extracted with EtOAc (2×200 mL). The combined organicextracts were washed with 1N NaOH (1×200 mL), dried (Na₂SO₄), filtered,and the solvent removed under vacuum—silica gel was added at this stageso that the crude product was absorbed directly on to silica gel. Thecrude product was purified by column chromatography on silica gel usingEtOAc/hexanes (30-50% EtOAc in increments of 10% EtOAc) to give theproduct 1-(3-cyclopropyl-2-fluoro-5-nitrophenyl)-1H-tetrazole (1.49 g,92%) as a light-yellow solid.

¹H NMR (DMSO d₆, 300 MHz): δ 10.01 (s, 1H), 8.58 (dd, J=2.70 Hz, 5.70Hz, 1H), 8.02 (dd, J=3.0, 6.3 Hz, 1H), 2.19-2.28 (m, 1H), 1.09-1.17 (m,2H), 0.97-1.03 (m, 2H); LCMS (m/z): 250 (MH⁺).

Example 33 Synthesis of3-Cyclopropyl-4-Fluoro-5-(1H-Tetrazol-1-yl)Benzenamine

A round-bottom flask was charged with1-(3-cyclopropyl-2-fluoro-5-nitrophenyl)-1H-tetrazole (1.41 g, 5.65mmol), EtOH (50 mL), and 10% Pd/C (50% in water, Degussa type E101; 1.20g, 85% by weight of the starting nitro compound) giving a suspension.The flask was sealed with a rubber septum, degassed, and back-filledwith H₂ (×3) from a balloon filled with H₂. The reaction was stirred for2 hours using a H₂ filled balloon. LCMS analysis indicated 4% cleavageof the cyclopropyl moiety to the isopropyl. The reaction mixture wasfiltered through a pad of Celite, and the pad of Celite was rinsed withDCM/MeOH (1:9, 300 mL). The filtrate was evaporated to dryness—silicagel was added at this stage so that the crude product was absorbeddirectly on to silica gel. The crude product was purified by columnchromatography on silica gel using EtOAc/hexanes (50-60% EtOAc inincrements of 10% EtOAc) to give the product,3-cyclopropyl-4-fluoro-5-(1H-tetrazol-1-yl)benzenamine (1.0 g, 81%) as areddish-brown solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.84 (br. s, 1H), 6.66-6.69 (m, 1H),6.31-6.33 (m, 1H), 5.34 (br. s, 2H), 1.97-2.05 (m, 1H), 0.95-1.01 (m,2H), 0.66-0.69 (m, 2H); LCMS (m/z): 220 (MH⁺).

Example 34 Synthesis of4-(2,2,6,6-Tetramethylpiperidin-4-ylamino)-2-(3-Cyclopropyl-4-Fluoro-5-(1H-Tetrazol-1-yl)Phenylamino)Pyrimidine-5-Carbonitrile

A mixture of4-(2,2,6,6-tetramethylpiperidin-4-ylamino)-2-chloropyrimidine-5-carbonitrile(112 mg, 0.380 mmol, 1 equiv),3-cyclopropyl-4-fluoro-5-(1H-tetrazol-1-yl)benzenamine (100 mg, 0.456mmol, 1.2 equiv), and PTSA monohydrate (58 mg, 0.304 mmol, 0.8 equiv) inIPA (4 mL) were heated to 60° C. for 5 days. After cooling to ambienttemperature, the crude mixture was concentrated to dryness. The residuewas taken in ice-cold water and EtOAc then adjusted to ca. pH 12-14 with1N NaOH. The aqueous and organic layers were partitioned, and theaqueous layer was extracted with EtOAc (1×150 mL). The combined organicextracts were dried (Na₂SO₄), filtered, and the solvent removed undervacuum. The crude product was submitted to the analytical department forpurification by reverse-phase HPLC using 0.1% formic acid as a modifierin water and acetonitrile (compound unstable in TFA). The product as theformate salt was taken in ice-cold water and EtOAc then adjusted to ca.pH 12-14 with 1N NaOH. The aqueous and organic layers were partitioned,and the aqueous layer was extracted with EtOAc (2×150 mL). The combinedorganic extracts were dried (Na₂SO₄), filtered, and concentrated to givedesired compound (63 mg, 35%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.94 (s, 1H), 9.80 (br. s, 1H), 8.34 (s,1H), 8.00-8.11 (m, 1H), 7.35 (d, 1H, J=8.1 Hz), 7.22 (br. s, 1H), 4.29(br. s, 1H), 2.01-2.11 (m, 1H), 1.48-1.52 (m, 2H), 0.75-1.19 (m, 17H);LCMS (m/z): 477 (MH⁺).

Example 35 Synthesis ofN2-(3-Cyclopropyl-4-Fluoro-5-(1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (246 mg, 0.760 mmol, 1 equiv),3-cyclopropyl-4-fluoro-5-(1H-tetrazol-1-yl)benzenamine (200 mg, 0.912mmol, 1.2 equiv), and PTSA monohydrate (116 mg, 0.608 mmol, 0.8 equiv)in IPA (8 mL) were heated to 70° C. for 3 days. LCMS indicated 2-4% ofthe cleaved tetrazole product. After cooling to ambient temperature, thecrude mixture was quenched with 2M NH₃/MeOH followed by concentrating todryness and repeating twice. The crude product was purified by flashchromatography and eluted with DCM:2M NH₃/MeOH=100:0 to 96:4 using 1% 2MNH₃/MeOH increments to provide the desired product which wasrecrystallized with IPA/hexane to give desired compound (154 mg, 43%) asa solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.92 (br. s, 1H), 9.16 (br. s, 1H),8.11-8.15 (m, 1H), 7.86-7.91 (m, 1H), 7.52 (d, 1H, J=7.5 Hz), 7.16-7.21(m, 1H), 4.26-4.32 (m, 1H), 1.94-2.06 (m, 1H), 1.73-1.81 (m, 2H),1.47-1.58 (m, 2H), 0.99-1.30 (m, 15H), 0.69-0.70 (m, 2H); LCMS (m/z):470 (MH⁺).

Example 36 Synthesis of 4-Fluoro-5-Nitro-2-(Prop-1-en-2-yl)Benzenamine

A mixture of 2-bromo-4-fluoro-5-nitroaniline (2.85 g, 12.13 mmol, 1.0eq), isopropenylboronic acid pinacol ester (5.09 g, 30.33 mmol, 2.5 eq),Pd(OAc)₂ (0.82 g, 3.64 mmol, 0.3 eq), Cy₃P (1.70 g, 6.07 mmol, 0.5 eq)and Cs₂CO₃ (39.51 g, 121.28 mmol, 10 eq) in toluene (100 mL) and H₂O (25mL) was de-gassed with N₂ for 15 minutes. The mixture was then heated at100° C. (oil bath temperature). After allowing to cool to roomtemperature, the mixture was diluted with EtOAc (100 mL) and H₂O (50 mL)and the mixture filtered through celite. The filter cake was washed withEtOAc (2×50 mL) and the filtrate partitioned. The organic layer wasdried (Na₂SO₄), filtered and the solvent removed under vacuum to leave acrude residue. The residue was purified by column chromatography onsilica gel (residue dry-loaded on to silica gel) using EtOAc/hexanes(1:5 gradient) as eluent to give the product (1.59 g, 64%) as a darkbrown solid.

¹H NMR (DMSO-d₆, 300 MHz): δ 7.35 (d, 1H), 7.10 (d, 1H), 5.32 (br. s,3H), 5.09 (s, 1H), 1.99 (s, 3H); m/z=197.0 (M+)⁺.

Example 37 Synthesis of2-Fluoro-4-Isopropyl-5-(1H-Tetrazol-1-yl)Benzenamine

Step 1: 1-(4-Fluoro-5-nitro-2-(prop-1-en-2-yl)phenyl)-1H-tetrazole

N.b.: TMS-N₃ and tetrazole product are potentially explosive. Use ablast shield for this reaction and glassware with no scratches, cracks,etc. Avoid contact with metals, including metal spatulas. Keep theproduct slightly wet with residual solvent from the column.

A mixture of 2-isoPropenyl-4-fluoro-5-nitroaniline (1.32 g, 6.70 mmol,1.0 eq), trimethylsilyl azide (3.90 g, 33.50 mmol, 5.0 eq),trimethylorthoformate (7.11 g, 67 mmol, 10 eq) in AcOH (10 mL) washeated to 75° C. and stirred overnight behind a blast shield. Afterallowing the reaction mixture to cool to room temperature, the mixturewas concentrated under vacuum behind a blast shield. The crude reactionmixture was neutralized using 3N NaOH (30 mL) in ice bath. The tanprecipitate formed was filtered and dried under vacuum. The crudeproduct was taken to the next step with out further purification.m/z=250.

Step 2: 2-Fluoro-4-isopropyl-5-(1H-tetrazol-1-yl)benzenamine

A Parr vessel was charged with1-(2-isopropenyl-4-fluoro-5-nitrophenyl)-1H-tetrazole (0.100 g, 4.0mmol), EtOH (25 mL), AcOH (1 mL), and 10% Pd/C (50% in water, Degussatype E101; 0.050 g, 50% by weight of the starting nitro compound) givinga suspension. The vessel was sealed, degassed, and back-filled with H₂(×3). The vessel was then charged with 60 psi H₂ and allowed to shakeuntil LCMS analysis indicated complete conversion. The reaction mixturewas filtered through a pad of Celite, and the pad of Celite was rinsedwith DCM/MeOH (1:9, 50 mL). The filtrate was evaporated to dryness. Thecrude product was purified by column chromatography on silica gel usingEtOAc/hexanes (25-50% EtOAc in increments of 5% EtOAc) to give theproduct, 4-isopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (0.075 g,85%) as a brown solid.

¹H NMR (CDCl₃, 300 MHz): δ 8.70 (s, 1H), 7.06 (d, 1H, J=12.1 Hz), 6.66(d, 1H, J=8.0 Hz), 3.95 (br. s, 2H), 2.39 (m, 1H), 1.11 (s, 3H), 1.08(s, 3H); m/z=222 (M+H)⁺.

Example 38 Synthesis of4-(2,2,6,6-Tetramethylpiperidin-4-ylamino)-2-(2-Fluoro-4-Isopropyl-5-(1H-Tetrazol-1-yl)Phenylamino)Pyrimidine-5-Carbonitrile

A mixture of2-chloro-5-cyano-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-amine(0.05 g, 0.17 mmol, 1 equiv),4-isopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (0.045 g, 0.204mmol, 1.2 equiv), and para-toluenesulfonic acid monohydrate (0.025 g,0.136 mmol, 0.8 equiv) in IPA (5 mL) were heated to 80° C. overnight.LCMS indicated desired product plus approximately 10% of5-fluoro-2-isopropoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminebyproduct. After cooling to ambient temperature, the crude mixture wasquenched with 2M NH₃/MeOH followed by concentrating to dryness andrepeating once. The crude product was purified by flash chromatographyand eluted with DCM:2M NH₃/MeOH (100:0 to 95:5 using 1% 2M NH₃/MeOHincrements) to provide the desired product which was recrystallized withDCM/IPA to give the title compound (45 mg, 55%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.77 (s, 1H), 9.53 (br. s, 1H), 8.27 (s,1H), 7.56 (d, J=6.9 Hz, 1H), 7.45 (d, J=11.8 Hz, 1H), 7.37 (d, J=8.0 Hz,1H), 4.30 (br. s, 1H), 2.34 (m, 1H), 1.45-1.48 (m, 2H), 1.11-1.17 (m,2H), 1.09 (s, 6H), 1.06 (s, 3H), 0.95 (s, 6H), 0.90 (s, 3H); m/z=479(M+H)⁺.

Example 39 Synthesis of 2-Cyclopropyl 5-Nitrobenzenamine

In a 250 mL round bottom flask to a solution of 2-bromo 5-nitroaniline(2.30 g, 10.60 mmol) in toluene (90 mL) tricyclohexylphosphine (0.89 g,3.18 mmol), Cs₂CO₃ (17.22 g, 52.99 mmol), cyclopropylboronic acid MIDAester (2.92 g, 14.84 mmol) and 10 ml de-ionized water were added and thesolution was degassed with nitrogen for 30 minutes. To the abovesolution Pd(OAc)₂ (0.36 g, 1.59 mmol) was added under nitrogen and thereaction mixture was refluxed for 12 hours. LC MS analysis of the crudereaction indicated the completion of the reaction. The crude reactionmixture was filtered on Celite pad and the volatiles were removed underreduced pressure. The dark brown oil was worked-up with 2×100 mL ethylacetate and water (100 mL), dried on MgSO₄ and ethyl acetate wasevaporated under reduced pressure. The crude reaction mixture wasseparated by column chromatography to give2-cyclopropyl-5-nitrobenzeneamine in 70% yield.

¹H NMR (DMSO d₆, 300 MHz): δ 7.43 (d, J=2.5 Hz, 1H), 7.26 (dd, J=1.9,8.3 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 5.70 (s, 2H), 1.75 (m, 1H),0.92-0.95 (m, 2H), 0.56-0.59 (m, 2H); LCMS (m/z): 179 (MH⁺).

Example 40 Synthesis of1-(2-Cyclopropyl-5-Nitrophenyl)-5-(Trifluoromethyl)-1H-Tetrazole

Step: 1(Z)—N-(1-chloro-2,2,2-trifluoroethylidene)-2-cyclopropyl-5-nitrobenzenamine

A mixture of CF₃CO₂H (0.98 mL, 12.65 mmol, 0.9 eq), PPh₃ (9.21 g, 35.13mmol, 2.5 eq) and Et₃N (1.96 mL, 14.05 mmol, 1.0 eq), in 25 mL CCl₄ wasstirred at 0° C. for 10 minutes. 2-Cyclopropyl-5-nitrobenzeneamine (2.50g, 14.05 mmol, 1.0 eq) was then added to the reaction mixture and themixture was heated to reflux for 12 hours. Solvent was removed underreduced pressure and the residue was purified by column chromatography,eluting with n-hexane: ethyl acetate (10:1), giving the(Z)—N-(1-chloro-2,2,2-trifluoroethylidene)-2-cyclopropyl-5-nitrobenzenamineintermediate in semi pure form as a light yellow solid. This compoundwas taken to the next step with out further purification.

Step 2: 1-(2-Cyclopropyl-5-nitrophenyl)-5-(trifluoromethyl)-1H-tetrazole

A mixture of NaN₃ (0.56 g, 8.57 mmol, 2.5 eq) and(Z)—N-(1-chloro-2,2,2-trifluoroethylidene)-2-cyclopropyl-5-nitrobenzenamineintermediate (1.0 g, 3.43 mmol, 1.0 eq) in 15 mL dry acetonitrile wasstirred at room temperature for 16 hours. The reaction mixture waspoured into ice-cold aqueous Na₂CO₃ solution, extracted with ethylacetate. The organic layer washed with brine, dried over Na₂SO₄,filtered, and concentrated in vacuo. The resulting crude mixture waspurified by column chromatography, eluting with n-hexane: ethyl acetate(10-50% EtOAc in increments of 10% EtOAc)), giving the desired productin 37% overall yield (1.55 g).

¹H NMR (DMSO d₆, 300 MHz): δ 8.45 (dd, 1H), 8.20 (d, 1H), 7.29 (d, 1H),1.28 (m, 1H), 1.18 (m, 2H), 0.85 (m, 2H); m/z=300 (M+H)⁺.

Example 41 Synthesis of4-Cyclopropyl-3-(5-(Trifluoromethyl)-1H-Tetrazol-1-yl)Benzenamine

A mixture of nitro compound (0.25 g, 0.836 mmol, 1.0 eq), Fe (0.140 g,2.51 mmol, 3.0 eq) and NH₄Cl (0.134 g, 2.51 mmol, 3.0 eq) in EtOH/H₂O(3:1) was refluxed for 1 hour. The reaction mixture was filtered on acelite pad and solvents were removed under reduced pressure. The crudereaction mixture was purified by column chromatography, eluting withn-hexane: ethyl acetate (10-70% EtOAc in increments of 10% EtOAc)),giving the required product in 78% yield (0.18 g).

¹H NMR (CDCl₃, 300 MHz): δ 6.99 (d, 1H), 6.83 (d, 1H), 6.55 (br. s, 1H),1.25 (m, 1H), 0.65 (m, 2H), 0.49 (m, 2H); m/z=270 (M+H)⁺.

Example 42 Synthesis ofN2-(4-Cyclopropyl-3-(5-(Trifluoromethyl)-1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (0.210 g, 0.65 mmol, 1 equiv),4-cyclopropyl-5-(1-trifluoromethyl-tetrazol-1-yl)benzenamine (0.245 g,0.910 mmol, 1.4 equiv), and para-toluenesulfonic acid monohydrate (0.099g, 0.520 mmol, 0.8 equiv) in IPA (10 mL) were heated to 100° C.overnight. After cooling to ambient temperature, the crude mixture wasquenched with 2M NH₃/MeOH followed by concentrating to dryness andrepeating once. The crude product was purified by flash chromatographyand eluted with DCM:2M NH₃/MeOH (100:0 to 95:5 using 1% 2M NH₃/MeOHincrements) to provide the desired product which was recrystallized withDCM/IPA to give the title compound (0.18 g, 53% yield) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.34 (s, 1H), 7.84-7.89 (m, 3H), 7.23 (d,J=8.0 Hz, 1H), 7.05 (d, J=9.1 Hz, 1H), 4.31 (br. m, 1H), 1.59-1.63 (m,2H), 1.09-1.17 (m, 4H), 0.99 (s, 12H), 0.66-0.68 (m, 2H), 0.52-0.55 (m,2H); m/z=520 (M+H)⁺.

Example 43 Synthesis ofN2-(4-Cyclopropyl-2-Fluoro-5-(1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(1,2,2,6,6-Pentamethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (0.196 g, 0.58 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (0.140 g, 0.64mmol, 1.1 equiv), and para-toluenesulfonic acid monohydrate (0.090 g,0.47 mmol, 0.8 equiv) in IPA (15 mL) were heated to 100° C. overnight.After cooling to ambient temperature, the crude mixture was quenchedwith 2M NH₃/MeOH followed by concentrating to dryness and repeatingonce. The crude product was purified by flash chromatography and elutedwith DCM:2M NH₃/MeOH (100:0 to 95:5 using 1% 2M NH₃/MeOH increments) toprovide the desired product which was titurated with DCM/Hexane to givethe title compound (0.100 g, in 36% yield) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.84 (s, 1H), 8.60 (s, 1H), 7.89 (d, J=7.4Hz, 1H), 7.82 (d, J=3.9 Hz, 1H), 7.21 (d, J=6.9 Hz, 1H), 7.08 (d, J=11.8Hz, 1H), 4.11-4.15 (m, 1H), 2.10 (s, 3H), 1.50-1.57 (m, 2H), 1.30-1.44(m, 3H), 1.01 (s, 6H), 0.76 (s, 6H), 0.71-0.73 (m, 2H), 0.55-0.57 (m,2H); m/z=484 (M+H)⁺.

Example 44 Synthesis of4-(1,2,2,6,6-Pentamethylpiperidin-4-ylamino)-2-(4-Cyclopropyl-2-Fluoro-5-(1H-Tetrazol-1-yl)Phenylamino)Pyrimidine-5-Carbonitrile

A mixture of2-chloro-5-cyano-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidin-4-amine(0.205 g, 0.66 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(1H-tetrazol-1-yl)benzenamine (0.160 g, 0.730mmol, 1.1 equiv), and para-toluenesulfonic acid monohydrate (0.100 g,0.530 mmol, 0.8 equiv) in IPA (25 mL) were heated to 100° C. overnight.After cooling to ambient temperature, the crude mixture was quenchedwith 2M NH₃/MeOH followed by concentrating to dryness and repeatingonce. The crude product was purified by flash chromatography and elutedwith DCM:2M NH₃/MeOH (100:0 to 95:5 using 2% 2M NH₃/MeOH increments) toprovide the desired product which was recrystallized with DCM/Hexanes togive the title compound (0.170 mg, 52%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.81 (s, 1H), 9.51 (br. s, 1H), 8.29 (s,1H), 7.64 (d, J=6.6 Hz, 1H), 7.41 (d, J=7.7 Hz, 1H), 7.11 (d, J=11.6 Hz,1H), 4.10-4.18 (m, 1H), 2.09 (s, 3H), 1.50-1.57 (m, 2H), 1.37-1.49 (m,5H), 0.89-0.99 (m, 6H), 0.72-0.82 (m, 8H), 0.59-0.62 (m, 2H); m/z=491(M+H)⁺.

Example 45 Synthesis of 2-Isopropyl-5-Nitroaniline

70% HNO₃ (5.1 mL, 84.76 mmol, 1.2 equiv) was added dropwise to a mixtureof 2-isopropylaniline (10 mL, 9.55 g, 70.63 mmol, 1 equiv) in 70 mL ofconc. sulfuric acid at 0° C. The reaction mixture was stirred at thistemperature for 30 minutes and then poured onto ice. The aqueous mixturewas extracted with EtOAc (2×150 mL). The organic layers were combinedand washed with sat′d NaHCO₃. After evaporation, the residue waspurified by column chromatography on silica gel using EtOAc/hexanes(3/7) to give 2 g of product (16%) as a dark red oil.

¹H NMR (CDCl₃, 300 MHz): δ 7.60 (dd, J=8.1, 2.7 Hz, 1H), 7.50 (d, J=2.7Hz, 1H), 7.23 (d, J=8.7 Hz, 1H), 2.91 (sept, J=6.6 Hz, 1H), 1.28 (d,J=6.9 Hz, 6H); m/z=181 (M+H)⁺.

Example 46 Synthesis of 1-(2-Isopropyl-5-Nitrophenyl)-1H-Tetrazole

N.b.: TMS-N₃ and tetrazole product are potentially explosive. Use ablast shield for this reaction and glassware with no scratches, cracks,etc. Avoid contact with metals, including metal spatulas. Keep theproduct slightly wet with residual solvent from the column.

To a solution of 2-isopropyl-5-nitroaniline (1.02 g, 5.67 mmol, 1 equiv)in 15 mL of acetic acid, trimethylorthoformate (3.1 mL, 28.35 mmol, 5equiv) was added and the reaction mixture was stirred at roomtemperature for 10 minutes. The sodium azide (921 mg, 14.2 mmol, 2.5equiv) was added and the reaction mixture was heated to 120° C. for 1hour behind a blast shield. After allowing to cool to 0° C., 15 mL of 6NHCl was added. To the above solution sodium nitrite (587 mg, 8.51 mmol,1.5 equiv) in 7.5 mL of water was added dropwise. The resulting solutionwas stirred at 0° C. for 15 minutes behind a blast shield. Around 60 mLof 2N NaOH was added to the above solution (ca. pH 4-5), the resultingprecipitate was filtered and dried to give the desired product (780 mg)as a tan solid. The filtrate was extracted with EtOAc. The organic layerwas separated and evaporated. The residue was purified by columnchromatography on silica gel using EtOAc/hexanes (3/7) to give another200 mg of product (total 76%).

¹H NMR (CDCl₃, 300 MHz): δ 8.85 (s, 1H), 8.45 (dd, J=8.7, 2.4 Hz, 1H),8.18 (d, J=2.1 Hz, 1H), 7.76 (d, J=8.7 Hz, 1H), 2.72 (sept, J=6.9 Hz,1H), 1.25 (d, J=6.9 Hz, 6H); m/z=234 (M+H)⁺

Example 47 Synthesis of 4-Isopropyl-3-(1H-Tetrazol-1-yl)Benzenamine

A mixture of 1-(2-isopropyl-4-5-nitrophenyl)-1H-tetrazole (780 mg, 3.35mmol, 1 equiv), iron powder (564 mg, 10.03 mmol, 3 equiv) and ammoniumchloride (541 mg, 10.10 mmol, 3 equiv) in EtOH (20 mL) and water (4 mL)was refluxed for 2 hours. After cooling to room temperature, thereaction mixture was filtered through a pad of Celite, and the pad ofCelite was rinsed with EtOAc (50 mL). The filtrate was washed withwater. The organic layer was separated and evaporated to dryness. Theresidue was purified by column chromatography on silica gel usingEtOAc/hexanes (1/1) to give the product (500 mg, 74%) as a tan solid.m/z=204 (M+H)⁺.

Example 48 Synthesis ofN2-(4-Isopropyl-3-(1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (160 mg, 0.495 mmol, 1 equiv),4-isopropyl-3-(1H-tetrazol-1-yl)benzenamine (121 mg, 0.594 mmol, 1.2equiv), and para-toluenesulfonic acid monohydrate (75 mg, 0.396 mmol,0.8 equiv) in IPA (3 mL) were heated to 100° C. for 3 hours. Aftercooling to ambient temperature, the crude mixture was quenched with 2MNH₃/MeOH followed by concentrating to dryness. The crude product waspurified by flash chromatography and eluted with DCM:2M NH₃/MeOH (95:5)to provide the desired product (120 mg, 54%) as a white solid.

¹H NMR (DMSO-d₆, 300 MHz): δ 9.84 (s, 1H), 9.25 (br. s, 1H), 7.98-7.92(m, 1H), 7.85 (d, J=2.1 Hz, 1H), 7.64 (br. s, 1H), 7.38 (d, J=8.7 Hz,1H), 7.25-7.15 (m, 1H), 4.40-4.30 (m, 1H), 2.28-2.22 (m, 1H), 1.65-1.60(m, 2H), 1.20-1.10 (m, 2H), 1.05 (d, J=6.6 Hz, 6H), 1.05-1.00 (m, 12H);m/z=454 (M+H)⁺.

Example 49 Synthesis of2-(4-Isopropyl-3-(1H-Tetrazol-1-yl)Phenylamino)-4-(2,2,6,6-Tetramethylpiperidin-4-ylamino)Pyrimidino-5-Carboxyamide

A mixture of2-chloro-4-(2,2,6,6-tetramethylpiperidin-4-ylamino)pyrimidino-5-carboxyamide(160 mg, 0.513 mmol, 1 equiv),4-isopropyl-3-(1H-tetrazol-1-yl)benzenamine (125 mg, 0.616 mmol, 1.2equiv), and para-toluenesulfonic acid monohydrate (78 mg, 0.410 mmol,0.8 equiv) in IPA (3 mL) were heated to 100° C. for 3 hours. The solidwas filtered, washed with IPA and sonicated in 1N NaOH. The resultingsolid was filtered, washed with water and dried to give the titlecompound (200 mg, 81%) as a pale white solid.

¹H NMR (DMSO-d₆, 300 MHz): δ 9.85 (s, 1H), 9.69 (br. s, 1H), 9.15 (br.s, 1H), 8.51 (s, 1H), 8.06 (br. s, 1H), 7.78 (br. s, 1H), 7.62 (br. s,1H), 7.42 (d, J=9.0 Hz, 1H), 7.18 (br. s, 1H), 4.35-4.25 (m, 1H),2.30-2.26 (m, 1H), 1.79-1.75 (m, 2H), 1.17-1.13 (m, 2H), 1.05 (d, J=6.9Hz, 6H), 1.04 (s, 12H); m/z=479 (M+H)⁺.

Example 50 Synthesis of2-(4-Isopropyl-3-(1H-Tetrazol-1-yl)Phenylamino)-4-(2,2,6,6-Tetramethylpiperidin-4-ylamino)Pyrimidino-5-Carbonitrile

A mixture of4-(2,2,6,6-tetramethylpiperidin-4-ylamino)-2-chloropyrimidine-5-carbonitrile(80 mg, 0.272 mmol, 1 equiv),4-isopropyl-3-(1H-tetrazol-1-yl)benzenamine (66 mg, 0.326 mmol, 1.2equiv), and para-toluenesulfonic acid monohydrate (41 mg, 0.218 mmol,0.8 equiv) in IPA (2 mL) were heated to 80° C. for 3 hours. Aftercooling to ambient temperature, the crude mixture was quenched with 2MNH₃/MeOH followed by concentrating to dryness. The crude product waspurified by flash chromatography and eluted with DCM:2M NH₃/MeOH (95:5)to provide the desired product (87 mg, 70%) as a white solid.

¹H NMR (DMSO-d₆, 300 MHz): δ 9.95 (br. s, 1H), 9.83 (s, 1H), 8.32 (s,1H), 8.05 (br. s, 1H), 7.52 (br. s, 1H), 7.44 (d, J=8.1 Hz, 2H),4.50-4.40 (m, 1H), 2.32-2.25 (m, 1H), 1.59-1.55 (m, 2H), 1.25-1.17 (m,2H), 1.05 (d, J=6.6 Hz, 6H), 1.01 (s, 6H), 0.99 (s, 6H); m/z=461 (M+H)⁺.

Synthesis of Compounds with Substituted Tetrazolyl Substituents

Example 51 Synthesis ofN-(2-Cyclopropyl-4-Fluoro-5-Nitrophenyl)Isobutyramide

To a solution of 2-cyclopropyl-4-fluoro-5-nitrobenzenamine (as describedin WO2011068898) (1.98 g, 10.09 mmol, 1 equiv) in dichloromethane (50mL) at room temperature, was added NaHCO₃ (7.65 g, 90.84 mmol, 9 equiv),followed by 2-methylpropanoyl chloride (6.34 mL, 60.56 mmol, 6 equiv).The reaction mixture was stirred overnight. The reaction mixture wastaken in water, and the layers were separated. The organic layer waswashed with ice-cold 1N NaOH 2×, brine 1×, dried over Na₂SO₄, andconcentrated to dryness. The crude product was absorbed onto silica geland purified by flash chromatography and eluted with hex:EtOAc=100:0 to50%-70% EtOAc using 10% EtOAc increments to affordN-(2-cyclopropyl-4-fluoro-5-nitrophenyl)isobutyramide (2.04 g, 84%) as alight-brown solid.

¹H NMR (DMSO d₆, 300 MHz): δ 9.63 (br. s, 1H), 8.17-8.19 (d, J=7.5 Hz,1H), 7.05-7.10 (d, J=12.9 Hz, 1H), 2.66-2.75 (m, 1H), 2.02-2.11 (m, 1H),1.04-1.12 (m, 8H), 0.78-0.83 (m, 2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ−122.0 (t); LCMS (m/z): 267 (MH⁺).

Example 52 Synthesis ofN-(2-Cyclopropyl-4-Fluoro-5-Nitrophenyl)Cyclopropane Carboxamide

The general procedure described in Example 51 was followed.N-(2-Cyclopropyl-4-fluoro-5-nitrophenyl)cyclopropane carboxamide (2.46g, 92%) was obtained from 2-cyclopropyl-4-fluoro-5-nitrobenzenamine(described in WO2011068898) and cyclopropanecarboxyl chloride.

¹H NMR (DMSO d₆, 300 MHz): δ 9.94 (br. s, 1H), 8.27-8.30 (d, J=7.4 Hz,1H), 7.04-7.09 (d, J=12.7 Hz, 1H), 2.11-2.20 (m, 1H), 1.90-1.98 (m, 1H),1.07-1.14 (m, 2H), 0.81-0.86 (m, 6H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ−123.0 (t); LCMS (m/z): 265 (MH⁺).

Example 53 Synthesis ofN-(2-Cyclopropyl-4-Fluoro-5-Nitrophenyl)Acetamide

The general procedure described in Example 51 was followed.N-(2-Cyclopropyl-4-fluoro-5-nitrophenyl)acetamide (2.04 g, 84%) wasobtained from 2-cyclopropyl-4-fluoro-5-nitrobenzenamine (described inWO2011068898) and acetyl chloride.

¹H NMR (DMSO d₆, 300 MHz): δ 9.71 (br. s, 1H), 8.23-8.26 (d, J=7.8 Hz,1H), 7.03-7.07 (d, J=12.9 Hz, 1H), 2.08-2.16 (m, 4H), 1.05-1.12 (m, 2H),0.80-0.85 (m, 2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ −123.0 (t); LCMS (m/z):239 (MH⁺).

Example 54 Synthesis of1-(2-Cyclopropyl-4-Fluoro-5-Nitrophenyl)-5-Isopropyl-1H-Tetrazole

N-(2-Cyclopropyl-4-fluoro-5-nitrophenyl)isobutyramide (1.90 g, 7.14mmol, 1 equiv) was dissolved in acetonitrile (40 mL) under argon andcooled to −5° C. (external temperature). While maintaining thetemperature at −5° C., trifluoromethanesulfonic anhydride (2.40 mL, 4.03g, 14.27 mmol, 2 equiv) was added slowly dropwise and stirred for 1-2minutes. Then trimethylsilyl azide (3.75 mL, 28.54 mmol, 4 equiv) wasadded slowly dropwise while maintaining the temperature at −5° C. TLC,LCMS indicated the reaction was complete in less than 1 minute. Whilemaintaining the temperature at −5° C., the reaction was slowly quenchedwith ice-cold saturated NaHCO₃ and diluted with EtOAc. The layers wereseparated, and the organic layer was washed with brine 1×, dried overNa₂SO₄, and concentrated to dryness. The crude product was absorbed ontosilica gel and purified by flash chromatography and eluted withhex:EtOAc=100:0 to 25%-30% EtOAc using 5% EtOAc increments to afford1-(2-cyclopropyl-4-fluoro-5-nitrophenyl)-5-isopropyl-1H-tetrazole (1.69g, 78%) as a yellow solid.

¹H NMR (DMSO d₆, 300 MHz): δ 8.59-8.63 (m, 1H), 7.35-7.40 (m, 1H),2.96-3.08 (m, 1H), 0.96-1.24 (m, 11H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ−114.0 (t); LCMS (m/z): 292 (MH⁺).

Example 55 Synthesis of5-Cyclopropyl-1-(2-Cyclopropyl-4-Fluoro-5-Nitrophenyl)-1H-Tetrazole

The general procedure described in Example 54 was followed.5-Cyclopropyl-1-(2-cyclopropyl-4-fluoro-5-nitrophenyl)-1H-tetrazole(2.14 g, 89%) was obtained from reaction ofN-(2-cyclopropyl-4-fluoro-5-nitrophenyl)cyclopropanecarboxamide at −20°C. for 1 hour.

¹H NMR (DMSO d₆, 300 MHz): δ 8.56-8.59 (d, J=7.2 Hz, 1H), 7.41-7.45 (d,J=12.6 Hz, 1H), 1.81-1.90 (m, 1H), 1.23-1.32 (m, 1H), 0.93-1.15 (m, 8H);¹⁹F NMR (282 MHz; d₆-DMSO) δ −114.0 (t); LCMS (m/z): 290 (MH⁺).

Example 56 Synthesis of1-(2-Cyclopropyl-4-Fluoro-5-Nitrophenyl)-5-Methyl-1H-Tetrazole

The general procedure described in Example 54 was followed.1-(2-Cyclopropyl-4-fluoro-5-nitrophenyl)-5-methyl-1H-tetrazole (1.95 g,92%) was obtained from reaction ofN-(2-cyclopropyl-4-fluoro-5-nitrophenyl)acetamide at −78° C. to roomtemperature for overnight.

¹H NMR (DMSO d₆, 300 MHz): δ 8.52-8.54 (d, J=7.3 Hz, 1H), 7.39-7.44 (d,J=12.7 Hz, 1H), 2.43 (s, 3H), 1.21-1.30 (m, 1H), 0.92-1.04 (m, 4H); ¹⁹FNMR (282 MHz; d₆-DMSO) δ −114.0 (t); LCMS (m/z): 264 (MH⁺).

Example 57 Synthesis of4-Cyclopropyl-2-Fluoro-5-(5-Isopropyl-1H-Tetrazol-1-yl)Benzenamine

A Parr vessel was charged with1-(2-cyclopropyl-4-fluoro-5-nitrophenyl)-5-isopropyl-1H-tetrazole (1.69g, 5.80 mmol), EtOH (60 mL), AcOH (900 uL), and 10% Pd/C (50% in water,Degussa type E101; 340 mg, 20% by weight of the starting nitro compound)giving a suspension. The vessel was sealed, degassed, and back-filledwith H₂ (×3). The vessel was then charged with 30 psi H₂ and allowed toshake until LCMS analysis indicated conversion. For this reaction, LCMSanalysis indicated conversion at 2 days. The reaction mixture wasfiltered through a pad of Celite, and the pad of Celite was rinsed withMeOH. The filtrate was evaporated to dryness. The crude product waspartitioned between EtOAc and H₂O which had been adjusted to ca. pH12-14 with 3N NaOH. The aqueous and organic layers were partitioned, andthe organic layer washed with 3N NaOH 1×. The aqueous layer wasextracted with EtOAc 3×. The combined organic extracts were dried(Na₂SO₄), filtered, and the solvent removed in vacuo to give4-cyclopropyl-2-fluoro-5-(5-isopropyl-1H-tetrazol-1-yl)benzenamine (1.08g, 71%) off-white solid.

¹H NMR (DMSO d₆, 300 MHz): δ 6.74-6.77 (m, 1H), 6.81-6.86 (m, 1H), 5.42(br. s, 2H), 2.92-3.01 (m, 1H), 1.21-1.24 (m, 6H), 0.94-1.04 (m, 1H),0.63-0.67 (m, 2H), 0.44-0.57 (m, 2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ−130.0 (t); LCMS (m/z): 262 (MH⁺).

Example 58 Synthesis of4-Cyclopropyl-5-(5-Cyclopropyl-1H-Tetrazol-1-yl)-2-Fluorobenzenamine

The general procedure described in Example 57 was followed.4-Cyclopropyl-5-(5-cyclopropyl-1H-tetrazol-1-yl)-2-fluorobenzenamine(205 mg, 97%) was obtained from reaction of5-cyclopropyl-1-(2-cyclopropyl-4-fluoro-5-nitrophenyl)-1H-tetrazole for2 hours.

¹H NMR (DMSO d₆, 300 MHz): δ 6.87-6.91 (d, J=12.6 Hz, 1H), 6.77-6.80 (d,J=8.70 Hz, 1H), 5.45 (br. s, 2H), 1.72-1.81 (m, 1H), 1.03-1.21 (m, 5H),0.61-0.67 (m, 2H), 0.48-0.54 (m, 2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ−130.0 (t); LCMS (m/z): 260 (MH⁺).

Example 59 Synthesis of4-Cyclopropyl-2-Fluoro-5-(5-Methyl-1H-Tetrazol-1-yl)Benzenamine

The general procedure described in Example 57 was followed.4-Cyclopropyl-2-fluoro-5-(5-methyl-1H-tetrazol-1-yl)benzenamine (1.68 g,97%) was obtained from reaction of1-(2-cyclopropyl-4-fluoro-5-nitrophenyl)-5-methyl-1H-tetrazole for 5hours.

¹H NMR (DMSO d₆, 300 MHz): δ 6.84-6.89 (d, J=12.4 Hz, 1H), 6.73-6.76 (d,J=8.80 Hz, 1H), 5.42 (br. s, 2H), 2.38 (s, 3H), 1.05-1.14 (m, 1H),0.60-0.66 (m, 2H), 0.47-0.52 (m, 2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ−130.0 (t); LCMS (m/z): 234 (MH⁺).

Example 60 Synthesis ofN2-(4-Cyclopropyl-2-Fluoro-5-(5-Isopropyl-1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (300 mg, 0.928 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(5-isopropyl-1H-tetrazol-1-yl)benzenamine (291mg, 1.11 mmol, 1.2 equiv), and PTSA monohydrate (191 mg, 0.742 mmol, 0.8equiv) in isopropyl alcohol (10 mL) were heated to 70° C. for 7 days.After cooling to ambient temperature, the crude reaction mixture wasconcentrated to dryness and taken in water, EtOAc, and 1N NaOH. Thelayers were separated. The organic layer was washed with 1N NaOH 2×,dried over Na₂SO₄, filtered, and concentrated to dryness. The crudeproduct was purified by flash chromatography and eluted with DCM:2MNH₃/MeOH=100:0 to 96:4 using 1% 2M NH₃/MeOH increments to give compoundN2-(4-cyclopropyl-2-fluoro-5-(5-isopropyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine(245 mg, 52%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 8.55 (s, 1H), 7.71-7.82 (m, 2H), 7.12-7.19(m, 1H), 6.96-7.00 (d, J=11.1 Hz, 1H), 4.01-4.39 (m, 1H), 2.91-2.99 (m,1H), 1.52-1.59 (m, 2H), 0.98-1.24 (m, 22H), 0.78-0.81 (m, 2H), 0.60-0.69(m, 2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ −117 (s), 167 (s); LCMS (m/z): 512(MH⁺).

Example 61 Synthesis ofN2-(4-Cyclopropyl-5-(5-Cyclopropyl-1H-Tetrazol-1-yl)-2-Fluorophenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (256 mg, 0.791 mmol, 1 equiv),4-cyclopropyl-5-(5-cyclopropyl-1H-tetrazol-1-yl)-2-fluorobenzenamine(205 mg, 0.791 mmol, 1 equiv), and PTSA monohydrate (120 mg, 0.633 mmol,0.8 equiv) in IPA (8 mL) were heated to 70° C. for 8 days. After coolingto ambient temperature, the crude mixture was concentrated to drynessand taken in water, EtOAc, and 1N NaOH. The layers were separated. Theorganic layer was washed with 1N NaOH 2×, dried over Na₂SO₄, filtered,and concentrated to dryness. The crude product was purified bytrituration from EtOAc:hexane to give compoundN2-(4-cyclopropyl-5-(5-cyclopropyl-1H-tetrazol-1-yl)-2-fluorophenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine(276 mg, 68%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 8.52 (s, 1H), 7.81-7.88 (m, 2H), 7.16-7.20(m, 1H), 7.02-7.06 (d, J=12.0 Hz, 1H), 4.01-4.39 (m, 1H), 1.69-1.81 (m,1H), 1.52-1.59 (m, 2H), 0.94-1.24 (m, 20H), 0.75-0.79 (m, 2H), 0.60-0.68(m, 2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ −118 (s), 166 (s); LCMS (m/z): 510(MH⁺).

Example 62 Synthesis ofN2-(4-Cyclopropyl-2-Fluoro-5-(5-Methyl-1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture of2-chloro-5-fluoro-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-4-aminehydrochloride (416 mg, 1.29 mmol, 1 equiv),4-cyclopropyl-2-fluoro-5-(5-methyl-1H-tetrazol-1-yl)benzenamine (300 mg,1.29 mmol, 1 equiv), and PTSA monohydrate (196 mg, 1.03 mmol, 0.8 equiv)in IPA (13 mL) were heated to 70° C. for 6 days. After cooling toambient temperature, the crude mixture was concentrated to dryness andtaken in water, EtOAc, and 1N NaOH. The layers were separated. Theorganic layer was washed with 1N NaOH 2×, dried over Na₂SO₄, filtered,and concentrated to dryness. The crude product was purified bytrituration from EtOAc:hexane to give compoundN2-(4-cyclopropyl-2-fluoro-5-(5-methyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine(361 mg, 58%) as a solid.

¹H NMR (DMSO d₆, 300 MHz): δ 8.52 (s, 1H), 7.74-7.81 (m, 2H), 7.14-7.19(m, 1H), 6.98-7.08 (d, J=12.0 Hz, 1H), 4.01-4.35 (m, 1H), 2.39 (s, 3H),1.52-1.59 (m, 2H), 0.95-1.14 (m, 16H), 0.74-0.78 (m, 2H), 0.61-0.67 (m,2H); ¹⁹F NMR (282 MHz; d₆-DMSO) δ −118 (s), 167 (s); LCMS (m/z): 484(MH⁺).

Example 63 Synthesis ofN2-(4-Cyclopropyl-2-Fluoro-5-(5-(Trifluoromethyl)-1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N4-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

The general procedures described in Examples 40 and 41 were followed.

Characterization data of title compound: ¹H NMR (DMSO) δ: 8.53 (s, 1H),7.79-7.82 (m, 2H), 7.17 (d, 1H), 7.01 (d, 1H), 4.32 (br. m, 1H), 1.61(d, 2H), 1.09-1.17 (m, 4H), 0.99 (s, 12H), 0.67 (d, 2H), 0.52 (m, 2H);¹⁹F NMR (DMSO) δ: −165.9, −119.1, −60.7; LCMS (m/z): 538 (MH⁺).

Example 64 Synthesis ofN²-(4-Cyclopropyl-2-Fluoro-5-(5-(Fluoromethyl)-1H-Tetrazol-1-yl)Phenyl)-5-Fluoro-N⁴-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidin-2,4-Diamine

The general procedure described in Example 51 was followed where thelast reduction step was performed with conditions from Example 41.

¹H NMR (300 MHz; d₆-DMSO) δ 8.62 (s, 1H), 8.26 (s, 1H), 7.84 (br. s,1H), 7.26 (d, 1H), 7.06 (d, 1H), 5.67 (d, J=47.4 Hz, 2H), 4.30-4.20 (m,1H), 2.31-2.25 (m, 1H), 1.68-1.64 (m, 2H), 1.24-1.20 (m, 2H), 1.11 (s,6H), 1.05 (s, 6H), 0.74 (m, 2H), 0.62 (m, 2H); m/z=502.4 (M+H)⁺;m/z=500.3 (M−H)⁺.

Synthesis ofTrans-5-Fluoro-N²-(2-Fluoro-4-(2-Trifluoromethyl)Cyclopropyl)5-(1H-Tetrazol-1-yl)Phenyl)-N¹-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

Example 65 Preparation of Trans-2-(Trifluoromethyl)CyclopropylboronicAcid MIDA Ester

Step 1: Preparation of trifluoromethyl diazomethane

Sodium nitrite (4.6 g, 66 mmol) in water (10 mL) was added in oneportion to a stirred solution of 2,2,2-trifluoroethylamine hydrochloride(8.1 g, 60 mmol) in water (25 mL) and ether (45 mL) at 0° C. Thereaction vessel was sealed with a teflon stopper and the mixture stirredfrom 0° C. to room temperature and stirred at room temperature forapproximately 3 hours. The mixture was then partitioned in a separatingfunnel and the ether layer containing the product was used directly inthe next step without further purification. The yield of thetrifluoromethyl diazomethane product was assumed to be approximately 50%based on literature citation herein (=3.32 g).

A safety notice for the procedure: Diazo compounds are potentiallyexplosive. The reaction was performed behind a blast shield in glasswarefree from cracks or prominent scratches and glassware was inspectedprior to use. Reference for the procedure is made to J. Am. Chem. Soc.1943, 65, 1458, which is hereby incorporated by reference in itsentirety.

Step 2: Preparation of trans-2-(trifluoromethyl)cyclopropylboronic acidMIDA ester

A mixture of trifluoromethyl diazomethane (3.32 g, 30 mmol) in Et₂O (45mL) was added dropwise to a stirred suspension of vinylboronic acid MIDAester (Sigma-Aldrich, St. Louis, Mo.; 1.65 g, 9.0 mmol) and Pd(OAc)₂ (50mg) in Et₂O at room temperature. After adding for 10 minutes (about aquarter of the trifluoromethyl diazomethane had been added at thisstage), more Pd(OAc)₂ (50 mg) and Et₂O (100 mL) was added, andtrifluoromethyl diazomethane was added dropwise for another 20 minutes(approximately three quarters added after this time). EtOAc (50 mL) andPd(OAc)₂ (50 mg) were added at this point and the remainingtrifluoromethyl diazomethane was added dropwise over 10 minutes. Aftercomplete addition of the trifluoromethyl diazomethane the mixture wasanalysed by TLC which indicated complete reaction. The solvent wasremoved under vacuum and the residue was dry-loaded on to silica gel andpurified by column chromatography on silica gel using EtOAc as eluent togive the product (1.45 g, 61%) as a solid. A sample was recrystallisedfrom EtOAc, and then a small sample recrystallized again from1,2-dichloroethane, to give crystals suitable for analysis by x-raycrystallography. X-ray studies indicated confirmed the material to bethe trans-isomer. Note: product is trans-isomer but racemic.

Reference for the procedure is made to Tetrahedron Letters 2010, 51,1009-1011, which is hereby incorporated by reference in its entirety.Reference for the procedure and procedures below is made to U.S.Provisional Patent Application Ser. No. 61/418,654 (Attorney Docket No.RIGL-071PRV), entitled ‘Cyclopropyl MIDA Boronate’, filed Dec. 1, 2010,which is hereby incorporated in its entirety.

¹H NMR (DMSO-d₆, 300 MHz): δ 3.99-3.72 (m, 4H), 2.70 (s, 3H), 1.28 (m,1H), 0.53 (m, 1H), 0.31 (m, 1H), 0.00 (m, 1H); ¹⁹F NMR (DMSO-d₆, 282MHz): −65.4.

Example 66 Preparation ofTrans-4-Fluoro-2-(2-Trifluoromethyl)Cyclopropyl)-5-Nitrobenzeneamine

A mixture of 2-bromo-4-fluoro-5-nitroaniline (353 mg, 1.5 mmol),trans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester (477 mg, 1.8mmol), Pd(OAc)₂ (51 mg, 0.23 mmol), Cy₃P (126 mg, 0.45 mmol) and Cs₂CO₃(2.93 g, 9.0 mmol) in toluene (5 mL) and H₂O (1.5 mL) was de-gassed withN₂ for 15 minutes, then placed under a nitrogen atmosphere and heated toreflux for 3 hours. The temperature of the mixture was reduced to 100°C. (block temperature) and the mixture stirred overnight. Aftercompletion of the reaction, the mixture was cooled and EtOAc (100 mL)and H₂O (100 mL) were added. The mixture was filtered through Celite andthe filter cake washed with H₂O (50 mL) and EtOAc (50 mL). The aqueousand organic layers of the filtrate were partitioned, and the aqueouslayer was extracted with EtOAc (1×50 mL). The combined organic layerswere washed with brine (1×50 mL), dried (MgSO₄), filtered and thesolvent removed under vacuum to leave a crude residue. The residue wasdry-loaded on to silica gel and purified by column chromatography onsilica gel using EtOAc/hexane (2:8 to 3:7) as eluent to give the product(214 mg, 54%). Note: product is trans-isomer but racemic.

¹H NMR (300 MHz, d₆-DMSO): δ 7.32 (dd, J=6.8, 2.3 Hz, 1H), 7.03 (dd,J=12.6, 2.0 Hz, 1H), 5.60 (br. s, 2H), 2.49-2.41 (m, 1H), 2.36-2.29 (m,1H), 1.42-1.35 (m, 1H), 1.16-1.11 (m, 1H); ¹⁹F NMR (282 MHz, d₆-DMSO): δ−135.7 (dd), −64.8 (d); m/z=265.87 (M+H)⁺; m/z=263.00 (M−H)⁺.

Example 67 Preparation ofTrans-(4-Fluoro-2-(2-Trifluoromethyl)Cyclopropyl)-5-Nitrophenyl-1H-Tetrazole

A mixture oftrans-4-fluoro-2-(2-trifluoromethyl)cyclopropyl)-5-nitrobenzeneamine(200 mg, 0.76 mmol), trimethylorthoformate (0.83 mL, 7.6 mmol),trimethylsilyl azide (200 μL, 1.52 mmol) and AcOH (3 mL) were heated to70° C. and stirred overnight. After cooling, the mixture wasconcentrated under vacuum. The residue was partitioned between EtOAc (75mL0 and 1N NaOH (30 mL). The organic layer was dried (MgSO₄), filteredand the solvent removed under vacuum to leave a crude residue. Theresidue was purified by column chromatography on silica gel (residuedry-loaded on to silica gel) using EtOAc/hexane (3:7 to 4:6) as eluentto give the product (154 mg, 64%). Note: product is trans-isomer butracemic.

¹H NMR (300 MHz, d₆-DMSO): δ 9.85 (s, 1H), 8.57 (d, J=7.0 Hz, 1H), 7.69(d, J=12.1 Hz, 1H), 2.52 (m, 1H), 2.19-2.20 (m, 1H), 1.55-1.49 (m, 1H),1.38-1.30 (m, 1H); ¹⁹F NMR (282 MHz, d₆-DMSO): δ −114.6, −65.8 (d);m/z=359.10 (M+MeCN+H)⁺; m/z=316.04 (M−H)⁺.

Example 68 Preparation ofTrans-(2-Fluoro-4-(2-Trifluoromethyl)Cyclopropyl)-5-(1H-Tetrazol-1-yl)Benzeneamine

A mixture oftrans-(4-fluoro-2-(2-trifluoromethyl)cyclopropyl)-5-nitrophenyl-1H-tetrazole(150 mg, 0.47 mmol) and palladium, 10% by weight on charcoal, Degussagrade E101 (30 mg), AcOH (75 μL) and EtOH (20 mL) were hydrogenated at25-30 psi for 1 week (until LC/MS showed >95% conversion to product.Note: the reduction of a hydroxylamine intermediate to the anilineproduct is the slow step). The mixture was then filtered through Celiteand the filter cake washed with EtOH (3×20 mL). The filtrate wasconcentrated under vacuum to leave a crude residue that was purified bycolumn chromatography on silica gel (residue dry-loaded on to silicagel) using EtOAc/hexane (4:6) as eluent to give the product (94 mg, 69%)as a solid. Note: product is trans-isomer but racemic.

¹H NMR (300 MHz, d₆-DMSO): δ 9.79 (m, 1H), 7.07 (d, J=12.2 Hz, 1H), 6.81(d, J=8.3 Hz, 1H), 5.65 (br. s, 2H), 2.07-1.95 (m, 2H), 1.17-1.11 (m,1H), 1.08-1.01 (m, 1H); ¹⁹F NMR (282 MHz, d₆-DMSO): δ −131.5 (dd), 65.5(d); m/z=329.15 (M+MeCN+H)⁺; m/z=286.08 (M−H)⁺.

Example 69 Preparation ofTrans-5-Fluoro-N²-(2-Fluoro-4-(2-Trifluoromethyl)Cyclopropyl)5-(1H-Tetrazol-1-yl)Phenyl)-N¹-(2,2,6,6-Tetramethylpiperidin-4-yl)Pyrimidine-2,4-Diamine

A mixture oftrans-(2-fluoro-4-(2-trifluoromethyl)cyclopropyl)-5-(1H-tetrazol-1-yl)benzeneamine(90 mg, 0.31 mmol),2-chloro-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)-4-pyrimidineaminehydrochloride (85 mg, 0.26 mmol) and para-toluenesulfonic acidmonohydrate (40 mg, 0.21 mmol) in isopropyl alcohol (2 mL) was heated to70° C. and stirred over a weekend. More isopropyl alcohol (10 mL) wasadded and the mixture became homogenous after this reached 70° C. Themixture was allowed to cool to room temperature whereupon a precipitateemerged. The mixture was filtered and the filter cake was washed withisopropyl alcohol (2 mL) [Note: there is still a lot of product in thefiltrate]. The filter cake was then suspended in EtOAc (50 mL) and 0.5 NNaOH (30 mL) was added. The aqueous and organic layers were partitionedand the organic layer was washed with brine (1×20 mL), dried (MgSO₄),filtered and the solvent removed under vacuum to leave the product (49mg, 35%) as a solid. Note: product is trans-isomer but racemic.

¹H NMR (300 MHz, d₆-DMSO): δ 9.83 (d, J=1.5 Hz, 1H), 8.65 (br. s, 1H),8.00 (d, J=7.3 Hz, 1H), 7.83 (d, J=3.8 Hz, 1H), 7.28 (d, J=11.7 Hz, 1H),7.20 (br. d, J=7.7 Hz, 1H), 4.29-4.15 (m, 1H), 2.19-2.10 (m, 1H),2.09-2.01 (m, 1H), 1.61-1.52 (m, 2H), 1.25-1.02 (m, 4H), 0.97 (s, 6H),0.92 (s, 6H); ¹⁹F NMR (282 MHz, d₆-DMSO): δ −165.7, −119.6, −65.6;m/z=538.48 (M+H)⁺; m/z=536.38 (M−H)⁺.

Example 70 PKC Assay

The inhibition of PKC-alpha, PKC-beta, PKC-delta, PKC epsilon andPKC-theta activity was determined via ELISA as follows: NUNC MAXISORP(#436110) or Costar High Binding (#3922) plates were coated with 0.01mg/mL Neutravidin (Pierce #PI-31000) in 1×PBS (100 μL/well) for 18-24hours at 4° C. When ready to be used, plates were washed with 1×PBST andthen blocked with 2% BSA in 1×PBST (100 μL/well) for a minimum of 1 hourat room temperature. The reactions were conducted in a volume of 60μL/well. When ready to begin, the plates were washed with 1×PBST toremove the 2% BSA blocking solution. Reaction solution containing thenecessary buffer components as well as the appropriate concentrations ofATP and peptide substrate was then added to each well (see Table 3).Appropriate concentrations of test compound was then added—with thevolume added should taking into consideration the DMSO tolerance of thekinases being about 0.2%. The reaction was then initiated by theaddition of kinase—the approximate final concentration of which islisted in Table 3 (note that this will vary depending on the batch tobatch variability in the activity of enzymes). After allowing thereaction to stand at room temperature for 20 minutes, the plates werethen washed with 1×PBST.

TABLE 3 Buffer [ATP] Time 1° and 2° Kinase components (uM) [peptide](uM)(min) antibodies Notes PKCs 20 mM 1 μM 1 μM PKC peptide 20Rabbit pSer PKC 0.15 mg/mL α: ~8 Hepes (biotin- min substrate Ab (CellDAG (Sigma ng/mL pH 7.4 RFARKGSLRQKNV) Signaling #2261); #D0138) β: ~165 mM MgCl₂ (Invitrogen #P2760) HRP-goat a-rabbit 0.75 mg/mL ng/mL 0.2 mM(Jackson Phosphoserine δ: ~13 CaCl₂ Immunoresearch (Sigma #P6641) ng/mL1 mM DTT #111-035-003) DMSO tolerance ε: ~13 0.05% Chaps ~0.2% ng/mLθ: ~8 ng/mL

After removal of the reaction mixture from the plate and washing with1×PBST, an antibody developing solution containing a 1:10,000 dilutionof the appropriate primary and secondary antibodies (Table 3) in a 0.1%BSA solution in 1×PBST was then added to each well (100 μL/well). Thiswas then allowed to stand at room temperature for a minimum of 1 hour.After this time, the plates were once again washed with 1×PBST. TheSuperSignal ELISA Pico Chemiluminescent substrate (Pierce #PI-37069) wasthen added (100 μL/well) and the plate was read on a luminescence platereader

Example 71 PKC Assay

Alternatively, the inhibition of PKC activity is measured by monitoringthe production of phosphorylated peptide by fluorescence polarization atdifferent concentrations of the inhibitor. Reactions are carried out in96-well plate format with a total volume of 20 μL, containing 20 mMHEPES, pH 7.4, 5 mM MgCl₂, 0.2 mM CaCl₂, 1 mM DTT, 0.02% Brij-35, 0.1mg/mL phosphatidylserine, 0.02 mg/mL dioleoyl-sn-glycerol and 5 μM eachof ATP and the peptide substrate. Compounds are first diluted seriallyin DMSO and then transferred to a solution containing the aboveconcentrations of HEPES, MgCl₂, CaCl₂, DTT, and Brij-35 to yield 5×compound solutions in 2% DMSO, which is then added to the reactionsolution. Reactions are initiated by the addition of PKC at a typicalconcentration as described in Table 4, and then allowed to incubate atroom temperature for 20 min. At the end of this time, a combination ofquench (EDTA) and detection (peptide tracer and antibody) reagents isadded using the protocol of Invitrogen P2748. After a 30 min. period ofincubation, the amount of phosphorylated peptide generated is measuredby fluorescence polarization (Ex=485 nm, Em=535 nm) using a TecanPolarian instrument.

TABLE 4 Typical enzyme Peptide SEQ Enzyme concen- substrate ID sourcetration PKC RFARKGSLRQKNV Seq Upstate Bio- 40 theta ID technologies,ng/mL No. Temecula, CA, 1 cat. #14-444 PKC RFARKGSLRQKNV SeqUpstate Bio- 50 epsilon ID technologies, ng/mL No. Temecula, CA, 1cat. #14-518

Example 72 IL-2 ELISA, Human Primary T Cell, Anti-CD3+CD28+ (Whole CellAssay)

Human primary T cell isolation and culture: Human primary T cells wereprepared as follows. Whole blood was obtained from a healthy volunteer,mixed 1:1 with PBS, layered on to Ficoll Hypaque (Amersham PharmaciaBiotech, Piscataway, N.J., Catalog #17-1440-03) in 2:1 blood/PBS:ficollratio and centrifuged for 30 min at 4° C. at 1750 rpm. The cells at theserum: ficoll interface were recovered and washed twice with 5 volumesof PBS. These freshly isolated human peripheral blood mononuclear cellswere cultured in Yssel's medium containing 40 U/mL IL2 in a flaskpre-coated with 1 μg/mL αCD3 and 5 μg/mL αCD28 (Anti-Human CD3, BDPharmingen Catalog #555336, Anti-Human CD28, Beckman Coulter Catalog#1M1376). The cells were stimulated for 3-4 days, then transferred to afresh flask and maintained in RPMI (RPMI-1640 with L-Glutamine;Mediatech, Inc., Herndon Va., cat. #10-040-CM) with 10% FBS and 40 U/mLIL-2. The primary T-cells were then washed twice with PBS to remove theIL-2.

Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000cells per well) were pre-incubated with or without test compound inYssel's medium for 1 hr at 37° C. Cells were then stimulated bytransferring them to round-bottom 96-well plates pre-coated with 1 μg/mlαCD3 and 5 μg/ml αCD28. For counter assay, cells were instead stimulatedby adding 8× stock solutions of PMA and ionomycin in Yssels (for finalconcentrations of 0.5 ng/ml PMA and 0.1 μM ionomycin, both fromCalbiochem). Cells were incubated at 37° C. for 24 hours before 100 μLsupernatants were harvested for quantification of IL-2 by ELISA usingHuman IL-2 Duoset ELISA Kit from R and D Systems, Cat. # DY202E.

Table 5 shows the IC₅₀ values for compounds tested in the whole cellassay, in which “A” indicates an IC₅₀ in the indicated assay of lessthan 0.25 μM; “B” is 0.25 to 0.5 μM; “C” is 0.5 to 1 μM; and “D”indicates that the IC₅₀ is greater than 1 μM.

TABLE 5 Whole Cell Compound assay I-1 A I-2 A I-3 C I-4 A I-5 A I-6 AI-7 A I-8 A I-9 A I-10 B I-11 A I-12 A I-13 A I-14 A I-15 A I-16 A I-17A I-18 A I-19 A I-20 A

Example 73 Calcium Influx

HEK-FLPTREX cells are stably transfected with pcDNA5/FRT/TO+hTRPV4a, ratTRPV1-HA or rTRPA1-HA are grown in Dulbecco's Modified Eagle's Medium(DMEM) containing 10% tetracycline-free fetal bovine serum, hygromycin(50 μg/ml) and blasticidin (10 μg/ml). Cells are treated withtetracycline (0.1 μg/ml, 20 h) to induce TRP expression. DRG fromthoracic and lumbar spinal cord of rats or mice are minced in coldHank's Balanced Salt Solution (HBSS) and incubated for 60 at 37° C. inDMEM containing 1 mg/ml of collagenase type IA and 0.1 mg/ml of DNAsetype IV, pelleted and incubated with 0.25% trypsin for 30 min. Neuronsare pelleted, suspended in DMEM containing 10% fetal bovine serum, 10%horse serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mMglutamine, dissociated by gentle trituration until the solution appearscloudy and homogeneous and plated on glass coverslips coated withPolyOnitine/laminin. Neurons are cultured for 3-4 days before theexperiment.

Cells grown on coverslips or on a 96 multiwell plate are incubated inHBSS (pH 7.4) containing Ca2+ and Mg2+, 20 mM HEPES buffer, 0.1% BSA,100 U/ml penicillin, 100 μg/ml streptomycin, with 2.5-5 μM Fura-2AM(Invitrogen) for 20-45 min at 37° C. Cells are washed and fluorescenceis measured at 340 nm and 380 nm excitation and 510 nm emission in aF-2500 spectrophotometer, or in a Flexstation 3 Microplate Reader III(for the measurement of the calcium in the cell population) or using aZeiss Axiovert microscope, an ICCD video camera and a video microscopyacquisition program (for the measurement of the calcium influx in thesingle neurons). Substances are injected directly into the chamber (20ml into 2 ml, for the spectrophotometer; 20 ml in 200 ml for theFlexstation, 50 ml in 350 ml in the chamber for the single cells).

Example 74 In Vivo Hyperplasia

Mechanical pain is quantified as the number of times the hind paw iswithdrawn in response to 5 applications of a 0.173 mN von Frey hair.Responses are expressed as a percentage (e.g. 3 withdrawals out of 5 arerecorded as 60%) and mechanical hyperalgesia defined as increase in thepercentage of withdrawal compared to basal measurement. 2) Mechanicalpain is quantified using the ‘up-down paradigm’, determining the 50%response threshold to the von Frey filaments applied to the mid-plantarsurface for 5 s or until a withdrawal response occurred. Von Freyfilaments are in this range of intensities: 1.65, 2.44, 2.83, 3.22,3.61, 3.84, 4.08.

Thermal hyperalgesia is assessed in mice using a plantar test apparatusand quantified as the latency of paw withdrawal to a radiant heat.Thermal hyperalgesia is defined as a decrease in the withdrawal latencycompared to the basal measurement. After measuring basal level mice,under light halothane anesthesia (5%), are injected with testingcompound into the left or right paws (5-10 μl intraplantar injection)and paw withdrawal measurements repeated at different time point. Toassess PAR2 TRPV1, TRPV4 and TRPA1 mediated hyperalgesia andpotentiation of TRPV-mediated responses, mice are treated with PAR2-APfor 15 min followed by capsaicin, 4αPDD or HNE. To assess the role ofprotein kinases, the antagonists or the corresponding vehicles areinjected 20-30 minutes before the challenge with agonists. The effectsinduced by the different treatments are evaluated within the same ratcomparing the responses recorded in the right paw (receiving for examplesaline, or vehicle) with the responses obtained in the left paw(receiving for example PAR2-AP or 4αPDD).

Formalin induced hyperalgesia is assessed using 5% solution of formalinadministered by intradermal injection into the dorsal surface of themouse or rat forepaw to induce a painful behavior. Pain is accessed on afour-level scale related to posture: 0, normal posture; 1, with theinjected paw remaining on the ground but not supporting the animal; 2,with the injected paw clearly raised; and 3, with the injected paw beinglicked, nibbled, or shaken. Animals are observed and scored for behaviorat 3 minutes after the injection (defined as initial phase that resultsfrom the direct stimulation of nociceptors), and then at 30-60 minutesafter the injection (defined as second phase that involves a period ofsensitization during which inflammatory phenomena occur). Thenociceptive behavioral score for each 3-min interval is calculated asthe weighted average of the number of seconds spent in each behavior.2.5% solution of formalin is administered by intraplantar injection andthermal and mechanical pain measured as described above after 30-60 min.To assess the role of protein kinases, antagonists or their vehicles(control) are injected into the right paws 20-30 minutes beforeformalin. Nociceptive behavior will be scored for each rats and comparedto control.

While the present invention has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of theinvention. In addition, many modifications may be made to adapt aparticular situation, material, composition of matter, process, processstep or steps, to the objective, spirit and scope of the presentinvention. All such modifications are intended to be within the scope ofthe claims appended hereto.

What is claimed is:
 1. A compound of the formula (I):

wherein R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy,cyano, halogen, acyl, aminoacyl, and nitro; Y¹ and Y² are independentlyselected from hydrogen, alkyl, and acyl; R¹ is selected from hydrogen,alkyl, and substituted alkyl; R^(a) and R^(b) are independently selectedfrom hydrogen and alkyl; R^(c) and R^(d) are independently selected fromhydrogen and alkyl; R^(6a) is selected from hydrogen, alkyl, substitutedalkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, andsubstituted cycloalkyl; R^(6b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R⁸ is selected from hydrogen, C₂₋₁₀ alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7x) is selected from hydrogen, alkyl,haloalkyl, cycloalkyl, and substituted cycloalkyl; wherein at least oneof R^(6a), R^(6b), R^(7b), and R⁸ is not hydrogen; wherein if R⁸ isfluoro, then R^(7b) is not hydrogen; wherein if R^(7b) is cyclopropyl,then at least one of R^(6a), R^(6b), R⁸, and R^(7x) is not hydrogen; andwherein if R⁸ is cyclopropyl, then at least one of R^(6a), R^(6b),R^(7b), and R^(7x) is not hydrogen; or a salt or stereoisomer thereof.2. The compound of claim 1, wherein the compound is of the formula (II):

wherein R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy,cyano, halogen, acyl, aminoacyl, and nitro; Y¹ and Y² are independentlyselected from hydrogen, alkyl, and acyl; R¹ is selected from hydrogen,alkyl, and substituted alkyl; R^(a) and R^(b) are independently selectedfrom hydrogen and alkyl; R^(c) and R^(d) are independently selected fromhydrogen and alkyl; R^(6a) is selected from hydrogen, alkyl, substitutedalkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, andsubstituted cycloalkyl; R^(6b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R⁸ is selected from hydrogen, C₂₋₁₀ alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7x) is selected from hydrogen, alkyl,haloalkyl, cycloalkyl, and substituted cycloalkyl; wherein at least oneof R^(6a) and R^(6b) is not hydrogen; or a salt or stereoisomer thereof.3. The compound of claim 1, wherein the compound is of the formula(III):

wherein R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy,cyano, halogen, acyl, aminoacyl, and nitro; Y¹ and Y² are independentlyselected from hydrogen, alkyl, and acyl; R¹ is selected from hydrogen,alkyl, and substituted alkyl; R^(a) and R^(b) are independently selectedfrom hydrogen and alkyl; R^(c) and R^(d) are independently selected fromhydrogen and alkyl; R^(6a) is selected from hydrogen, alkyl, substitutedalkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, andsubstituted cycloalkyl; R^(6b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R⁸ is selected from hydrogen, C₂₋₁₀ alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7x) is selected from hydrogen, alkyl,haloalkyl, cycloalkyl, and substituted cycloalkyl; wherein at least oneof R^(6a), R^(6b), R^(7b), and R⁸ is halogen; and wherein at least oneof R^(6a), R^(6b), R^(7b), and R⁸ is cycloalkyl, alkyl, or C₂₋₁₀ alkyl;or a salt or stereoisomer thereof.
 4. The compound of claim 1, whereinthe compound is of the formula (IV):

wherein R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy,cyano, halogen, acyl, aminoacyl, and nitro; Y¹ and Y² are independentlyselected from hydrogen, alkyl, and acyl; R¹ is selected from hydrogen,alkyl, and substituted alkyl; R^(a) and R^(b) are independently selectedfrom hydrogen and alkyl; R^(c) and R^(d) are independently selected fromhydrogen and alkyl; R^(6a) is selected from hydrogen, alkyl, substitutedalkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, andsubstituted cycloalkyl; R^(6b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R⁸ is selected from hydrogen, C₂₋₁₀ alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7x) is selected from hydrogen, alkyl,haloalkyl, cycloalkyl, and substituted cycloalkyl; wherein at least oneof R^(6a), R^(6b), R^(7b), and R⁸ is C₂₋₁₀ alkyl; or a salt orstereoisomer thereof.
 5. The compound of claim 1, wherein the compoundis of the formula (V):

wherein R⁵ is selected from haloalkyl, alkoxy, substituted alkoxy,cyano, halogen, acyl, aminoacyl, and nitro; Y¹ and Y² are independentlyselected from hydrogen, alkyl, and acyl; R¹ is selected from hydrogen,alkyl, and substituted alkyl; R^(a) and R^(b) are independently selectedfrom hydrogen and alkyl; R^(c) and R^(d) are independently selected fromhydrogen and alkyl; R^(6a) is selected from hydrogen, alkyl, substitutedalkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, andsubstituted cycloalkyl; R^(6b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7b) is selected from hydrogen, alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R⁸ is selected from hydrogen, C₂₋₁₀ alkyl,substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl,and substituted cycloalkyl; R^(7x) is haloalkyl; or a salt orstereoisomer thereof.
 6. The compound of claim 1, wherein R⁵ is cyano,halogen, acyl, or aminoacyl.
 7. The compound of claim 1, wherein Y¹ ishydrogen and Y² is hydrogen.
 8. The compound of claim 1, wherein R¹ ishydrogen.
 9. The compound of claim 1, wherein R^(a) and R^(b) are bothalkyl and R^(c) and R^(d) are both alkyl.
 10. The compound of claim 1,wherein at least one of R^(6a), R^(6b), R^(7b), and R⁸ is selected fromC₂₋₁₀ alkyl, halogen, and cycloalkyl.
 11. The compound of claim 1,wherein R^(6a) is hydrogen.
 12. The compound of claim 1, wherein R^(6b)is hydrogen or halogen.
 13. The compound of claim 1, wherein R⁸ iscyclopropyl or substituted cyclopropyl.
 14. The compound of claim 1,wherein R^(7x) is hydrogen.
 15. The compound of claim 1, wherein R^(7x)is trifluoromethyl or fluoromethyl.
 16. The compound of claim 1, whereinR^(7x) is alkyl or cycloalkyl.
 17. The compound of claim 1, wherein thecompound is selected from I-1:N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;I-2:2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;I-3:2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylicacid amide; I-4:2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;I-5:N2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;I-6:2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;I-7:N2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;I-8:2-(2-Fluoro-4-isopropyl-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;I-9:5-Fluoro-N2-(4-isopropyl-3-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;I-10:2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylicacid amide; I-11:2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;I-12:N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;I-13:5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;I-14:5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;and I-15:N2-[4-Cyclopropyl-3-(5-trifluoromethyl-tetrazol-1-yl)-phenyl]-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;I-16:N2-(4-cyclopropyl-2-fluoro-5-(5-isopropyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;I-17:N2-(4-cyclopropyl-5-(5-cyclopropyl-1H-tetrazol-1-yl)-2-fluorophenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;I-18:N2-(4-cyclopropyl-2-fluoro-5-(5-methyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;I-19:N2-(4-cyclopropyl-2-fluoro-5-(5-(trifluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;I-20:N2-(4-cyclopropyl-2-fluoro-5-(5-(fluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;and I-21:Trans-5-fluoro-N2-(2-fluoro-5-(1H-tetrazol-1-yl)-4-(2-(trifluoromethyl)cyclopropyl)phenyl)-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;or a solvate, prodrug, or a pharmaceutically acceptable salt thereof.18. A compound of the formula:

N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine(I-12), or a pharmaceutically acceptable salt or stereoisomer thereof.19. The compound of claim 18, wherein the pharmaceutically acceptablesalt is a formate salt.
 20. A pharmaceutical composition comprising acompound of claim 1 and a pharmaceutically acceptable carrier.
 21. Amethod of inhibiting a protein kinase C (PKC) activity in a biologicalsample or a patient, which method comprises contacting the biologicalsample or administering to the patient a compound of claim
 1. 22. Themethod of claim 21, wherein the inhibition of PKC results in treatmentof a disease or disorder that is mediated or sustained through theactivity of a PKC activity and wherein the disease or disorder isselected from an inflammatory disease, autoimmune disease, an oculardisease or disorder involving inflammatory and/or neovascular events;atherosclerosis, vascular occlusion due to vascular injury, angioplasty,restenosis, obesity, syndrome X, impaired glucose tolerance, polycysticovary syndrome, hypertension, heart failure, chronic obstructivepulmonary disease, CNS diseases, Alzheimer disease, amyotrophic lateralsclerosis, bipolar disease, cancer, infectious disease, AIDS, septicshock, adult respiratory distress syndrome, ischemia/reperfusion injury,myocardial infarction, stroke, gut ischemia, renal failure, hemorrhageshock, and traumatic shock, traumatic brain injury; T-cell mediatedacute or chronic inflammatory diseases or disorders or autoimmunediseases, rheumatoid arthritis, osteoarthritis, systemic lupuserythematosus, Hashimoto's thyroiditis, multiple sclerosis, myastheniagravis, diabetes type I or II and the disorders associated therewith,transplant rejection, graft versus host disease, respiratory diseases,asthma, inflammatory lung injury, inflammatory liver injury,inflammatory glomerular injury, cutaneous manifestations ofimmunologically-mediated disorders or illnesses, inflammatory andhyperproliferative skin diseases, psoriasis, atopic dermatitis, allergiccontact dermatitis, irritant contact dermatitis and further eczematousdermatitises, seborrhoeic dermatitis, inflammatory eye diseases,Sjoegren's syndrome, keratoconjunctivitis, uveitis, inflammatory boweldisease, Crohn's disease or ulcerative colitis, Guillain-Barre syndrome,and allergies.